score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5208	96.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A5ER-01A-12D-A27K-08	TCGA-BF-A5ER-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6207	87.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A299-01A-21D-A197-08	TCGA-EB-A299-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4776	67.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A9SD-06A-11D-A401-08	TCGA-GN-A9SD-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4862	109.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A4EO-06A-12D-A24R-08	TCGA-GF-A4EO-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.68	125.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A3F5-06A-11D-A20D-08	TCGA-DA-A3F5-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5116	43.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2809	89.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GB-06A-11D-A372-08	TCGA-D3-A8GB-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2967	91.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZH-06A-11D-A197-08	TCGA-FS-A1ZH-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9444	72.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZD-06A-11D-A197-08	TCGA-FS-A1ZD-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1023	88.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3XD-01A-22D-A23B-08	TCGA-EB-A3XD-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4717	53.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5	90.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6786	56.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5324	139.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3MO-06A-11D-A21A-08	TCGA-D3-A3MO-10A-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.506	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3J3-06A-11D-A20D-08	TCGA-EE-A3J3-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4024	82.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5	98.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MH-06A-11D-A197-08	TCGA-EE-A2MH-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2143	98.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GH-06A-11D-A196-08	TCGA-EE-A2GH-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3394	109.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JE-06A-11D-A372-08	TCGA-D3-A2JE-10B-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5263	114.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4615	39.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3XF-01A-31D-A23B-08	TCGA-EB-A3XF-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6176	68.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GB-06A-11D-A197-08	TCGA-EE-A2GB-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5329	152.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A5DX-01A-11D-A27K-08	TCGA-FW-A5DX-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5143	70.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4412	34.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JD-06A-11D-A19A-08	TCGA-D3-A2JD-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9714	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4217	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2035	113.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.436	172.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A3Z3-06A-11D-A23B-08	TCGA-D9-A3Z3-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5524	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6747	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-XV-AAZW-01A-12D-A401-08	TCGA-XV-AAZW-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5556	162.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A4U7-06A-21D-A32N-08	TCGA-GN-A4U7-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7447	141.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5SE-01A-11D-A30X-08	TCGA-EB-A5SE-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3363	113.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GN-06A-11D-A372-08	TCGA-D3-A8GN-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6397	136.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A42K-06A-11D-A24R-08	TCGA-ER-A42K-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3621	58.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6705	88.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4839	93.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JG-06A-11D-A196-08	TCGA-D3-A2JG-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3818	55.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3898	59.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A3DM-01A-11D-A20D-08	TCGA-BF-A3DM-10A-02D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8598	214.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.25	112.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2M6-06A-12D-A197-08	TCGA-EE-A2M6-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4732	112.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A5GT-01A-12D-A30X-08	TCGA-D3-A5GT-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4258	155.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5752	113.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I7-06A-22D-A197-08	TCGA-DA-A1I7-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3846	78.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1818	55.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A269-01A-11D-A19A-08	TCGA-GN-A269-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3604	111.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A4U5-01A-11D-A32N-08	TCGA-GN-A4U5-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2419	62.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29P-06A-11D-A197-08	TCGA-EE-A29P-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5656	122.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4225	71.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A6E9-06A-12D-A30X-08	TCGA-D9-A6E9-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5312	64.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7619	42.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1YX-06A-11D-A197-08	TCGA-FS-A1YX-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5267	131.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6549	142.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3614	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JA-06A-11D-A196-08	TCGA-D3-A2JA-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3731	134.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3J4-06A-11D-A20D-08	TCGA-EE-A3J4-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4298	121.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4382	89.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51N-06A-11D-A25O-08	TCGA-D3-A51N-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3012	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4722	72.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I2-06A-21D-A19A-08	TCGA-DA-A1I2-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4167	72.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q9-06A-11D-A19A-08	TCGA-D3-A1Q9-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4	80.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZN-01A-11D-A197-08	TCGA-FS-A1ZN-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4213	178.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3MU-06A-11D-A21A-08	TCGA-D3-A3MU-10A-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5577	104.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A4Z2-01A-11D-A24R-08	TCGA-D9-A4Z2-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6067	89.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZR-06A-21D-A197-08	TCGA-FS-A1ZR-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4248	113.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3	50.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2963	81.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A550-01A-61D-A27K-08	TCGA-EB-A550-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5125	80.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-YD-A9TB-06A-12D-A401-08	TCGA-YD-A9TB-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1129	62.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-WE-AAA4-06A-12D-A38G-08	TCGA-WE-AAA4-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3134	67.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4026	77.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A24C-01A-11D-A197-08	TCGA-EB-A24C-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.378	82.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-HR-A2OH-06A-11D-A197-08	TCGA-HR-A2OH-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6162	99.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A42Z-01A-12D-A24R-08	TCGA-EB-A42Z-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4016	127.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A44A-06A-11D-A24R-08	TCGA-FR-A44A-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6364	99.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5241	145.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A769-01A-32D-A32N-08	TCGA-GF-A769-10A-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3291	79.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GD-06A-11D-A372-08	TCGA-D3-A8GD-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6092	87.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A95W-06A-11D-A372-08	TCGA-DA-A95W-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5135	74.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1875	64.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1692	65.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A265-06A-21D-A197-08	TCGA-GN-A265-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3382	68.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19Q-06A-11D-A197-08	TCGA-ER-A19Q-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5213	94.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A5GR-06A-11D-A27K-08	TCGA-D3-A5GR-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3175	63.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3433	67.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3XE-01A-12D-A23B-08	TCGA-EB-A3XE-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3922	153.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4779	113.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3649	74.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3CB-06A-11D-A196-08	TCGA-D3-A3CB-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3043	69.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JK-06A-11D-A196-08	TCGA-D3-A2JK-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4892	139.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3HV-01A-11D-A21A-08	TCGA-EB-A3HV-10B-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.747	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I8-06A-11D-A197-08	TCGA-DA-A1I8-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2222	72.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4416	77.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3036	56.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9706	34.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9225	142.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.209	67.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4714	70.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3902	82.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.381	84.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4636	151.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZF-06A-12D-A197-08	TCGA-FS-A1ZF-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6735	147.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8ZQ-06A-41D-A372-08	TCGA-WE-A8ZQ-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4	65.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51J-06A-11D-A25O-08	TCGA-D3-A51J-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8267	75.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.65	120.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1304	46.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A44N-01A-11D-A25O-08	TCGA-EB-A44N-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5521	96.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.125	56.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2M8-06A-12D-A196-08	TCGA-EE-A2M8-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5664	113.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8793	58.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6068	117.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4381	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAP0-06A-11D-A397-08	TCGA-BF-AAP0-10A-01D-A39A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3846	39.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MP-06A-11D-A197-08	TCGA-EE-A2MP-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4444	54.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A2NG-06A-11D-A196-08	TCGA-ER-A2NG-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1714	35.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A26A-06A-11D-A19A-08	TCGA-GN-A26A-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5217	92.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1HW-06A-11D-A19A-08	TCGA-DA-A1HW-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3758	149.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A6QY-01A-12D-A32N-08	TCGA-EB-A6QY-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2202	109.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A8YE-06A-11D-A372-08	TCGA-FR-A8YE-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3143	105.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A3DN-01A-11D-A20D-08	TCGA-BF-A3DN-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2714	70.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A148-06A-11D-A19A-08	TCGA-D9-A148-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.325	120.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A2ND-06A-11D-A196-08	TCGA-ER-A2ND-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7899	119.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3C1-06A-12D-A196-08	TCGA-D3-A3C1-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7113	97.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3902	41.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A4FB-06A-11D-A25O-08	TCGA-FS-A4FB-10B-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4386	57.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4928	69.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4578	83.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8ZR-06A-11D-A372-08	TCGA-WE-A8ZR-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7119	118.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A9VF-01A-11D-A372-08	TCGA-BF-A9VF-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3908	87.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A85I-01A-11D-A34U-08	TCGA-EB-A85I-10B-01D-A34X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6207	145.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2381	63.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3421	76.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A17Y-06A-11D-A196-08	TCGA-EE-A17Y-10B-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7283	92.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZS-06A-12D-A197-08	TCGA-FS-A1ZS-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3556	45.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.48	50.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q4-06A-11D-A196-08	TCGA-D3-A1Q4-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3737	99.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1169	77.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19P-06A-11D-A196-08	TCGA-ER-A19P-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6067	89.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAP6-01A-11D-A401-08	TCGA-BF-AAP6-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8772	57.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19J-06A-11D-A196-08	TCGA-ER-A19J-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3793	58.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1765	102.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A728-01A-11D-A32N-08	TCGA-FR-A728-10A-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5652	184.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.59	100.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A6EG-06A-12D-A32N-08	TCGA-D9-A6EG-10A-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3681	144.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3146	89.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3649	74.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3Y6-01A-21D-A23B-08	TCGA-EB-A3Y6-10A-01D-A23B-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2581	62.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2J7-06A-11D-A196-08	TCGA-D3-A2J7-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4882	127.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A6QZ-01A-12D-A32N-08	TCGA-EB-A6QZ-10B-01D-A32N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4	115.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2817	71.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3C6-06A-12D-A196-08	TCGA-D3-A3C6-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4051	79.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19C-06A-11D-A196-08	TCGA-ER-A19C-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4444	63.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29W-06A-11D-A196-08	TCGA-EE-A29W-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.9623	53.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A1PU-01A-11D-A19A-08	TCGA-BF-A1PU-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7802	91.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19B-06A-11D-A196-08	TCGA-ER-A19B-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.732	97.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2M7-06A-11D-A197-08	TCGA-EE-A2M7-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.7667	60.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1739	92.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1649	97.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GJ-06A-11D-A372-08	TCGA-D3-A8GJ-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.325	80.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5	42.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1489	94.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3JE-06A-11D-A20D-08	TCGA-EE-A3JE-10A-01D-A20D-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8721	86.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3CE-06A-11D-A19A-08	TCGA-D3-A3CE-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8	70.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A20B-06A-11D-A196-08	TCGA-EE-A20B-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1053	95.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2ME-06A-11D-A197-08	TCGA-EE-A2ME-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1918	73.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MG-06A-11D-A197-08	TCGA-EE-A2MG-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5522	67.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A4P0-01A-41D-A25O-08	TCGA-EB-A4P0-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4179	67.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4307	137.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29T-06A-11D-A197-08	TCGA-EE-A29T-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2128	47.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A4F8-06A-11D-A25O-08	TCGA-FS-A4F8-10B-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2456	57.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GT-06A-12D-A197-08	TCGA-EE-A2GT-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3636	99.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GS-06A-12D-A372-08	TCGA-D3-A8GS-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6667	90.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.359	117.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1143	35.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q7-06A-11D-A19A-08	TCGA-D3-A1Q7-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3934	61.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A183-06A-11D-A196-08	TCGA-EE-A183-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5391	115.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2	65.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-Z2-AA3V-06A-11D-A397-08	TCGA-Z2-AA3V-10A-01D-A39A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.809	89.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5631	103.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1Z7-06A-11D-A197-08	TCGA-FS-A1Z7-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5283	106.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZM-06A-12D-A197-08	TCGA-FS-A1ZM-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3803	71.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-HR-A5NC-01A-11D-A27K-08	TCGA-HR-A5NC-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2321	56.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19S-06A-11D-A196-08	TCGA-ER-A19S-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.21	100.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A7UA-06A-32D-A34U-08	TCGA-FR-A7UA-10A-01D-A34X-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8684	76.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-LH-A9QB-06A-11D-A38G-08	TCGA-LH-A9QB-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6139	101.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6522	46.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q5-06A-11D-A196-08	TCGA-D3-A1Q5-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4658	73.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-XV-A9W5-01A-11D-A38G-08	TCGA-XV-A9W5-10A-01D-A38J-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4886	88.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A1JX-06A-11D-A19A-08	TCGA-D9-A1JX-10A-01D-A19A-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5077	65.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A262-06A-11D-A196-08	TCGA-GN-A262-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.675	120.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A2C7-01A-11D-A197-08	TCGA-GF-A2C7-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.461	154.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A553-01A-12D-A27K-08	TCGA-EB-A553-10A-01D-A27N-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4828	87.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8K6-06A-11D-A372-08	TCGA-WE-A8K6-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.5735	68.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3418	79.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6585	41.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MK-06A-11D-A196-08	TCGA-EE-A2MK-10A-01D-A198-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4767	86.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-XV-AAZV-01A-11D-A401-08	TCGA-XV-AAZV-10A-01D-A401-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1837	49.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A4IS-01A-21D-A25O-08	TCGA-EB-A4IS-10A-01D-A25O-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8547	117.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.32	75.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A3DJ-01A-11D-A20D-08	TCGA-BF-A3DJ-10A-02D-A20D-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.5	96.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_VARSCAN2	TCGA-YG-AA3P-06A-11D-A38G-08	TCGA-YG-AA3P-10A-01D-A38J-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.5044	113.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A42Y-01A-12D-A24R-08	TCGA-EB-A42Y-10A-01D-A24R-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.832	369.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A1Q3-06A-11D-A196-08	TCGA-D3-A1Q3-10A-01D-A198-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.V559A	0.2742	62.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V559A (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.L576P	0.5167	60.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.L576P (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A5ES-01A-11D-A27K-08	TCGA-BF-A5ES-10A-01D-A27N-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.9753	162.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_VARSCAN2	TCGA-ER-A42H-01A-11D-A24R-08	TCGA-ER-A42H-10A-01D-A24R-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.4656	247.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A57M-01A-51D-A30X-08	TCGA-EB-A57M-10A-01D-A30X-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.K642E	0.7011	87.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642E (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A5KH-06A-11D-A27K-08	TCGA-EB-A5KH-10A-01D-A27N-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.L576P	0.9528	509.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.L576P (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A51K-06A-11D-A25O-08	TCGA-D3-A51K-10A-01D-A25O-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.V559A	0.3784	111.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V559A (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.W557R	0.7379	103.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.W557R (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.V559A	0.1974	76.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V559A (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.8889	18.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZG-06A-11D-A197-08	TCGA-FS-A1ZG-10A-01D-A199-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.9556	45.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4437	142.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7143	77.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.686	293.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.8687	99.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.25	136.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7321	265.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A69P-06A-21D-A30X-08	TCGA-FR-A69P-10A-01D-A30X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4825	114.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAP2-01A-11D-A401-08	TCGA-BF-AAP2-10A-01D-A401-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6856	194.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A7U8-06A-21D-A34U-08	TCGA-FR-A7U8-10A-01D-A34X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6349	126.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6519	181.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5846	260.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12R	0.7538	130.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q1-06A-21D-A196-08	TCGA-D3-A1Q1-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7982	441.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5VU-01A-21D-A32N-08	TCGA-EB-A5VU-10A-01D-A32N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.8062	160.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8ZO-06A-11D-A372-08	TCGA-WE-A8ZO-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4505	111.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A44Q-06A-11D-A25O-08	TCGA-EB-A44Q-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.2969	128.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19N-06A-11D-A197-08	TCGA-ER-A19N-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.681	116.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZY-06A-11D-A197-08	TCGA-FS-A1ZY-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4664	223.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4331	127.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZT-06A-11D-A197-08	TCGA-FS-A1ZT-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5458	262.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12R	0.2388	134.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JL-06A-11D-A196-08	TCGA-D3-A2JL-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7627	118.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7	120.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G13D	0.8662	284.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G13D (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A44R-06A-41D-A25O-08	TCGA-EB-A44R-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3586	198.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A3F3-06A-11D-A20D-08	TCGA-DA-A3F3-10A-01D-A20D-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6471	153.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51E-06A-11D-A25O-08	TCGA-D3-A51E-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.6781	146.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12S	0.3723	137.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12S (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5992	242.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.2963	108.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4752	101.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12A	0.4314	102.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12A (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3193	119.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2ML-06A-11D-A197-08	TCGA-EE-A2ML-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.2603	146.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A199-06A-11D-A197-08	TCGA-ER-A199-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7922	231.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A3Z4-01A-11D-A23B-08	TCGA-D9-A3Z4-10A-01D-A23B-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4553	123.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4095	105.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G13R	0.3689	103.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G13R (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.885	113.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7756	352.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A2NH-06A-11D-A196-08	TCGA-ER-A2NH-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6316	171.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A4U9-06A-11D-A32N-08	TCGA-GN-A4U9-10B-01D-A32N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3	120.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4744	156.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8ZY-06A-11D-A372-08	TCGA-WE-A8ZY-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.156	141.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5SG-06A-11D-A30X-08	TCGA-EB-A5SG-10A-01D-A30X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4839	124.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-XV-AAZY-01A-12D-A401-08	TCGA-XV-AAZY-10A-01D-A401-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6815	135.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3MV-06A-11D-A21A-08	TCGA-D3-A3MV-10A-01D-A21A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.1603	131.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5232	151.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.2527	91.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4206	252.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.8704	108.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A1PZ-01A-11D-A19A-08	TCGA-BF-A1PZ-10A-01D-A19A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.9115	192.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3598	164.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3559	118.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6	160.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-HR-A2OG-06A-21D-A197-08	TCGA-HR-A2OG-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6096	146.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3643	129.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZQ-06A-11D-A197-08	TCGA-FS-A1ZQ-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.2075	159.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2J8-06A-11D-A196-08	TCGA-D3-A2J8-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.3399	912.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.8144	97.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8JZ-06A-11D-A372-08	TCGA-WE-A8JZ-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4722	72.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A4FD-06A-11D-A25O-08	TCGA-FS-A4FD-10B-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.6388	335.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.525	120.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5458	251.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.5385	221.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.461	141.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29Q-06A-11D-A197-08	TCGA-EE-A29Q-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6413	329.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6132	106.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1Z0-06A-11D-A197-08	TCGA-FS-A1Z0-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G13R	0.3521	142.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G13R (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3452	168.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZB-06A-12D-A197-08	TCGA-FS-A1ZB-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4598	87.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-WE-AAA3-06A-11D-A38G-08	TCGA-WE-AAA3-10A-01D-A38J-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5448	279.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.5664	113.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.1962	158.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.2836	134.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A1NK-01A-11D-A196-08	TCGA-EB-A1NK-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.326	181.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8K1-06A-21D-A372-08	TCGA-WE-A8K1-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5938	128.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2A5-06A-11D-A197-08	TCGA-EE-A2A5-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.6027	219.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29X-06A-11D-A196-08	TCGA-EE-A29X-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.2395	263.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5371	175.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12D	0.4961	129.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12D (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.8819	144.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.162	142.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2A1-06A-11D-A197-08	TCGA-EE-A2A1-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.3372	86.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A4Z3-01A-11D-A25O-08	TCGA-D9-A4Z3-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.454	163.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A2NB-01A-12D-A196-08	TCGA-ER-A2NB-10A-01D-A198-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.9068	118.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1Z3-06A-11D-A197-08	TCGA-FS-A1Z3-10A-01D-A199-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5523	239.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3J8-06A-11D-A20D-08	TCGA-EE-A3J8-10A-01D-A20D-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.7214	201.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.419	105.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I1-06A-12D-A196-08	TCGA-DA-A1I1-10A-01D-A198-08
Putatively Actionable	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124L	0.4	100.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124L (Missense)	0	SKCM_VARSCAN2	TCGA-ER-A42H-01A-11D-A24R-08	TCGA-ER-A42H-10A-01D-A24R-08
Putatively Actionable	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124L	0.3542	96.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124L (Missense)	0	SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Putatively Actionable	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124L	0.4412	102.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124L (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Putatively Actionable	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124L	0.2653	49.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124L (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Putatively Actionable	Preclinical	Preclinical		Somatic Variant	MAP2K1	Missense	p.Q56P	0.6083	120.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Vemurafenib	B-RAF inhibition	Targeted therapy	Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.Q56P (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.4407	59.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZF-06A-12D-A197-08	TCGA-FS-A1ZF-10A-01D-A199-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2388	67.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.6667	33.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Putatively Actionable	Preclinical			Somatic Variant	AKT1	Missense	p.E17K	0.3704	27.0	0.0	0.0		Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E17K (Missense)	0	SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Putatively Actionable	Preclinical			Somatic Variant	AKT1	Missense	p.E17K	0.3548	31.0	0.0	0.0		Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E17K (Missense)	0	SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.431	58.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U8-06A-21D-A34U-08	TCGA-FR-A7U8-10A-01D-A34X-08
Putatively Actionable			Guideline	Somatic Variant	SETBP1	Missense	p.E858K	0.3	40.0	0.0	0.0																Putatively Actionable	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E858K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.2424	33.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		SKCM_VARSCAN2	TCGA-ER-A2NF-01A-11D-A19A-08	TCGA-ER-A2NF-10A-01D-A19A-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.2	55.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.6829	41.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		SKCM_VARSCAN2	TCGA-ER-A3ES-06A-11D-A20D-08	TCGA-ER-A3ES-10A-01D-A20D-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.4762	42.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		SKCM_VARSCAN2	TCGA-RP-A690-06A-11D-A30X-08	TCGA-RP-A690-10A-01D-A30X-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.N626Y	0.2935	92.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.N626Y (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.1026	39.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		SKCM_VARSCAN2	TCGA-ER-A19S-06A-11D-A196-08	TCGA-ER-A19S-10A-01D-A198-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.K700E	0.2857	49.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K700E (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YD-06A-11D-A372-08	TCGA-FR-A8YD-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.S467L	0.4308	65.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.S467L (Missense)	1	SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5158	95.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A5ER-01A-12D-A27K-08	TCGA-BF-A5ER-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K183E	0.1475	122.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K183E (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A4EO-06A-12D-A24R-08	TCGA-GF-A4EO-10A-01D-A24R-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.N581T	0.1818	33.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.N581T (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A1JW-06A-11D-A19A-08	TCGA-D9-A1JW-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.5163	153.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.N581S	0.5571	70.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.N581S (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P348T	0.3894	113.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P348T (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3902	82.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P318L	0.1913	115.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P318L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GH-06A-11D-A196-08	TCGA-EE-A2GH-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P318S	0.181	116.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P318S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GH-06A-11D-A196-08	TCGA-EE-A2GH-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.4	65.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JH-06A-11D-A196-08	TCGA-D3-A2JH-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4474	38.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3XF-01A-31D-A23B-08	TCGA-EB-A3XF-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6176	68.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GB-06A-11D-A197-08	TCGA-EE-A2GB-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5294	68.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.9714	105.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5495	111.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6667	87.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3898	59.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A3DM-01A-11D-A20D-08	TCGA-BF-A3DM-10A-02D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.414	157.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3636	77.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.E695K	0.1748	103.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.E695K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.2254	71.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H725Y	0.276	192.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H725Y (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G469E	0.1742	178.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G469E (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5191	131.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.S467L	0.1615	192.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.S467L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3JD-06A-11D-A20D-08	TCGA-EE-A3JD-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4174	115.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3333	51.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3182	66.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H235Y	0.5735	68.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H235Y (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3893	149.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.S467L	0.2885	52.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.S467L (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H574Y	0.3824	34.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H574Y (Missense)	1	SKCM_VARSCAN2	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.4444	81.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600G	0.6379	116.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600G (Missense)	1	SKCM_VARSCAN2	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6522	115.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.2113	71.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4211	76.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.L485F	0.5536	56.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L485F (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H725Y	0.4731	93.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H725Y (Missense)	1	SKCM_VARSCAN2	TCGA-3N-A9WB-06A-11D-A38G-08	TCGA-3N-A9WB-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G469R	0.3521	71.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G469R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.8378	74.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6612	121.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.D594N	0.1882	85.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.D594N (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29N-06A-12D-A197-08	TCGA-EE-A29N-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.1633	49.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3JH-06A-11D-A21A-08	TCGA-EE-A3JH-10A-01D-A21A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P731S	0.633	218.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P731S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MQ-06A-11D-A197-08	TCGA-EE-A2MQ-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.5446	101.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MQ-06A-11D-A197-08	TCGA-EE-A2MQ-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5752	113.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6154	117.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4369	103.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAP0-06A-11D-A397-08	TCGA-BF-AAP0-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.Y566C	0.127	126.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.Y566C (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3767	146.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A6QY-01A-12D-A32N-08	TCGA-EB-A6QY-10B-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.S467L	0.1133	150.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.S467L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.2308	65.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.8772	57.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19J-06A-11D-A196-08	TCGA-ER-A19J-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5738	183.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3706	143.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.7667	60.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.5	42.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.2281	57.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GT-06A-12D-A197-08	TCGA-EE-A2GT-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.3168	101.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.3426	108.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.4	60.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A183-06A-11D-A196-08	TCGA-EE-A183-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600G	0.6933	75.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600G (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6933	75.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G469R	0.1852	135.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G469R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.L597Q	0.3636	88.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L597Q (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P367S	0.379	124.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P367S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.21	100.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A7UA-06A-32D-A34U-08	TCGA-FR-A7UA-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600G	0.3619	268.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600G (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.3579	271.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.N581H	0.5082	61.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.N581H (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A4Z5-01A-11D-A25O-08	TCGA-D9-A4Z5-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.2759	174.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.R726C	0.4015	132.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.R726C (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A4Z6-06A-12D-A25O-08	TCGA-D9-A4Z6-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600G	0.8406	69.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600G (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1QA-06A-11D-A196-08	TCGA-D3-A1QA-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.8551	69.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600M (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1QA-06A-11D-A196-08	TCGA-D3-A1QA-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601E	0.5288	104.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601E (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.L245F	0.4848	33.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L245F (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S116F	0.1111	72.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S116F (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GB-06A-11D-A372-08	TCGA-D3-A8GB-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.L101F	0.382	89.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.L101F (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E400K	0.3222	90.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E400K (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.M650I	0.2823	124.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.M650I (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P699L	0.3607	183.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P699L (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.L782F	0.3193	166.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.L782F (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.G917R	0.2846	123.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.G917R (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P1178L	0.2308	26.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P1178L (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P272L	0.2923	65.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P272L (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D379N	0.45	120.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.D379N (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.N234S	0.1361	147.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.N234S (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A269-01A-11D-A19A-08	TCGA-GN-A269-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D303N	0.1923	104.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.D303N (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S364F	0.1837	98.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S364F (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P934S	0.2083	72.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P934S (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R958C	0.2248	129.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R958C (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.Q982*	0.2533	75.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.Q982* (Nonsense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.K737E	0.973	37.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.K737E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.N604D	0.3929	84.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.N604D (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A3F3-06A-11D-A20D-08	TCGA-DA-A3F3-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.Q390K	0.1525	59.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.Q390K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.Q581*	0.5735	68.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.Q581* (Nonsense)	1	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D368N	0.2254	71.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.D368N (Missense)	1	SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.E1180*	0.4082	49.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E1180* (Nonsense)	1	SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S464P	0.1111	63.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S464P (Missense)	1	SKCM_VARSCAN2	TCGA-WE-AAA4-06A-12D-A38G-08	TCGA-WE-AAA4-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.H47Y	0.16	100.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.H47Y (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E922K	0.2828	99.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E922K (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P100S	0.4422	147.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P100S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S116F	0.4385	130.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S116F (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P753S	0.1698	53.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P753S (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.G983R	0.3458	107.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.G983R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S227F	0.3907	215.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S227F (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.Q982*	0.4783	92.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.Q982* (Nonsense)	1	SKCM_VARSCAN2	TCGA-EB-A4XL-01A-11D-A27K-08	TCGA-EB-A4XL-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P622S	0.2449	49.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P622S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.L541F	0.2611	157.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.L541F (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P589L	0.4141	99.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P589L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P228L	0.2522	226.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P228L (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.C264Y	0.1887	53.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.C264Y (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2M7-06A-11D-A197-08	TCGA-EE-A2M7-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P192S	0.2264	53.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P192S (Missense)	1	SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D1009N	0.395	119.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.D1009N (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S447F	0.4118	85.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S447F (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E114K	0.3421	76.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E114K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.R456S	0.1781	73.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.R456S (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.Y641F	0.2	40.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.Y641F (Missense)		SKCM_VARSCAN2	TCGA-D9-A1JW-06A-11D-A19A-08	TCGA-D9-A1JW-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.P426S	0.4143	70.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.P426S (Missense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.L338F	0.3264	193.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.L338F (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3P-06A-11D-A38G-08	TCGA-YG-AA3P-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.T4I	0.3728	279.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.T4I (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.T4P	0.3768	276.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.T4P (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.T666I	0.3204	103.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.T666I (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.Y641N	0.4247	73.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.Y641N (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.L706F	0.4186	86.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.L706F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.C530W	0.2609	46.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.C530W (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N822K	0.6319	144.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N822K (Missense)		SKCM_VARSCAN2	TCGA-GN-A264-06A-11D-A196-08	TCGA-GN-A264-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.S123F	0.3448	29.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S123F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.G137E	0.9787	47.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.G137E (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.Y641N	0.4286	21.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.Y641N (Missense)		SKCM_VARSCAN2	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.P363S	0.4667	15.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.P363S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.S405L	0.1852	351.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.S405L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.S228F	0.4437	151.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.S228F (Missense)		SKCM_VARSCAN2	TCGA-EB-A41B-01A-11D-A24R-08	TCGA-EB-A41B-10A-01D-A24R-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.P132S	0.359	39.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.P132S (Missense)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.T245M	0.2879	66.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.T245M (Missense)		SKCM_VARSCAN2	TCGA-RP-A693-06A-13D-A30X-08	TCGA-RP-A693-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.S533L	0.6567	67.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.S533L (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.S451C	0.9	30.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S451C (Missense)		SKCM_VARSCAN2	TCGA-EB-A5SH-06A-11D-A30X-08	TCGA-EB-A5SH-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N822I	0.9785	186.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N822I (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.R49C	0.2571	35.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.R49C (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.R216Q	0.3404	141.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.R216Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.D142V	0.3651	63.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.D142V (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.E135K	0.1087	46.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.E135K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P696L	0.2	60.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P696L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P63S	0.625	88.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P63S (Missense)		SKCM_VARSCAN2	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.H274Y	0.4545	308.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.H274Y (Missense)		SKCM_VARSCAN2	TCGA-D9-A1X3-06A-11D-A197-08	TCGA-D9-A1X3-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.W911*	0.1389	72.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.W911* (Nonsense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G137E	0.3636	22.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G137E (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S130F	0.2778	18.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S130F (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.Q1017*	0.3387	62.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.Q1017* (Nonsense)		SKCM_VARSCAN2	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.D580H	0.1151	252.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.D580H (Missense)		SKCM_VARSCAN2	TCGA-EB-A6QY-01A-12D-A32N-08	TCGA-EB-A6QY-10B-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.Q1011*	0.1724	58.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.Q1011* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S679F	0.3182	22.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S679F (Missense)		SKCM_VARSCAN2	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P699L	0.5667	30.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P699L (Missense)		SKCM_VARSCAN2	TCGA-Z2-AA3S-06A-11D-A397-08	TCGA-Z2-AA3S-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P62L	0.1986	146.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P62L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.S796*	0.5	210.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.S796* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.D576N	0.6486	37.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.D576N (Missense)		SKCM_VARSCAN2	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.E686K	0.2895	38.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.E686K (Missense)		SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.K702M	0.3421	38.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.K702M (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R748K	0.5897	39.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R748K (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P6Q	0.2821	156.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P6Q (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P155L	0.322	59.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P155L (Missense)	0	SKCM_VARSCAN2	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E1068K	0.4255	94.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1068K (Missense)	0	SKCM_VARSCAN2	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E34K	0.1893	169.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E34K (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.H425Y	0.2333	120.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.H425Y (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S470L	0.215	107.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S470L (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D691N	0.1771	96.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D691N (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E1085K	0.536	125.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1085K (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P345S	0.5472	53.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P345S (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D480N	0.4068	59.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D480N (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S890F	0.274	73.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S890F (Missense)	0	SKCM_VARSCAN2	TCGA-ER-A199-06A-11D-A197-08	TCGA-ER-A199-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.A7T	0.2627	118.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.A7T (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L891F	0.4444	108.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L891F (Missense)	0	SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.T440M	0.3789	95.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.T440M (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A42Z-01A-12D-A24R-08	TCGA-EB-A42Z-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E996K	0.569	58.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E996K (Missense)	0	SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D706N	0.3797	79.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D706N (Missense)	0	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P519S	0.8621	29.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P519S (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A1PZ-01A-11D-A19A-08	TCGA-BF-A1PZ-10A-01D-A19A-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P414S	0.2128	47.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P414S (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G662R	0.4	45.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.G662R (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A1ZF-06A-12D-A197-08	TCGA-FS-A1ZF-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L790P	0.4048	84.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L790P (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P895L	0.3542	48.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P895L (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.C235S	0.1429	49.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.C235S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GL-06A-11D-A196-08	TCGA-EE-A2GL-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R72K	0.408	174.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R72K (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.N907T	0.4706	34.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.N907T (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L506F	0.3889	54.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L506F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E331K	0.5395	76.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E331K (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29Q-06A-11D-A197-08	TCGA-EE-A29Q-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E63K	0.24	200.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E63K (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L161V	0.1984	126.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L161V (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G430R	0.1345	171.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.G430R (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P1027L	0.3718	78.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P1027L (Missense)	0	SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E459K	0.3386	127.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E459K (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E229K	0.3692	130.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E229K (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.H477Y	0.5714	84.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.H477Y (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.I888N	0.4835	91.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.I888N (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A1Z3-06A-11D-A197-08	TCGA-FS-A1Z3-10A-01D-A199-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.2391	46.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	SKCM_VARSCAN2	TCGA-XV-A9W2-01A-11D-A397-08	TCGA-XV-A9W2-10A-01D-A39A-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.375	24.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61L	0.6232	69.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.E62K	0.4783	23.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.E62K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61R	0.4783	23.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61K	0.4493	69.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5UM-01A-11D-A30X-08	TCGA-EB-A5UM-10A-01D-A30X-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12R	0.4545	11.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.K117N	0.233	103.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.K117N (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29N-06A-12D-A197-08	TCGA-EE-A29N-10A-01D-A199-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.E63K	0.3506	77.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.E63K (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAOU-01A-12D-A397-08	TCGA-BF-AAOU-10A-01D-A39A-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q2433*	0.7273	11.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q2433* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MN-06A-11D-A197-08	TCGA-EE-A2MN-10A-01D-A199-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R35*	0.6852	54.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R35* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A82C-01A-11D-A34U-08	TCGA-EB-A82C-10B-01D-A34X-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X2325_splice	0.5484	31.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X2325_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EB-A57M-01A-51D-A30X-08	TCGA-EB-A57M-10A-01D-A30X-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift		0.2787	61.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM  (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A2GN-06A-11D-A196-08	TCGA-EE-A2GN-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P1049S	0.4135	133.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.P1049S (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G823E	0.2143	42.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G823E (Missense)		SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D1000N	0.3905	105.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D1000N (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P320S	0.4118	17.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.P320S (Missense)		SKCM_VARSCAN2	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G1032D	0.2514	183.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G1032D (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A741T	0.4151	159.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A741T (Missense)		SKCM_VARSCAN2	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D1093N	0.1171	111.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D1093N (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R1050Q	0.4561	57.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R1050Q (Missense)		SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D698N	0.3684	19.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D698N (Missense)		SKCM_VARSCAN2	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M970I	0.4091	66.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M970I (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P155S	0.5789	38.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.P155S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G823E	0.4055	291.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G823E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R912Q	0.2967	910.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R912Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E337K	0.2162	37.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E337K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A342V	0.1714	35.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A342V (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G736R	0.1053	190.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G736R (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E62K	0.4474	38.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E62K (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A472V	0.1828	93.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A472V (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E366Q	0.3953	43.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E366Q (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q3026*	0.2105	38.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q3026* (Nonsense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D322N	0.2857	49.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D322N (Missense)		SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E480K	0.2564	39.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E480K (Missense)		SKCM_VARSCAN2	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.S936F	0.1075	93.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.S936F (Missense)		SKCM_VARSCAN2	TCGA-EE-A183-06A-11D-A196-08	TCGA-EE-A183-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.T92I	0.4138	29.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.T92I (Missense)		SKCM_VARSCAN2	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R417C	0.7333	15.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R417C (Missense)		SKCM_VARSCAN2	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q2870*	0.475	40.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2870* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D627N	0.3889	18.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D627N (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GD-06A-11D-A196-08	TCGA-EE-A2GD-10A-01D-A198-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q1562*	0.3525	122.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q1562* (Nonsense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q22K	0.5283	53.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q22K (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3659	123.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MN-06A-11D-A197-08	TCGA-EE-A2MN-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.7297	259.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.6061	132.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.P34L	0.9574	47.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.P34L (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3684	152.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.6714	70.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4874	119.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4198	131.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A2NE-06A-21D-A196-08	TCGA-ER-A2NE-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3515	202.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A3F3-06A-11D-A20D-08	TCGA-DA-A3F3-10A-01D-A20D-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3714	175.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A267-06A-21D-A196-08	TCGA-GN-A267-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2925	106.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A195-06A-11D-A196-08	TCGA-ER-A195-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3504	137.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A85J-01A-12D-A34U-08	TCGA-EB-A85J-10B-01D-A34X-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.8969	97.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A185-06A-11D-A196-08	TCGA-EE-A185-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.5082	122.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4274	248.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4255	322.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.7614	306.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19D-06A-11D-A197-08	TCGA-ER-A19D-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.8125	192.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-3N-A9WB-06A-11D-A38G-08	TCGA-3N-A9WB-10A-01D-A38J-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.298	198.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3333	162.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JO-06A-11D-A196-08	TCGA-D3-A2JO-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3178	107.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.1777	197.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29G-06A-12D-A196-08	TCGA-EE-A29G-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.8198	172.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.308	224.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GL-06A-11D-A196-08	TCGA-EE-A2GL-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.8229	96.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-WE-A8JZ-06A-11D-A372-08	TCGA-WE-A8JZ-10A-01D-A375-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3938	193.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3455	110.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4861	144.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5UL-06A-11D-A30X-08	TCGA-EB-A5UL-10A-01D-A30X-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.E62K	0.1961	153.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.E62K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.375	160.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A268-06A-11D-A196-08	TCGA-GN-A268-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2687	134.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2941	102.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GN-06A-11D-A196-08	TCGA-EE-A2GN-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.1953	169.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q8-06A-11D-A19A-08	TCGA-D3-A1Q8-10A-01D-A19A-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4545	154.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZE-06A-11D-A197-08	TCGA-FS-A1ZE-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4497	169.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A4F9-06A-11D-A24R-08	TCGA-FS-A4F9-10A-01D-A24R-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4403	159.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1YW-06A-11D-A197-08	TCGA-FS-A1YW-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2	110.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GD-06A-11D-A196-08	TCGA-EE-A2GD-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.8889	162.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.6059	307.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.1813	171.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19W-06A-41D-A23B-08	TCGA-ER-A19W-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.R366Q	0.28	50.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.R366Q (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.E139K	0.4	130.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.E139K (Missense)		SKCM_VARSCAN2	TCGA-ER-A42K-06A-11D-A24R-08	TCGA-ER-A42K-10A-01D-A24R-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.G128E	0.1562	64.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.G128E (Missense)		SKCM_VARSCAN2	TCGA-ER-A19N-06A-11D-A197-08	TCGA-ER-A19N-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R695C	0.3333	60.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R695C (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1185*	0.9286	28.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1185* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2M6-06A-12D-A197-08	TCGA-EE-A2M6-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.Q516*	0.25	52.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Q516* (Nonsense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.G81E	0.3548	93.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.G81E (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A102T	0.2092	153.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A102T (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S243F	0.3088	68.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S243F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L755M	0.4318	44.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L755M (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.D228V	0.4043	47.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.D228V (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.R328W	0.119	42.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R328W (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.R751*	0.3577	123.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.R751* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.C1600Wfs*2	0.1132	53.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.C1600Wfs*2 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S427R	0.1528	72.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S427R (Missense)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.E1214Rfs*6	0.1538	52.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1214Rfs*6 (Frameshift)		SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.L361*	0.1836	256.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L361* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D993N	0.1868	91.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D993N (Missense)		SKCM_VARSCAN2	TCGA-GN-A267-06A-21D-A196-08	TCGA-GN-A267-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.P182L	0.403	67.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.P182L (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L403P	0.4706	34.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L403P (Missense)		SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D171N	0.1543	188.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D171N (Missense)		SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P1170L	0.3607	61.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P1170L (Missense)		SKCM_VARSCAN2	TCGA-BF-A5ES-01A-11D-A27K-08	TCGA-BF-A5ES-10A-01D-A27N-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R138W	0.3488	43.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R138W (Missense)		SKCM_VARSCAN2	TCGA-D3-A3MV-06A-11D-A21A-08	TCGA-D3-A3MV-10A-01D-A21A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.P285S	0.2051	39.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.P285S (Missense)		SKCM_VARSCAN2	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E1258K	0.2143	70.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E1258K (Missense)		SKCM_VARSCAN2	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R710*	0.7308	78.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R710* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.S214F	0.4667	90.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.S214F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.F154L	0.2	25.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.F154L (Missense)	0	SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P381L	0.3333	114.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P381L (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.E645K	0.371	62.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.E645K (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G1188R	0.1385	65.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G1188R (Missense)		SKCM_VARSCAN2	TCGA-EE-A29N-06A-12D-A197-08	TCGA-EE-A29N-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G1188E	0.1406	64.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G1188E (Missense)		SKCM_VARSCAN2	TCGA-EE-A29N-06A-12D-A197-08	TCGA-EE-A29N-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y1063*	0.4206	126.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1063* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.L804*	0.3604	111.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L804* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S1178F	0.2	55.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S1178F (Missense)		SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S407L	0.1	80.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S407L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P291L	0.2857	42.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P291L (Missense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K717*	0.3235	68.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K717* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.W1183*	0.4688	32.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.W1183* (Nonsense)		SKCM_VARSCAN2	TCGA-ER-A2NG-06A-11D-A196-08	TCGA-ER-A2NG-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.S140F	0.4737	19.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.S140F (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.R1138*	0.2636	129.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.R1138* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Nonsense	p.Q424*	0.625	40.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.Q424* (Nonsense)	0	SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.A293V	0.4531	64.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.A293V (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.R245*	0.4688	32.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.R245* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.P446L	0.12	25.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.P446L (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.G342E	0.3803	71.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.G342E (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.S1391Efs*5	0.5419	179.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S1391Efs*5 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S140F	0.2527	91.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S140F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.L701F	0.4267	75.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.L701F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.V232F	0.2759	29.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.V232F (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.H532Y	0.3214	112.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.H532Y (Missense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S426F	0.3412	85.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S426F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S407L	0.5319	47.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S407L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.P594S	0.1389	36.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.P594S (Missense)		SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G1097E	0.5938	64.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G1097E (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.Y46D	0.2366	131.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.Y46D (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YD-06A-11D-A372-08	TCGA-FR-A8YD-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y85*	0.7907	43.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y85* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q298*	0.2642	53.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q298* (Nonsense)	1	SKCM_VARSCAN2	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X70_splice	0.7333	15.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X70_splice (Splice Site)	1	SKCM_VARSCAN2	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.V290Sfs*8	0.3143	35.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.V290Sfs*8 (Frameshift)	1	SKCM_VARSCAN2	TCGA-EE-A29P-06A-11D-A197-08	TCGA-EE-A29P-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.R234Hfs*23	0.5368	95.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R234Hfs*23 (Frameshift)	1	SKCM_VARSCAN2	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q87*	0.3095	84.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q87* (Nonsense)	1	SKCM_VARSCAN2	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.L320Yfs*6	0.5579	95.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.L320Yfs*6 (Frameshift)	1	SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q298*	0.5	34.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q298* (Nonsense)	1	SKCM_VARSCAN2	TCGA-D3-A2JK-06A-11D-A196-08	TCGA-D3-A2JK-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.W274*	0.8125	32.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.W274* (Nonsense)	1	SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.Y46*	0.9091	33.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y46* (Frameshift)	1	SKCM_VARSCAN2	TCGA-WE-A8ZQ-06A-41D-A372-08	TCGA-WE-A8ZQ-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.V166Sfs*14	0.8333	42.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.V166Sfs*14 (Frameshift)	1	SKCM_VARSCAN2	TCGA-FW-A3I3-06A-11D-A21A-08	TCGA-FW-A3I3-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K125Vfs*10	0.359	156.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K125Vfs*10 (Frameshift)	1	SKCM_VARSCAN2	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.N63Tfs*36	0.3333	18.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N63Tfs*36 (Frameshift)	1	SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.E242Sfs*14	0.6809	47.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E242Sfs*14 (Frameshift)	1	SKCM_VARSCAN2	TCGA-BF-AAP6-01A-11D-A401-08	TCGA-BF-AAP6-10A-01D-A401-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.V166Sfs*14	0.6667	27.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.V166Sfs*14 (Frameshift)	1	SKCM_VARSCAN2	TCGA-ER-A19J-06A-11D-A196-08	TCGA-ER-A19J-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.L146Ffs*34	0.2308	78.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.L146Ffs*34 (Frameshift)	1	SKCM_VARSCAN2	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.R130*	0.75	52.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130* (Nonsense)	1	SKCM_VARSCAN2	TCGA-BF-A1PU-01A-11D-A19A-08	TCGA-BF-A1PU-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.R74Tfs*3	0.6842	19.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R74Tfs*3 (Frameshift)	1	SKCM_VARSCAN2	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.E256*	0.5	20.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E256* (Nonsense)	1	SKCM_VARSCAN2	TCGA-EE-A2GN-06A-11D-A196-08	TCGA-EE-A2GN-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K80Nfs*2	0.6111	36.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K80Nfs*2 (Frameshift)	1	SKCM_VARSCAN2	TCGA-XV-A9W5-01A-11D-A38G-08	TCGA-XV-A9W5-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.V166Sfs*14	0.64	25.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.V166Sfs*14 (Frameshift)	1	SKCM_VARSCAN2	TCGA-GF-A2C7-01A-11D-A197-08	TCGA-GF-A2C7-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X342_splice	0.6471	51.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X342_splice (Splice Site)	1	SKCM_VARSCAN2	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.1429	42.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A299-01A-21D-A197-08	TCGA-EB-A299-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.M176L	0.2381	63.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.M176L (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.T713A	0.1562	128.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.T713A (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZH-06A-11D-A197-08	TCGA-FS-A1ZH-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E775K	0.5823	79.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E775K (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.N122D	0.4533	75.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.N122D (Missense)	0	SKCM_VARSCAN2	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P888S	0.4	15.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P888S (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S941L	0.2532	79.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S941L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JE-06A-11D-A372-08	TCGA-D3-A2JE-10B-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.D248N	0.375	128.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.D248N (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S201L	0.2925	106.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S201L (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E77K	0.2906	117.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E77K (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.1429	77.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A3XF-01A-31D-A23B-08	TCGA-EB-A3XF-10A-01D-A23B-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S618L	0.327	211.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S618L (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A3Z3-06A-11D-A23B-08	TCGA-D9-A3Z3-10A-01D-A23B-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.L118V	0.4444	54.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.L118V (Missense)	0	SKCM_VARSCAN2	TCGA-XV-AAZW-01A-12D-A401-08	TCGA-XV-AAZW-10A-01D-A401-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.26	50.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E880K	0.4889	45.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E880K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2M6-06A-12D-A197-08	TCGA-EE-A2M6-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G617E	0.1361	147.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G617E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G414E	0.4302	86.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G414E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.H276Y	0.131	84.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.H276Y (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3JD-06A-11D-A20D-08	TCGA-EE-A3JD-10A-01D-A20D-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S111A	0.36	75.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S111A (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3J4-06A-11D-A20D-08	TCGA-EE-A3J4-10A-01D-A20D-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.Y597N	0.3793	29.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.Y597N (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P211S	0.3673	49.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P211S (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S50L	0.2407	54.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S50L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.4727	55.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.V129I	0.3913	46.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.V129I (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.N609Y	0.3562	73.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.N609Y (Missense)	1	SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.F53I	0.2879	132.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.F53I (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A3MV-06A-11D-A21A-08	TCGA-D3-A3MV-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.M176I	0.2703	37.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.M176I (Missense)	1	SKCM_VARSCAN2	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E573K	0.2222	27.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E573K (Missense)	1	SKCM_VARSCAN2	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E360K	0.5	56.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E360K (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.3333	96.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.D398N	0.3015	136.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.D398N (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.122	41.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A51F-06A-11D-A25O-08	TCGA-D3-A51F-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.V56I	0.3188	69.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.V56I (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E880K	0.2397	121.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E880K (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E991K	0.434	53.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E991K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.F373L	0.4545	99.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.F373L (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.R387Q	0.127	63.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.R387Q (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A44N-01A-11D-A25O-08	TCGA-EB-A44N-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.E203K	0.2281	114.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.E203K (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3JH-06A-11D-A21A-08	TCGA-EE-A3JH-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G617E	0.1526	190.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G617E (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29G-06A-12D-A196-08	TCGA-EE-A29G-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S127F	0.1795	39.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S127F (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G613E	0.4437	142.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G613E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P937S	0.3095	42.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P937S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MP-06A-11D-A197-08	TCGA-EE-A2MP-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S941L	0.3286	70.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S941L (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1HW-06A-11D-A19A-08	TCGA-DA-A1HW-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.2857	77.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A3DN-01A-11D-A20D-08	TCGA-BF-A3DN-10A-01D-A20D-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P391S	0.5224	67.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P391S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G905V	0.6364	11.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G905V (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P534S	0.2308	26.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P534S (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G295D	0.1346	52.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G295D (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.18	50.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.V843A	0.3855	83.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.V843A (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.2982	57.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S618L	0.4796	98.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S618L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E266K	0.1899	79.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E266K (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S993L	0.1538	52.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S993L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.26	50.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MU-06A-21D-A196-08	TCGA-EE-A2MU-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.K57N	0.6135	207.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.K57N (Missense)	0	SKCM_VARSCAN2	TCGA-D9-A149-06A-11D-A196-08	TCGA-D9-A149-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.2917	72.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.G294E	0.2903	62.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.G294E (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.L131V	0.4462	65.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.L131V (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2A5-06A-11D-A197-08	TCGA-EE-A2A5-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.E203V	0.2945	146.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.E203V (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29T-06A-11D-A197-08	TCGA-EE-A29T-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.3875	80.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.E203K	0.2133	75.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.E203K (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A1Q8-06A-11D-A19A-08	TCGA-D3-A1Q8-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.4902	51.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P124S (Missense)	0	SKCM_VARSCAN2	TCGA-D9-A4Z6-06A-12D-A25O-08	TCGA-D9-A4Z6-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P986S	0.2754	69.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P986S (Missense)	1	SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G574E	0.3265	49.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G574E (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A1200V	0.4333	30.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A1200V (Missense)		SKCM_VARSCAN2	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P968L	0.219	137.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P968L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.N424S	0.2308	39.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.N424S (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G952E	0.3312	154.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G952E (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E296K	0.2915	199.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E296K (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G922R	0.3529	34.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G922R (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.N1544D	0.3565	345.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.N1544D (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.N411H	0.411	73.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.N411H (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G914R	0.6364	33.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G914R (Missense)		SKCM_VARSCAN2	TCGA-EB-A5SE-01A-11D-A30X-08	TCGA-EB-A5SE-10A-01D-A30X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G747E	0.2424	33.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G747E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P236S	0.1212	66.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P236S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1494E	0.2075	159.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1494E (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P1355L	0.2982	114.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P1355L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G869E	0.2593	108.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G869E (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G869R	0.2593	108.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G869R (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S277F	0.2685	108.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S277F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S295F	0.3191	94.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S295F (Missense)		SKCM_VARSCAN2	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A586V	0.2727	55.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A586V (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S319F	0.5111	45.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S319F (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G562E	0.4545	66.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G562E (Missense)		SKCM_VARSCAN2	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.I187N	0.1667	36.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.I187N (Missense)		SKCM_VARSCAN2	TCGA-ER-A3ET-06A-11D-A20D-08	TCGA-ER-A3ET-10A-01D-A20D-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P336L	0.1687	83.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P336L (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.D633N	0.3485	66.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.D633N (Missense)		SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E1110K	0.5806	31.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E1110K (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1011E	0.2737	95.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1011E (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G818R	0.3243	74.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G818R (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P547L	0.3226	31.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P547L (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G558E	0.2692	52.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G558E (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.H458Y	0.3784	74.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.H458Y (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1304E	0.2927	82.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1304E (Missense)		SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G903E	0.1613	31.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G903E (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G391E	0.3333	72.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G391E (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R401Q	0.3051	59.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R401Q (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZQ-06A-41D-A372-08	TCGA-WE-A8ZQ-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.M1615I	0.3415	41.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.M1615I (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E483K	0.537	108.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E483K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E1242K	0.1286	70.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E1242K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29G-06A-12D-A196-08	TCGA-EE-A29G-10A-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.L601F	0.2979	47.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.L601F (Missense)		SKCM_VARSCAN2	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G935V	0.3491	106.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G935V (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G558V	0.1972	71.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G558V (Missense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.H682Y	0.4167	24.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.H682Y (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P381L	0.6136	44.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P381L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G410E	0.3462	78.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G410E (Missense)		SKCM_VARSCAN2	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G667E	0.2667	75.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G667E (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P675L	0.8264	121.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P675L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E668K	0.2025	79.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E668K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1269E	0.4035	57.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1269E (Missense)		SKCM_VARSCAN2	TCGA-D9-A149-06A-11D-A196-08	TCGA-D9-A149-10A-01D-A198-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.M910I	0.2	35.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.M910I (Missense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G359E	0.3571	140.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G359E (Missense)		SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G902E	0.1818	22.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G902E (Missense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G902R	0.1739	23.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G902R (Missense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E1242K	0.3529	51.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E1242K (Missense)		SKCM_VARSCAN2	TCGA-FS-A4F9-06A-11D-A24R-08	TCGA-FS-A4F9-10A-01D-A24R-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E296K	0.4737	114.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E296K (Missense)		SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G865D	0.3636	22.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G865D (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.D746Y	0.3469	49.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.D746Y (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.S773F	0.248	125.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.S773F (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E737K	0.3651	63.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E737K (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P57L	0.25	48.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P57L (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.S379T	0.1495	107.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.S379T (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3JE-06A-11D-A20D-08	TCGA-EE-A3JE-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R818C	0.2593	27.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R818C (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S102F	0.3684	19.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S102F (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.A14V	0.1376	109.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.A14V (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JH-06A-11D-A196-08	TCGA-D3-A2JH-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E890D	0.6	15.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E890D (Missense)		SKCM_VARSCAN2	TCGA-W3-AA21-06A-11D-A38G-08	TCGA-W3-AA21-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1401*	0.2075	53.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1401* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R2158*	0.3696	92.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2158* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S398F	0.2778	72.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S398F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.L150F	0.3279	61.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L150F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1200*	0.3778	45.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1200* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.L686F	0.2092	153.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L686F (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.D684N	0.24	150.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.D684N (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.P743L	0.4928	69.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.P743L (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q920*	0.5325	77.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q920* (Nonsense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.P430S	0.4848	99.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.P430S (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q789*	0.3582	67.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q789* (Nonsense)		SKCM_VARSCAN2	TCGA-WE-A8ZQ-06A-41D-A372-08	TCGA-WE-A8ZQ-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.R1879Sfs*22	0.514	107.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1879Sfs*22 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1528*	0.1724	58.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1528* (Nonsense)		SKCM_VARSCAN2	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S512L	0.4444	27.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S512L (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.F958S	0.2683	41.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.F958S (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.Y933F	0.3909	110.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.Y933F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P97L	0.2	60.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P97L (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.H290Y	0.2286	35.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.H290Y (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.P176S	0.2708	48.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.P176S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.A1109V	0.3855	83.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.A1109V (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S2168L	0.431	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S2168L (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A69P-06A-21D-A30X-08	TCGA-FR-A69P-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.H355Y	0.5165	91.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.H355Y (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A3F5-06A-11D-A20D-08	TCGA-DA-A3F5-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G878R	0.1692	65.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.G878R (Missense)	0	SKCM_VARSCAN2	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.V557I	0.2948	346.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.V557I (Missense)	0	SKCM_VARSCAN2	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E601K	0.3333	75.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E601K (Missense)	0	SKCM_VARSCAN2	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S516R	0.1923	26.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S516R (Missense)		SKCM_VARSCAN2	TCGA-D9-A1JW-06A-11D-A19A-08	TCGA-D9-A1JW-10A-01D-A19A-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.H194Y	0.5938	32.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.H194Y (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A1ZD-06A-11D-A197-08	TCGA-FS-A1ZD-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.S311F	0.1151	304.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.S311F (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XD-01A-22D-A23B-08	TCGA-EB-A3XD-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P2759S	0.3929	112.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.P2759S (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E994K	0.5417	48.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E994K (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.G436E	0.2857	14.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.G436E (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P1013S	0.4045	89.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P1013S (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V2937G	0.3294	170.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.V2937G (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V462A	0.3099	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.V462A (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.D912N	0.6471	17.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.D912N (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.R274P	0.38	100.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.R274P (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A2JL-06A-11D-A196-08	TCGA-D3-A2JL-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.D543N	0.128	125.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.D543N (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.2462	65.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R887C	0.1667	126.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R887C (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E17K	0.375	16.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E17K (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R549Q	0.4785	163.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R549Q (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R1148Q	0.1429	70.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R1148Q (Missense)	0	SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2272K	0.3571	28.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2272K (Missense)	1	SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2295K	0.3143	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2295K (Missense)	1	SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E132K	0.4576	59.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E132K (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E131D	0.4576	59.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E131D (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.P373S	0.2704	159.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.P373S (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.M630I	0.4035	171.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.M630I (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G694E	0.3082	146.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.G694E (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.M1160I	0.54	100.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.M1160I (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.H1351Y	0.521	167.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.H1351Y (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.R170C	0.1226	106.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.R170C (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JD-06A-11D-A20D-08	TCGA-EE-A3JD-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R469Q	0.3592	142.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R469Q (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.C430S	0.4255	47.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.C430S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G221E	0.2895	38.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G221E (Missense)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G282E	0.4545	22.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G282E (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.S447F	0.3077	182.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.S447F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2ML-06A-11D-A197-08	TCGA-EE-A2ML-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.D972N	0.26	50.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.D972N (Missense)	0	SKCM_VARSCAN2	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.P373S	0.3704	162.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.P373S (Missense)		SKCM_VARSCAN2	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P742L	0.1132	53.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P742L (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E1388K	0.291	134.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E1388K (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.G155S	0.3214	28.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.G155S (Missense)	0	SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E76K	0.2941	34.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E76K (Missense)	0	SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G429E	0.3385	65.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G429E (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S601F	0.3871	31.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S601F (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S525Y	0.2348	132.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S525Y (Missense)	0	SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.L1140F	0.2099	81.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.L1140F (Missense)	0	SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.S238L	0.1786	28.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.S238L (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A5ES-01A-11D-A27K-08	TCGA-BF-A5ES-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.G161V	0.4129	155.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.G161V (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A185-06A-11D-A196-08	TCGA-EE-A185-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.H1443Y	0.1471	136.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.H1443Y (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.C533R	0.4766	107.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.C533R (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P1069S	0.6111	36.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.P1069S (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G109E	0.2683	82.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.G109E (Missense)	0	SKCM_VARSCAN2	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G460D	0.1791	67.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.G460D (Missense)	0	SKCM_VARSCAN2	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.P449S	0.2571	70.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.P449S (Missense)	0	SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.F241L	0.3415	41.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.F241L (Missense)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.4857	35.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.K183N	0.1694	124.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.K183N (Missense)	0	SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.L679V	0.1646	79.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.L679V (Missense)	0	SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.M937I	0.2674	86.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.M937I (Missense)	0	SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2623F	0.9643	28.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2623F (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S1947Y	0.8571	42.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S1947Y (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2526K	0.2778	18.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2526K (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.P298L	0.3542	48.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.P298L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.G311D	0.569	58.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.G311D (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.A330V	0.3679	2354.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.A330V (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P1311L	0.4688	128.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P1311L (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R1312K	0.5588	34.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R1312K (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.S474F	0.1163	43.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.S474F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P1366S	0.4074	135.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P1366S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S135N	0.2063	252.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S135N (Missense)	0	SKCM_VARSCAN2	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.H2099Y	0.6	55.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.H2099Y (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A4XL-01A-11D-A27K-08	TCGA-EB-A4XL-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.T180S	0.5776	116.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.T180S (Missense)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R1148Q	0.2817	142.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R1148Q (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.L49V	0.6667	12.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.L49V (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.E588K	0.3333	48.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.E588K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E76K	0.4516	93.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E76K (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R457Q	0.3804	92.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R457Q (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G239R	0.1231	65.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G239R (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G239E	0.1385	65.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G239E (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.V256I	0.3614	83.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.V256I (Missense)	0	SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.G1057D	0.8889	9.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.G1057D (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.G1057S	0.8	10.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.G1057S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E567K	0.3519	162.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E567K (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G600E	0.2745	51.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G600E (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZS-06A-12D-A197-08	TCGA-FS-A1ZS-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P2056S	0.3	20.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.P2056S (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R613Q	0.375	48.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R613Q (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.3538	65.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		SKCM_VARSCAN2	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.P843S	0.5361	97.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.P843S (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V996I	0.1695	59.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V996I (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S33F	0.12	75.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S33F (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A2J7-06A-11D-A196-08	TCGA-D3-A2J7-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R1279K	0.3019	361.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R1279K (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.R357Q	0.2336	107.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.R357Q (Missense)		SKCM_VARSCAN2	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S653F	0.47	200.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S653F (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.P93S	0.7826	23.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.P93S (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R547Q	0.3415	123.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R547Q (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.P319S	0.2809	89.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.P319S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GN-06A-11D-A196-08	TCGA-EE-A2GN-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V158A	0.6566	166.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V158A (Missense)	0	SKCM_VARSCAN2	TCGA-LH-A9QB-06A-11D-A38G-08	TCGA-LH-A9QB-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.K2363N	0.8	15.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.K2363N (Missense)	1	SKCM_VARSCAN2	TCGA-LH-A9QB-06A-11D-A38G-08	TCGA-LH-A9QB-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.S56F	0.662	71.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.S56F (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E781K	0.1754	57.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E781K (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.H500Y	1.0	45.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.H500Y (Missense)		SKCM_VARSCAN2	TCGA-GN-A262-06A-11D-A196-08	TCGA-GN-A262-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2691C	0.2273	44.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2691C (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S213L	0.3567	171.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S213L (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.L226F	0.2182	55.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.L226F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A1323V	0.3196	97.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A1323V (Missense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P1919S	0.3778	45.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P1919S (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L1915H	0.3837	86.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L1915H (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.A215G	0.6604	53.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.A215G (Missense)		SKCM_VARSCAN2	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P1549S	0.2125	80.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P1549S (Missense)		SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D392G	0.4231	78.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D392G (Missense)		SKCM_VARSCAN2	TCGA-EB-A5SE-01A-11D-A30X-08	TCGA-EB-A5SE-10A-01D-A30X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P2088S	0.1169	77.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P2088S (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D42N	0.6184	76.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D42N (Missense)		SKCM_VARSCAN2	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R553C	0.4154	65.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R553C (Missense)		SKCM_VARSCAN2	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P418S	0.3214	140.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P418S (Missense)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A760V	0.411	382.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A760V (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.G963R	0.4857	105.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.G963R (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D647N	0.1702	47.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D647N (Missense)		SKCM_VARSCAN2	TCGA-EB-A85J-01A-12D-A34U-08	TCGA-EB-A85J-10B-01D-A34X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R623W	0.25	84.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R623W (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1382C	0.8594	64.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1382C (Missense)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.L406F	0.4109	129.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.L406F (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.D911N	0.5	8.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.D911N (Missense)		SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P1389S	0.1124	89.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P1389S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R126C	0.3542	48.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R126C (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.S1687F	0.3333	60.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.S1687F (Missense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.N1036K	0.2157	51.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.N1036K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.P208L	0.3333	66.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.P208L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L607F	0.2895	38.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L607F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A0-06A-11D-A196-08	TCGA-EE-A2A0-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P1164L	0.2143	70.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P1164L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.7857	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		SKCM_VARSCAN2	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2143	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		SKCM_VARSCAN2	TCGA-EB-A299-01A-21D-A197-08	TCGA-EB-A299-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179Y	0.5227	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179Y (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP2-01A-11D-A401-08	TCGA-BF-AAP2-10A-01D-A401-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278S	0.5	18.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278S (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.4725	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		SKCM_VARSCAN2	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.1765	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.2593	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		SKCM_VARSCAN2	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.7917	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.6667	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.6667	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S215R	0.38	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S215R (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.3077	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P27S	0.9273	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P27S (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151L	0.1333	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151S	0.1667	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P27S	0.1818	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P27S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P191L	0.4054	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P191L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P152L	0.3971	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P152L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.6842	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.8947	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.8378	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		SKCM_VARSCAN2	TCGA-ER-A3ET-06A-11D-A20D-08	TCGA-ER-A3ET-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E198*	0.6364	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E198* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C141G	0.2903	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C141G (Missense)		SKCM_VARSCAN2	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.5577	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		SKCM_VARSCAN2	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P27L	0.5224	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P27L (Missense)		SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.2222	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R290C	0.4848	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R290C (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A159V	0.4444	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159V (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.5	18.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		SKCM_VARSCAN2	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R110P	0.7544	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R110P (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.434	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GR-06A-11D-A27K-08	TCGA-D3-A5GR-10A-01D-A27N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.5769	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.2188	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Y327*	0.9149	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y327* (Nonsense)		SKCM_VARSCAN2	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S127F	0.2121	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S127F (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179Y	0.8667	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179Y (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	1.0	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.3333	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P72S	0.2941	136.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P72S (Missense)		SKCM_VARSCAN2	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.3827	81.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.6842	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.72	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.4731	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L330R	0.6875	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L330R (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.5217	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.644	323.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.8056	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.6875	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A2MQ-06A-11D-A197-08	TCGA-EE-A2MQ-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.8421	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R213Q	0.6098	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K120E	0.5152	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K120E (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HW-06A-11D-A19A-08	TCGA-DA-A1HW-10A-01D-A19A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.7692	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.8545	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V97Sfs*26	0.1667	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V97Sfs*26 (Frameshift)		SKCM_VARSCAN2	TCGA-FS-A1Z4-06A-11D-A197-08	TCGA-FS-A1Z4-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V143G	0.9333	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V143G (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.68	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		SKCM_VARSCAN2	TCGA-BF-A1Q0-01A-21D-A19A-08	TCGA-BF-A1Q0-10A-01D-A19A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V143E	0.7059	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V143E (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P177L	0.1212	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P177L (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.C275*	0.7727	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275* (Nonsense)		SKCM_VARSCAN2	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F134L	0.3673	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F134L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278L	0.6842	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29X-06A-11D-A196-08	TCGA-EE-A29X-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.2	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2GT-06A-12D-A197-08	TCGA-EE-A2GT-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.I195Sfs*52	0.5	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195Sfs*52 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P177L	0.5581	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P177L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.122	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A3C8-06A-12D-A19A-08	TCGA-D3-A3C8-10A-01D-A19A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275Y	0.9	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Y (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.A276Lfs*29	0.65	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A276Lfs*29 (Frameshift)		SKCM_VARSCAN2	TCGA-FS-A4F9-06A-11D-A24R-08	TCGA-FS-A4F9-10A-01D-A24R-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G187S	0.3462	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G187S (Missense)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D48N	0.5945	582.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D48N (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F134L	0.9444	18.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F134L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J8-06A-11D-A20D-08	TCGA-EE-A3J8-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.9412	17.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.7812	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A841V	0.1842	38.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A841V (Missense)		SKCM_VARSCAN2	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A206V	0.3708	89.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A206V (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.R764G	0.3134	67.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.R764G (Missense)		SKCM_VARSCAN2	TCGA-ER-A2NE-06A-21D-A196-08	TCGA-ER-A2NE-10A-01D-A198-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S742F	0.2632	38.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S742F (Missense)		SKCM_VARSCAN2	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S348L	0.1186	59.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S348L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P982L	0.1157	121.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P982L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P1108L	0.4828	29.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P1108L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P310T	0.203	133.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P310T (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P310L	0.2045	132.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P310L (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P971S	0.301	103.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P971S (Missense)		SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S420F	0.3636	44.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S420F (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S709F	0.3673	49.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S709F (Missense)		SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P971S	0.14	100.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P971S (Missense)		SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A206V	0.6765	34.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A206V (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZF-06A-12D-A197-08	TCGA-FS-A1ZF-10A-01D-A199-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.G303R	0.4615	13.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.G303R (Missense)		SKCM_VARSCAN2	TCGA-D9-A148-06A-11D-A19A-08	TCGA-D9-A148-10A-01D-A19A-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.T277I	0.3333	45.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.T277I (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P551L	0.4483	29.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P551L (Missense)		SKCM_VARSCAN2	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P561S	0.4468	47.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P561S (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P918L	0.2941	34.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P918L (Missense)		SKCM_VARSCAN2	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.F57V	0.259	139.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.F57V (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.R787Q	0.7222	72.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R787Q (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.P381L	0.3462	26.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.P381L (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.G578R	0.3462	78.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.G578R (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.F57L	0.1585	82.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.F57L (Missense)		SKCM_VARSCAN2	TCGA-ER-A19N-06A-11D-A197-08	TCGA-ER-A19N-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.P291L	0.4167	12.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.P291L (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.P291S	0.3636	11.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.P291S (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D605N	0.6444	45.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D605N (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E645K	0.5	10.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E645K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D696N	0.2727	33.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D696N (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E830K	0.2	20.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E830K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E669K	0.8889	18.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E669K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.D71N	0.3935	155.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.D71N (Missense)		SKCM_VARSCAN2	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.F57L	0.5	70.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.F57L (Missense)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.P128L	0.1077	65.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.P128L (Missense)		SKCM_VARSCAN2	TCGA-D9-A4Z2-01A-11D-A24R-08	TCGA-D9-A4Z2-10A-01D-A24R-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D605N	0.3913	23.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D605N (Missense)		SKCM_VARSCAN2	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E541K	0.84	25.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E541K (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.D71N	0.3816	76.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.D71N (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.T919I	0.6667	33.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.T919I (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D733N	0.1622	37.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D733N (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E238K	0.24	25.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E238K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.E207K	0.5	14.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.E207K (Missense)		SKCM_VARSCAN2	TCGA-RP-A693-06A-13D-A30X-08	TCGA-RP-A693-10A-01D-A30X-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.M833I	0.7143	28.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.M833I (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.L46F	0.1375	80.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.L46F (Missense)		SKCM_VARSCAN2	TCGA-FS-A4F8-06A-11D-A25O-08	TCGA-FS-A4F8-10B-01D-A25O-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E289K	0.2105	19.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E289K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.Y448H	0.3795	224.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.Y448H (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P465S	0.1406	64.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P465S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P198S	0.3922	51.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P198S (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A630G	0.5505	109.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A630G (Missense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Nonsense	p.W153*	0.9136	81.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.W153* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.M197Wfs*28	0.5207	169.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.M197Wfs*28 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P106L	0.2121	99.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P106L (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.S229F	0.271	107.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.S229F (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P563S	0.2886	201.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P563S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D925E	0.3725	51.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D925E (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.H1256Y	0.5	16.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.H1256Y (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P49S	0.3125	16.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P49S (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E599K	0.2308	39.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E599K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G176E	0.3467	150.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G176E (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E979K	0.3354	161.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E979K (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S1443L	0.3824	34.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S1443L (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Splice Site	p.X1080_splice	0.2083	96.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.X1080_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.D894G	0.3243	37.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.D894G (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JL-06A-11D-A196-08	TCGA-D3-A2JL-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P115L	0.3043	46.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P115L (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.R1297C	0.4118	34.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R1297C (Missense)		SKCM_VARSCAN2	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R184K	0.3019	53.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R184K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S886L	0.175	40.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S886L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K267E	0.3148	54.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.K267E (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S259F	0.2188	64.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S259F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29P-06A-11D-A197-08	TCGA-EE-A29P-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G1045E	0.3103	29.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G1045E (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.E428K	0.4337	83.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E428K (Missense)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P1255L	0.4318	44.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P1255L (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.G685E	0.3	70.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.G685E (Missense)		SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.T156I	0.2202	218.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.T156I (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P405S	0.2093	43.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P405S (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.A242V	0.1444	90.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.A242V (Missense)		SKCM_VARSCAN2	TCGA-FR-A44A-06A-11D-A24R-08	TCGA-FR-A44A-10A-01D-A24R-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G638R	0.3182	66.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G638R (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UM-01A-11D-A30X-08	TCGA-EB-A5UM-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P351L	0.2394	71.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P351L (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P351S	0.2464	69.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P351S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P462S	0.3951	81.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P462S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P76S	0.2368	38.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P76S (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D61N	0.1463	41.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D61N (Missense)		SKCM_VARSCAN2	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L174F	0.1882	170.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L174F (Missense)		SKCM_VARSCAN2	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S606F	0.1733	75.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S606F (Missense)		SKCM_VARSCAN2	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L1173F	0.2	75.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L1173F (Missense)		SKCM_VARSCAN2	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P1003S	0.2481	133.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P1003S (Missense)		SKCM_VARSCAN2	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.Y898H	0.2414	58.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.Y898H (Missense)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S944N	0.1569	51.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S944N (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.M1060I	0.3889	54.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.M1060I (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S1282R	0.2692	52.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S1282R (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Splice Site	p.X866_splice	0.2857	28.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.X866_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A51J-06A-11D-A25O-08	TCGA-D3-A51J-10A-01D-A25O-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P742L	0.4412	34.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P742L (Missense)		SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P1255L	0.5152	33.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P1255L (Missense)		SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A1217V	0.6042	48.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A1217V (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.R1033*	0.7551	49.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R1033* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L1197F	0.2584	89.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L1197F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R530Q	0.3629	124.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R530Q (Missense)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P566L	0.4484	223.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P566L (Missense)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.D564E	0.617	47.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.D564E (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R987W	0.4437	151.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R987W (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P370L	0.3243	74.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P370L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P228S	0.383	47.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P228S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Nonsense	p.Q534*	0.1167	60.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.Q534* (Nonsense)		SKCM_VARSCAN2	TCGA-D9-A148-06A-11D-A19A-08	TCGA-D9-A148-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P419T	0.2037	54.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P419T (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D76N	0.5278	72.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D76N (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P563S	0.2556	180.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P563S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P491S	0.4044	136.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P491S (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P812S	0.3038	79.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P812S (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P742L	0.875	8.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P742L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P110S	0.125	64.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P110S (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Nonsense	p.R378*	0.6585	82.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R378* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A361T	0.3333	66.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A361T (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P274L	0.308	250.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P274L (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y6-01A-21D-A23B-08	TCGA-EB-A3Y6-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R626Q	0.413	46.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R626Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P983S	0.4474	114.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P983S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.H649Y	0.3429	35.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.H649Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A5-06A-11D-A197-08	TCGA-EE-A2A5-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E1160K	0.2727	44.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E1160K (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.E104Dfs*7	0.2889	180.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.E104Dfs*7 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A29T-06A-11D-A197-08	TCGA-EE-A29T-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P453L	0.2636	110.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P453L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P453S	0.2545	110.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P453S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.W860Lfs*4	0.6	30.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.W860Lfs*4 (Frameshift)		SKCM_VARSCAN2	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E1352K	0.24	50.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E1352K (Missense)		SKCM_VARSCAN2	TCGA-Z2-AA3V-06A-11D-A397-08	TCGA-Z2-AA3V-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R942Q	0.2174	23.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R942Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R749C	0.2136	103.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R749C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A1-06A-11D-A197-08	TCGA-EE-A2A1-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P696L	0.2778	18.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P696L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GN-06A-11D-A196-08	TCGA-EE-A2GN-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G821E	0.8571	49.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G821E (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S373L	0.9429	35.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.S373L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E744K	0.2937	143.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E744K (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P85S	0.6957	23.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P85S (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R133Q	0.1277	47.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R133Q (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JH-06A-11D-A196-08	TCGA-D3-A2JH-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P1128S	0.2338	77.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P1128S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.P279L	0.6852	54.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.P279L (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D908N	0.4762	105.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D908N (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P1091L	0.3864	132.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P1091L (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U7-06A-21D-A32N-08	TCGA-GN-A4U7-10B-01D-A32N-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R130K	0.3837	86.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R130K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.P870L	0.1639	61.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.P870L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R487C	0.3662	71.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R487C (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.F560S	0.3205	78.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.F560S (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.T1066I	0.9111	45.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.T1066I (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E1001K	0.2778	36.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E1001K (Missense)		SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.P727L	0.3083	133.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.P727L (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S904F	0.75	20.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S904F (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P1101S	0.5926	27.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P1101S (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P397S	0.1667	24.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P397S (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P1101S	0.84	25.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P1101S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E1076K	0.1231	65.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E1076K (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP0-06A-11D-A397-08	TCGA-BF-AAP0-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S1115F	0.3016	126.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S1115F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.Q1587H	0.7143	21.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.Q1587H (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S526L	0.5405	37.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.S526L (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UL-06A-11D-A30X-08	TCGA-EB-A5UL-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.K889N	0.2447	94.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.K889N (Missense)		SKCM_VARSCAN2	TCGA-BF-AAOU-01A-12D-A397-08	TCGA-BF-AAOU-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.L1047I	0.3611	36.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.L1047I (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.T796I	0.2678	183.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.T796I (Missense)		SKCM_VARSCAN2	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S126N	0.3906	64.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S126N (Missense)		SKCM_VARSCAN2	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.T715S	0.8293	41.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.T715S (Missense)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D1628E	0.5625	16.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D1628E (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Deletion	p.V600_K601delinsE	0.4359	156.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600_K601delinsE (Deletion)	1	SKCM_VARSCAN2	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Nonsense	p.L485*	0.5455	55.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L485* (Nonsense)	1	SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Deletion	p.N486_P490del	0.2564	78.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.N486_P490del (Deletion)	1	SKCM_VARSCAN2	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1876K	0.4459	74.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1876K (Missense)	0	SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Frameshift	p.F1003*	0.19	100.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.F1003* (Frameshift)	0	SKCM_VARSCAN2	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L35F	0.3294	85.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L35F (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P555L	0.4407	59.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P555L (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2307L	0.36	25.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2307L (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P1702L	0.375	40.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P1702L (Missense)	0	SKCM_VARSCAN2	TCGA-XV-AAZW-01A-12D-A401-08	TCGA-XV-AAZW-10A-01D-A401-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.N113K	0.447	132.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.N113K (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	RET	Nonsense	p.W85*	0.2	35.0	0.0	0.0		Investigate Actionability	Selpercatinib	RET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.	Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.W85* (Nonsense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P606L	0.2297	74.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P606L (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.H1752Y	0.3117	77.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.H1752Y (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P3324L	0.2838	74.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P3324L (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.H513Y	0.3023	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.H513Y (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.Q202*	0.4211	19.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.Q202* (Nonsense)	0	SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.R316K	0.45	40.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.R316K (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A51E-06A-11D-A25O-08	TCGA-D3-A51E-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P740S	0.4217	83.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P740S (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.T1087I	0.3441	93.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T1087I (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q3398H	0.2963	54.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q3398H (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P985L	0.3261	92.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P985L (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D1547E	0.3302	106.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D1547E (Missense)	0	SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P606S	0.7667	30.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P606S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P2107S	0.283	53.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P2107S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2ML-06A-11D-A197-08	TCGA-EE-A2ML-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2067F	0.3636	33.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2067F (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E272K	0.1622	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E272K (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P493L	0.4091	66.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P493L (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2695L	0.3113	106.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2695L (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.S1211F	0.1463	41.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.S1211F (Missense)	1	SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.K1264E	0.3182	66.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K1264E (Missense)	0	SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.L269V	0.2593	54.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.L269V (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.F1092L	0.5755	106.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.F1092L (Missense)	0	SKCM_VARSCAN2	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L2917F	0.4286	28.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L2917F (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	RET	Splice Site	p.X25_splice	0.3485	66.0	0.0	0.0		Investigate Actionability	Selpercatinib	RET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.	Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.X25_splice (Splice Site)		SKCM_VARSCAN2	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	RET	Splice Site	p.X290_splice	0.1562	32.0	0.0	0.0		Investigate Actionability	Selpercatinib	RET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.	Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.X290_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.H334Y	0.3211	109.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.H334Y (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MP-06A-11D-A197-08	TCGA-EE-A2MP-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R1589C	0.245	200.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R1589C (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E402K	0.4364	55.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E402K (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P1749S	0.2581	310.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P1749S (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L1598F	0.2909	110.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L1598F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A17Y-06A-11D-A196-08	TCGA-EE-A17Y-10B-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S3252F	0.3163	98.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S3252F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P747L	0.2171	152.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P747L (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A728-01A-11D-A32N-08	TCGA-FR-A728-10A-01D-A32N-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G2529S	0.29	100.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.G2529S (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G2529D	0.299	97.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.G2529D (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2704F	0.1667	60.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2704F (Missense)	0	SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P375S	0.3864	440.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P375S (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P2187L	0.45	80.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P2187L (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E1214D	0.4474	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E1214D (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A4Z3-01A-11D-A25O-08	TCGA-D9-A4Z3-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P832S	0.4298	114.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P832S (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A4Z3-01A-11D-A25O-08	TCGA-D9-A4Z3-10A-01D-A25O-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P606L	0.3592	103.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P606L (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S1792F	0.4179	67.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S1792F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E626K	0.22	50.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E626K (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MK-06A-11D-A196-08	TCGA-EE-A2MK-10A-01D-A198-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P1859S	0.3	30.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P1859S (Missense)	1	SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.339	59.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-BF-A5ER-01A-12D-A27K-08	TCGA-BF-A5ER-10A-01D-A27N-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Splice Site	p.X174_splice	0.3833	60.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.X174_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.181	105.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-ER-A42L-06A-11D-A24R-08	TCGA-ER-A42L-10A-01D-A24R-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.1346	52.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-EE-A29P-06A-11D-A197-08	TCGA-EE-A29P-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2857	56.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3889	36.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.P33S	0.1324	68.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.P33S (Missense)		SKCM_VARSCAN2	TCGA-BF-A1PX-01A-12D-A19A-08	TCGA-BF-A1PX-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.4231	78.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Insertion	p.Y503delinsFAH	0.4105	95.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.Y503delinsFAH (Insertion)	0	SKCM_VARSCAN2	TCGA-FS-A1ZJ-06A-12D-A197-08	TCGA-FS-A1ZJ-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.P33S	0.2222	63.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.P33S (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.4432	88.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-ER-A3ES-06A-11D-A20D-08	TCGA-ER-A3ES-10A-01D-A20D-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.451	51.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2576	66.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2836	67.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Frameshift	p.V121Cfs*23	0.3163	98.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.V121Cfs*23 (Frameshift)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.E361K	0.2727	44.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.E361K (Missense)		SKCM_VARSCAN2	TCGA-RP-A693-06A-13D-A30X-08	TCGA-RP-A693-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3415	82.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132L	0.4211	38.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132L (Missense)		SKCM_VARSCAN2	TCGA-D9-A149-06A-11D-A196-08	TCGA-D9-A149-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.4143	70.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-GN-A268-06A-11D-A196-08	TCGA-GN-A268-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2688	93.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3861	101.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132L	0.2667	75.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132L (Missense)		SKCM_VARSCAN2	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.P33S	0.3218	87.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.P33S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.5349	86.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J8-06A-11D-A20D-08	TCGA-EE-A3J8-10A-01D-A20D-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P1077S	0.3409	44.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P1077S (Missense)	0	SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.R160C	0.2535	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.R160C (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P454S	0.2609	69.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P454S (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P411S	0.2617	107.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P411S (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P845S	0.2887	97.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P845S (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.F495I	0.3649	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.F495I (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.A527V	0.4828	29.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.A527V (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A2JC-06A-11D-A19A-08	TCGA-D3-A2JC-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S895F	0.4737	95.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S895F (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.P182S	0.6833	60.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.P182S (Missense)	0	SKCM_VARSCAN2	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Nonsense	p.R237*	0.2727	121.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.R237* (Nonsense)	1	SKCM_VARSCAN2	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.S296F	0.2394	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.S296F (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Nonsense	p.Q685*	0.3268	205.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.Q685* (Nonsense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.H317Y	0.1135	185.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.H317Y (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P47L	0.1552	116.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.P47L (Missense)	1	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.N118K	0.371	62.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.N118K (Missense)	0	SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.A435V	0.5333	15.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.A435V (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.F1071S	0.3548	31.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.F1071S (Missense)	0	SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.I983S	0.3846	39.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.I983S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.Q559*	0.1667	30.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.Q559* (Nonsense)	1	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.R249C	0.3592	103.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.R249C (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.F328S	0.381	63.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.F328S (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P1101L	0.3356	149.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.P1101L (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E892K	0.1188	101.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E892K (Missense)	0	SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.V917D	0.2857	21.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.V917D (Missense)	0	SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.G304E	0.3115	61.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.G304E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.P90S	0.4062	32.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.P90S (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Splice Site	p.X598_splice	0.4182	110.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.X598_splice (Splice Site)	1	SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.L1170F	0.3214	84.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.L1170F (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P113S	0.3148	54.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P113S (Missense)	0	SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.G162R	0.2317	82.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.G162R (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P1238S	0.4222	90.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.P1238S (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.G345R	0.8462	13.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.G345R (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A5UL-06A-11D-A30X-08	TCGA-EB-A5UL-10A-01D-A30X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P707S	0.4231	78.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P707S (Missense)	0	SKCM_VARSCAN2	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S206L	0.3636	77.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S206L (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.R249C	0.3967	121.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.R249C (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q4-06A-11D-A196-08	TCGA-D3-A1Q4-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S644L	0.4624	93.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S644L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.P90S	0.1842	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.P90S (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P1246L	0.2535	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.P1246L (Missense)	1	SKCM_VARSCAN2	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.Q1056*	0.2368	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.Q1056* (Nonsense)	1	SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Splice Site	p.X831_splice	0.5436	149.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.X831_splice (Splice Site)	1	SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S835P	0.1842	76.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S835P (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.G190E	0.3429	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.G190E (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.L679F	0.2586	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.L679F (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P812S	0.4394	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P812S (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.R21L	0.5185	27.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.R21L (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Frameshift	p.K1040Dfs*4	0.173	318.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.K1040Dfs*4 (Frameshift)	1	SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P1264L	0.5714	28.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P1264L (Missense)		SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.S212F	0.2703	37.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.S212F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P1098L	0.7692	13.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P1098L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.A12V	0.6304	46.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.A12V (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P589S	0.3824	34.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P589S (Missense)		SKCM_VARSCAN2	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.H230Y	0.1818	44.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.H230Y (Missense)		SKCM_VARSCAN2	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P683S	0.2529	87.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P683S (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P222L	0.2169	83.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P222L (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P568L	0.35	180.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P568L (Missense)	0	SKCM_VARSCAN2	TCGA-WE-A8ZO-06A-11D-A372-08	TCGA-WE-A8ZO-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.E340K	0.4753	162.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.E340K (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A4F0-06A-11D-A24R-08	TCGA-FS-A4F0-10A-01D-A24R-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.L177F	0.2468	154.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.L177F (Missense)		SKCM_VARSCAN2	TCGA-ER-A19N-06A-11D-A197-08	TCGA-ER-A19N-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.D386N	0.6145	83.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.D386N (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P961S	0.311	164.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P961S (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.Q944*	0.5435	46.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.Q944* (Nonsense)	0	SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.L171H	0.1722	151.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.L171H (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.R1097C	0.5238	42.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.R1097C (Missense)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.T209I	0.3784	37.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.T209I (Missense)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P878S	0.4138	29.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P878S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S987F	0.5068	73.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S987F (Missense)	0	SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P768L	0.3646	96.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P768L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.M1326I	0.2727	33.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.M1326I (Missense)		SKCM_VARSCAN2	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.R908Q	0.1895	153.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.R908Q (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Splice Site	p.X421_splice	0.1058	104.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.X421_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.E660K	0.28	50.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.E660K (Missense)	0	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1005L	0.2887	97.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P1005L (Missense)	0	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.S575F	0.5652	46.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.S575F (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.G193R	0.2329	73.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.G193R (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.I871L	0.3571	56.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.I871L (Missense)		SKCM_VARSCAN2	TCGA-EB-A41B-01A-11D-A24R-08	TCGA-EB-A41B-10A-01D-A24R-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1313S	0.3252	163.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P1313S (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A41B-01A-11D-A24R-08	TCGA-EB-A41B-10A-01D-A24R-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.P1675L	0.2941	34.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.P1675L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.Q1291Rfs*3	0.1271	181.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.Q1291Rfs*3 (Frameshift)	0	SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1398L	0.381	63.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P1398L (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R882W	0.3684	114.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R882W (Missense)	0	SKCM_VARSCAN2	TCGA-BF-A3DN-01A-11D-A20D-08	TCGA-BF-A3DN-10A-01D-A20D-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S1306F	0.2137	248.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S1306F (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R773C	0.4	30.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R773C (Missense)	0	SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.S30Y	0.2444	90.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.S30Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A17Y-06A-11D-A196-08	TCGA-EE-A17Y-10B-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.S1220T	0.3719	121.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.S1220T (Missense)		SKCM_VARSCAN2	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.T1206A	0.3571	70.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.T1206A (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.L796F	0.2188	32.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.L796F (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P585L	0.313	246.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P585L (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.E1757K	0.25	80.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.E1757K (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R1067Q	0.3939	132.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R1067Q (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P545L	0.2626	99.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P545L (Missense)	0	SKCM_VARSCAN2	TCGA-Z2-AA3V-06A-11D-A397-08	TCGA-Z2-AA3V-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.L1137F	0.2742	124.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.L1137F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P629S	0.4606	165.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P629S (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	ERBB2	Nonsense	p.Q156*	0.3867	75.0	0.0	0.0		Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	Ado-trasuzumab emtansine is an available targeted agent with activity against ERBB2 variants in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf																	ERBB2 p.Q156* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P465L	0.1562	64.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P465L (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JH-06A-11D-A196-08	TCGA-D3-A2JH-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L14P	0.3571	14.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L14P (Missense)		SKCM_VARSCAN2	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P46L	0.4375	32.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P46L (Missense)		SKCM_VARSCAN2	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.H682Y	0.3276	58.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.H682Y (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.K1094I	0.4762	42.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.K1094I (Missense)		SKCM_VARSCAN2	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.G614E	0.6552	29.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G614E (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.E219K	0.197	66.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E219K (Missense)		SKCM_VARSCAN2	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.T946I	0.2708	48.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.T946I (Missense)		SKCM_VARSCAN2	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.G92R	0.28	100.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G92R (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.G105R	0.3291	79.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G105R (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P474S	0.129	62.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P474S (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P474L	0.1452	62.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P474L (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S327L	0.6207	29.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S327L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Nonsense	p.W549*	0.1313	99.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.W549* (Nonsense)	0	SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.T1069A	0.3867	75.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.T1069A (Missense)		SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P555L	0.2344	64.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P555L (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S268L	0.24	50.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S268L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.N488S	0.2745	102.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.N488S (Missense)		SKCM_VARSCAN2	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Splice Site	p.X374_splice	0.1935	93.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.X374_splice (Splice Site)	0	SKCM_VARSCAN2	TCGA-FS-A1ZB-06A-12D-A197-08	TCGA-FS-A1ZB-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.E320K	0.4167	24.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E320K (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.H762Y	0.6042	48.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.H762Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.R550Q	0.1765	68.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.R550Q (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L596F	0.2273	88.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L596F (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P1013L	0.4	40.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P1013L (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P408L	0.5357	84.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P408L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Splice Site	p.X123_splice	0.45	100.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.X123_splice (Splice Site)	0	SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Splice Site	p.X775_splice	0.413	46.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.X775_splice (Splice Site)	0	SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S391F	0.3333	72.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S391F (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Nonsense	p.Q61*	0.3421	915.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61* (Nonsense)	1	SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Frameshift	p.Y157Lfs*19	0.4615	91.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Y157Lfs*19 (Frameshift)	1	SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Nonsense	p.Q1301*	0.3826	149.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.Q1301* (Nonsense)		SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Nonsense	p.G777*	0.3636	99.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.G777* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.H1408Y	0.2574	101.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.H1408Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Frameshift	p.A805Gfs*22	0.2113	71.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.A805Gfs*22 (Frameshift)		SKCM_VARSCAN2	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P1225S	0.2273	44.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1225S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GE-06A-11D-A196-08	TCGA-EE-A2GE-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.D380V	0.3182	22.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.D380V (Missense)		SKCM_VARSCAN2	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P179S	0.3725	51.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P179S (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.S490F	0.6132	106.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.S490F (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.R1423C	0.2651	83.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.R1423C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.P314S	0.552	125.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.P314S (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JG-06A-11D-A196-08	TCGA-D3-A2JG-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Nonsense	p.R326*	0.9615	26.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R326* (Nonsense)	0	SKCM_VARSCAN2	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.S307L	0.3037	191.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.S307L (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.P284T	0.3224	152.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.P284T (Missense)	0	SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.H1228Y	0.2586	58.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.H1228Y (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.K763E	0.3252	163.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.K763E (Missense)		SKCM_VARSCAN2	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.V474M	0.2857	35.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.V474M (Missense)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R1096C	0.4384	146.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1096C (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.Q395*	0.7857	70.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.Q395* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.E46K	0.2857	91.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.E46K (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.S457F	0.339	59.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.S457F (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.S869L	0.1538	143.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.S869L (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.H1152Y	0.2667	105.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.H1152Y (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.P354S	0.2609	115.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.P354S (Missense)	0	SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.N589D	0.3402	97.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N589D (Missense)		SKCM_VARSCAN2	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R876C	0.2727	33.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R876C (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.K1270Q	0.4762	63.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K1270Q (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JK-06A-11D-A196-08	TCGA-D3-A2JK-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Nonsense	p.W112*	0.3889	72.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.W112* (Nonsense)		SKCM_VARSCAN2	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.S677I	0.2308	156.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.S677I (Missense)		SKCM_VARSCAN2	TCGA-ER-A19D-06A-11D-A197-08	TCGA-ER-A19D-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P313S	0.5698	86.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P313S (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Nonsense	p.Y553*	0.1667	102.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y553* (Nonsense)	0	SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.K702T	0.122	82.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K702T (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.V1184A	0.4068	59.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V1184A (Missense)		SKCM_VARSCAN2	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.P333S	0.1655	139.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.P333S (Missense)	0	SKCM_VARSCAN2	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.P973S	0.3636	55.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.P973S (Missense)		SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.K155R	0.1224	49.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.K155R (Missense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.G338R	0.3853	109.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.G338R (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.Q462*	0.2667	60.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.Q462* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.L1672M	0.8387	93.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L1672M (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.D758N	0.5381	236.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.D758N (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Nonsense	p.Q698*	0.1154	52.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Q698* (Nonsense)	0	SKCM_VARSCAN2	TCGA-BF-A1Q0-01A-21D-A19A-08	TCGA-BF-A1Q0-10A-01D-A19A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Nonsense	p.R580*	0.2899	69.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R580* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.R121C	0.325	120.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R121C (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.G230E	0.2222	27.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.G230E (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.G230R	0.1923	26.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.G230R (Missense)	0	SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P412L	0.1573	89.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P412L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.G306R	0.1958	240.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.G306R (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.G306E	0.1909	241.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.G306E (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.D530V	0.4082	49.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.D530V (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.R1068Q	0.3947	38.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R1068Q (Missense)		SKCM_VARSCAN2	TCGA-EB-A97M-01A-11D-A38G-08	TCGA-EB-A97M-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.L1316F	0.1985	131.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.L1316F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GT-06A-12D-A197-08	TCGA-EE-A2GT-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.P326S	0.6042	192.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.P326S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.N528S	0.1489	47.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N528S (Missense)		SKCM_VARSCAN2	TCGA-D3-A3C8-06A-12D-A19A-08	TCGA-D3-A3C8-10A-01D-A19A-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R1062Q	0.4211	57.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1062Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.G371E	0.73	100.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.G371E (Missense)	0	SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.R680*	0.2833	60.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R680* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A553-01A-12D-A27K-08	TCGA-EB-A553-10A-01D-A27N-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.D80N	0.1959	97.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.D80N (Missense)		SKCM_VARSCAN2	TCGA-ER-A19W-06A-41D-A23B-08	TCGA-ER-A19W-10A-01D-A23B-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.G166E	0.4773	132.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.G166E (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.I8T	0.1716	169.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.I8T (Missense)	1	SKCM_VARSCAN2	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.L108P	0.9016	61.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.L108P (Missense)	1	SKCM_VARSCAN2	TCGA-FS-A1ZD-06A-11D-A197-08	TCGA-FS-A1ZD-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P89L	0.3	20.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P89L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2JC-06A-11D-A19A-08	TCGA-D3-A2JC-10A-01D-A19A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.E43K	0.6818	44.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E43K (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A42K-06A-11D-A24R-08	TCGA-ER-A42K-10A-01D-A24R-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Insertion	p.V275_N276insI	0.1429	35.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.V275_N276insI (Insertion)	1	SKCM_VARSCAN2	TCGA-GN-A4U5-01A-11D-A32N-08	TCGA-GN-A4U5-10B-01D-A32N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.M264R	0.4328	67.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.M264R (Missense)	1	SKCM_VARSCAN2	TCGA-EB-A42Y-01A-12D-A24R-08	TCGA-EB-A42Y-10A-01D-A24R-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.L108F	0.7083	96.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.L108F (Missense)	1	SKCM_VARSCAN2	TCGA-BF-A5EP-01A-12D-A27K-08	TCGA-BF-A5EP-10A-01D-A27N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P38S	0.2778	36.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P38S (Missense)	1	SKCM_VARSCAN2	TCGA-HR-A2OH-06A-11D-A197-08	TCGA-HR-A2OH-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P38L	0.2778	36.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P38L (Missense)	1	SKCM_VARSCAN2	TCGA-HR-A2OH-06A-11D-A197-08	TCGA-HR-A2OH-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.G251V	0.9444	18.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.G251V (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A17Z-06A-11D-A196-08	TCGA-EE-A17Z-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.F257L	0.4054	74.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.F257L (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A8GD-06A-11D-A372-08	TCGA-D3-A8GD-10A-01D-A375-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P38S	0.3438	32.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P38S (Missense)	1	SKCM_VARSCAN2	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.Y177F	0.8571	42.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y177F (Missense)	1	SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.Y29S	0.6875	16.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y29S (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.C105G	0.1642	67.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.C105G (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A2J8-06A-11D-A196-08	TCGA-D3-A2J8-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P246S	0.4028	72.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P246S (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P246L	0.3973	73.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P246L (Missense)	1	SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R130L	0.6596	47.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130L (Missense)	1	SKCM_VARSCAN2	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.G165E	0.32	50.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.G165E (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A1Q4-06A-11D-A196-08	TCGA-D3-A1Q4-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P38S	0.3111	45.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P38S (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.C136R	0.7593	54.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.C136R (Missense)	1	SKCM_VARSCAN2	TCGA-D3-A3C6-06A-12D-A196-08	TCGA-D3-A3C6-10A-01D-A198-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.H272R	0.75	8.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.H272R (Missense)	1	SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Nonsense	p.K175*	0.2667	90.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.K175* (Nonsense)	0	SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Nonsense	p.W247*	0.2565	191.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.W247* (Nonsense)	0	SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Nonsense	p.Q989*	0.3511	131.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.Q989* (Nonsense)	0	SKCM_VARSCAN2	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Nonsense	p.Q167*	0.1481	54.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.Q167* (Nonsense)		SKCM_VARSCAN2	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Frameshift	p.C928Afs*11	0.35	20.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.C928Afs*11 (Frameshift)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1747S	0.7397	73.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1747S (Missense)		SKCM_VARSCAN2	TCGA-FR-A69P-06A-21D-A30X-08	TCGA-FR-A69P-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P2077S	0.4074	54.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P2077S (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G2087R	0.4023	87.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G2087R (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G2087E	0.4091	88.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G2087E (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AF-06A-11D-A196-08	TCGA-EE-A3AF-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P531L	0.3529	119.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P531L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R1262C	0.4727	55.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1262C (Missense)		SKCM_VARSCAN2	TCGA-EB-A5SE-01A-11D-A30X-08	TCGA-EB-A5SE-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1456S	0.1575	127.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1456S (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JA-06A-11D-A196-08	TCGA-D3-A2JA-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P886S	0.2308	26.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P886S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P383S	0.1484	128.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P383S (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P798L	0.2658	237.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P798L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P855S	0.125	160.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P855S (Missense)		SKCM_VARSCAN2	TCGA-EB-A6QY-01A-12D-A32N-08	TCGA-EB-A6QY-10B-01D-A32N-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P776L	0.2947	95.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P776L (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1321S	0.3385	65.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1321S (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P2077S	0.3433	134.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P2077S (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Nonsense	p.E765*	0.4474	190.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E765* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A6QZ-01A-12D-A32N-08	TCGA-EB-A6QZ-10B-01D-A32N-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X911_splice	0.2941	17.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X911_splice (Splice Site)		SKCM_VARSCAN2	TCGA-ER-A19B-06A-11D-A196-08	TCGA-ER-A19B-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R710C	0.2941	51.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R710C (Missense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G869S	0.3091	55.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G869S (Missense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1123F	0.2258	31.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1123F (Missense)		SKCM_VARSCAN2	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1321S	0.3735	83.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1321S (Missense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1192C	0.3636	66.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1192C (Missense)		SKCM_VARSCAN2	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.K785R	0.303	33.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.K785R (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1190V	0.4821	56.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1190V (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S1001F	0.337	92.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.S1001F (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S1588F	0.2679	56.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.S1588F (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Nonsense	p.Q596*	0.1829	257.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.Q596* (Nonsense)	0	SKCM_VARSCAN2	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Nonsense	p.W582*	0.2672	408.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.W582* (Nonsense)	0	SKCM_VARSCAN2	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T950I	0.359	78.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T950I (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E1403G	0.2419	62.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E1403G (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R841S	0.25	24.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R841S (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP8-01A-11D-A401-08	TCGA-BF-AAP8-10A-01D-A401-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E780K	0.4045	89.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E780K (Missense)		SKCM_VARSCAN2	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.P615S	0.4384	146.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.P615S (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R847C	0.6081	74.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R847C (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P270S	0.4658	73.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P270S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Splice Site	p.X242_splice	0.28	75.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.X242_splice (Splice Site)	0	SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Nonsense	p.Q970*	0.35	360.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.Q970* (Nonsense)	0	SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P1504L	0.1304	69.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P1504L (Missense)		SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.C308*	0.2632	57.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.C308* (Nonsense)		SKCM_VARSCAN2	TCGA-GN-A4U9-06A-11D-A32N-08	TCGA-GN-A4U9-10B-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R973W	0.25	40.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R973W (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1135W	0.3846	13.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1135W (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.G423*	0.3583	187.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.G423* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E882K	0.3333	18.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E882K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P265S	0.2941	68.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P265S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P1344S	0.4091	22.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P1344S (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.Y244H	0.3214	501.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.Y244H (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G274S	0.2424	66.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G274S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P680S	0.28	25.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P680S (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.S211G	0.3333	36.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.S211G (Missense)	0	SKCM_VARSCAN2	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D1418N	0.5128	39.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D1418N (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Q120*	0.72	25.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q120* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E669K	0.3333	285.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E669K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P277S	0.3077	26.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P277S (Missense)		SKCM_VARSCAN2	TCGA-FS-A4FD-06A-11D-A25O-08	TCGA-FS-A4FD-10B-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Q120*	0.1884	69.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q120* (Nonsense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R978Q	0.3939	33.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R978Q (Missense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1468V	0.3125	32.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1468V (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.N1540H	0.4545	44.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.N1540H (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.K1461N	0.3889	18.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.K1461N (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E861K	0.3846	26.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E861K (Missense)		SKCM_VARSCAN2	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E554G	0.3711	97.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E554G (Missense)	0	SKCM_VARSCAN2	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.G423*	0.5057	176.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.G423* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Frameshift	p.Y351Sfs*224	0.1908	414.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.Y351Sfs*224 (Frameshift)	0	SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.K793E	0.3253	495.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.K793E (Missense)	0	SKCM_VARSCAN2	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.A277V	0.1851	281.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.A277V (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1468V	0.3239	71.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1468V (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R847C	0.3362	345.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R847C (Missense)	0	SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P389L	0.3333	132.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P389L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Nonsense	p.Q47*	0.3871	62.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.Q47* (Nonsense)	0	SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1192C	0.4017	117.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1192C (Missense)		SKCM_VARSCAN2	TCGA-D9-A4Z3-01A-11D-A25O-08	TCGA-D9-A4Z3-10A-01D-A25O-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P1424S	0.2414	29.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P1424S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E1051K	0.4516	93.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E1051K (Missense)	0	SKCM_VARSCAN2	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Nonsense	p.W369*	0.2192	73.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.W369* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Splice Site	p.X1021_splice	0.4138	58.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.X1021_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.P177_C182del	0.44	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P177_C182del (Deletion)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Frameshift	p.E509Gfs*38	0.4706	17.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.E509Gfs*38 (Frameshift)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Frameshift	p.V1071Gfs*22	0.38	100.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.V1071Gfs*22 (Frameshift)		SKCM_VARSCAN2	TCGA-FS-A4F9-06A-11D-A24R-08	TCGA-FS-A4F9-10A-01D-A24R-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.G415R	0.6429	14.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.G415R (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.S463F	0.3099	142.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.S463F (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P566L	0.4082	98.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P566L (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.R471K	0.2787	61.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.R471K (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.D629N	0.2371	97.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D629N (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.R243C	0.28	50.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.R243C (Missense)		SKCM_VARSCAN2	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Nonsense	p.Q739*	0.5862	29.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.Q739* (Nonsense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P269S	0.2632	57.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P269S (Missense)		SKCM_VARSCAN2	TCGA-D3-A51E-06A-11D-A25O-08	TCGA-D3-A51E-10A-01D-A25O-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.M287V	0.1852	27.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.M287V (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P896S	0.2388	67.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P896S (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.E247D	0.1429	42.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.E247D (Missense)		SKCM_VARSCAN2	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Nonsense	p.Q610*	0.4138	29.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.Q610* (Nonsense)		SKCM_VARSCAN2	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S459L	0.2115	52.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.S459L (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.E247K	0.2576	66.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.E247K (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.L661M	0.3559	59.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.L661M (Missense)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.D648N	0.2581	31.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D648N (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S235F	0.3898	59.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.S235F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P272S	0.2439	41.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P272S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S1092F	0.2874	87.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.S1092F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P1256S	0.2752	109.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P1256S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Nonsense	p.R787*	0.9167	36.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R787* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.L1182F	0.2673	101.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.L1182F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.R434W	0.5833	24.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.R434W (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.F7L	0.4286	21.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.F7L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.S575L	0.3433	67.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.S575L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P168L	0.3452	84.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P168L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.V656L	0.5769	26.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.V656L (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S317F	0.8462	13.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.S317F (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G345S	0.2604	96.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G345S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G505D	0.2414	87.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G505D (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.P406L	0.2791	129.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.P406L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Frameshift	p.Q556Tfs*15	0.2826	138.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.Q556Tfs*15 (Frameshift)		SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Nonsense	p.W827*	0.1548	84.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.W827* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.G301W	0.4306	72.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.G301W (Missense)		SKCM_VARSCAN2	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P2133L	0.551	98.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P2133L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.P432S	0.4333	30.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.P432S (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP2-01A-11D-A401-08	TCGA-BF-AAP2-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.H426L	0.2917	48.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.H426L (Missense)		SKCM_VARSCAN2	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P133S	0.4667	45.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P133S (Missense)		SKCM_VARSCAN2	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Frameshift	p.G407Wfs*39	0.2429	140.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.G407Wfs*39 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T468M	0.5833	216.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T468M (Missense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P1334L	0.4	40.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P1334L (Missense)		SKCM_VARSCAN2	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.Y414F	0.2754	69.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Y414F (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JH-06A-11D-A196-08	TCGA-D3-A2JH-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1354C	0.4227	97.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1354C (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.L886F	0.2361	72.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.L886F (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.E241K	0.2703	111.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.E241K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GB-06A-11D-A197-08	TCGA-EE-A2GB-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.E1175K	0.4118	51.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E1175K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P840S	0.1323	257.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P840S (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.Y351N	0.2721	136.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Y351N (Missense)		SKCM_VARSCAN2	TCGA-D9-A3Z3-06A-11D-A23B-08	TCGA-D9-A3Z3-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S132L	0.3298	191.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S132L (Missense)		SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.P267S	0.2821	78.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.P267S (Missense)		SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.S704L	0.3621	116.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.S704L (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.Q510H	0.9579	309.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.Q510H (Missense)		SKCM_VARSCAN2	TCGA-FS-A4F0-06A-11D-A24R-08	TCGA-FS-A4F0-10A-01D-A24R-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.C563F	0.319	116.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.C563F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R210C	0.5948	116.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R210C (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZT-06A-11D-A197-08	TCGA-FS-A1ZT-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.I829N	0.2126	127.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.I829N (Missense)		SKCM_VARSCAN2	TCGA-D3-A3C3-06A-12D-A19A-08	TCGA-D3-A3C3-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.S284F	0.1719	64.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.S284F (Missense)		SKCM_VARSCAN2	TCGA-GN-A269-01A-11D-A19A-08	TCGA-GN-A269-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.L117F	0.2903	155.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.L117F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P1724L	0.5	50.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P1724L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S475F	0.3286	140.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S475F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.G544E	0.3488	86.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.G544E (Missense)		SKCM_VARSCAN2	TCGA-D3-A3C7-06A-11D-A196-08	TCGA-D3-A3C7-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.Y592H	0.3562	146.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Y592H (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AB-06A-11D-A196-08	TCGA-EE-A3AB-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.L262F	0.2857	133.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.L262F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T468M	0.569	58.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T468M (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.H361Y	0.52	50.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.H361Y (Missense)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Splice Site	p.X1391_splice	0.4211	19.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.X1391_splice (Splice Site)		SKCM_VARSCAN2	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P317S	0.4664	223.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P317S (Missense)		SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R146Q	0.3553	76.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R146Q (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TB-06A-12D-A401-08	TCGA-YD-A9TB-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E1395K	0.4222	45.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E1395K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Nonsense	p.R425*	0.5135	37.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R425* (Nonsense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S1251F	0.2647	34.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S1251F (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P729L	0.488	125.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P729L (Missense)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1073L	0.5243	185.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1073L (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EA-06A-11D-A30X-08	TCGA-D9-A6EA-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.I602S	0.1549	142.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.I602S (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1949W	0.6087	115.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1949W (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.P204L	0.3727	110.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.P204L (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZQ-06A-11D-A197-08	TCGA-FS-A1ZQ-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.L145F	0.6488	168.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.L145F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.G137E	0.2981	104.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.G137E (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S526F	0.1244	193.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S526F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29N-06A-12D-A197-08	TCGA-EE-A29N-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.P33L	0.3411	129.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.P33L (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E1612K	0.6009	218.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E1612K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.L79S	0.2791	43.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.L79S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S203F	0.2632	57.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S203F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.T1115S	0.4714	140.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.T1115S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZM-06A-11D-A372-08	TCGA-WE-A8ZM-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A98T	0.2254	71.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A98T (Missense)		SKCM_VARSCAN2	TCGA-GN-A26A-06A-11D-A19A-08	TCGA-GN-A26A-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1094H	0.3884	121.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1094H (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.M224I	0.3824	34.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.M224I (Missense)		SKCM_VARSCAN2	TCGA-FS-A4FB-06A-11D-A25O-08	TCGA-FS-A4FB-10B-01D-A25O-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Nonsense	p.G330*	0.3966	116.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.G330* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.P271Q	0.2769	65.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.P271Q (Missense)		SKCM_VARSCAN2	TCGA-BF-AAOU-01A-12D-A397-08	TCGA-BF-AAOU-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R309W	0.1636	55.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R309W (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.F71L	0.2043	93.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.F71L (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P324L	0.2161	199.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P324L (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P567L	0.3148	54.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P567L (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S958L	0.5893	112.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S958L (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P1392L	0.4661	118.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P1392L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.M1868R	0.25	40.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.M1868R (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A2041T	0.4603	126.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A2041T (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1289W	0.2375	80.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1289W (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P2190L	0.3438	64.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P2190L (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K1-06A-21D-A372-08	TCGA-WE-A8K1-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P1452S	0.8676	68.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P1452S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.V1047G	0.3931	145.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.V1047G (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R14Q	0.2604	96.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R14Q (Missense)		SKCM_VARSCAN2	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.A461T	0.6629	178.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.A461T (Missense)		SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.S284F	0.1522	46.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.S284F (Missense)		SKCM_VARSCAN2	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.P194S	0.2242	223.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.P194S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29X-06A-11D-A196-08	TCGA-EE-A29X-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.H114Y	0.25	100.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.H114Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1195H	0.1143	35.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1195H (Missense)		SKCM_VARSCAN2	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.H1586Y	0.2943	384.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.H1586Y (Missense)		SKCM_VARSCAN2	TCGA-FS-A1Z7-06A-11D-A197-08	TCGA-FS-A1Z7-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S1344F	0.1646	79.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S1344F (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZM-06A-12D-A197-08	TCGA-FS-A1ZM-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.H114Y	0.1039	77.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.H114Y (Missense)		SKCM_VARSCAN2	TCGA-D3-A3C8-06A-12D-A19A-08	TCGA-D3-A3C8-10A-01D-A19A-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.S1178L	0.9016	122.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.S1178L (Missense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.P284L	0.4098	61.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.P284L (Missense)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S26L	0.3	70.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S26L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1273C	0.5057	87.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1273C (Missense)		SKCM_VARSCAN2	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K292E	0.3509	57.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K292E (Missense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.L335F	0.2623	61.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.L335F (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Nonsense	p.Q545*	0.4091	44.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.Q545* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R1347K	0.3529	68.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R1347K (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZO-06A-11D-A372-08	TCGA-WE-A8ZO-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R793Q	0.2903	31.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R793Q (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Deletion	p.S45del	0.4688	32.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45del (Deletion)		SKCM_VARSCAN2	TCGA-EE-A2M6-06A-12D-A197-08	TCGA-EE-A2M6-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34E	0.1842	38.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34E (Missense)		SKCM_VARSCAN2	TCGA-GN-A269-01A-11D-A19A-08	TCGA-GN-A269-10A-01D-A19A-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R132W	0.125	104.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R132W (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R818C	0.4194	155.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R818C (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D390E	0.3409	44.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D390E (Missense)		SKCM_VARSCAN2	TCGA-D9-A6E9-06A-12D-A30X-08	TCGA-D9-A6E9-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.4651	43.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		SKCM_VARSCAN2	TCGA-EB-A42Y-01A-12D-A24R-08	TCGA-EB-A42Y-10A-01D-A24R-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.2439	41.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		SKCM_VARSCAN2	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E638K	1.0	14.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E638K (Missense)		SKCM_VARSCAN2	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T595I	0.375	152.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T595I (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R808C	0.4301	93.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R808C (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.D816N	1.0	8.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.D816N (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P606L	0.4221	154.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P606L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.3333	51.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZN-06A-11D-A372-08	TCGA-WE-A8ZN-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.I749N	0.2262	84.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.I749N (Missense)		SKCM_VARSCAN2	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.A532V	0.1429	49.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.A532V (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Deletion	p.S45del	0.4194	31.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45del (Deletion)		SKCM_VARSCAN2	TCGA-XV-AB01-06A-12D-A401-08	TCGA-XV-AB01-10A-01D-A401-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.L762P	0.2353	34.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.L762P (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Deletion	p.S45del	0.3889	54.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45del (Deletion)		SKCM_VARSCAN2	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E215D	0.1683	101.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E215D (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GL-06A-11D-A196-08	TCGA-EE-A2GL-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.S315F	0.2727	33.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.S315F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GL-06A-11D-A196-08	TCGA-EE-A2GL-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.L916F	0.4062	128.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.L916F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S212F	0.383	47.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S212F (Missense)		SKCM_VARSCAN2	TCGA-BF-AAOU-01A-12D-A397-08	TCGA-BF-AAOU-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P714L	0.2973	37.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P714L (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.Q200*	0.3214	28.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.Q200* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.D1256E	0.1491	161.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D1256E (Missense)		SKCM_VARSCAN2	TCGA-ER-A3PL-06A-11D-A23B-08	TCGA-ER-A3PL-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41N	0.26	50.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41N (Missense)		SKCM_VARSCAN2	TCGA-EB-A5SH-06A-11D-A30X-08	TCGA-EB-A5SH-10A-01D-A30X-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Frameshift	p.S339Afs*4	0.3103	29.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.S339Afs*4 (Frameshift)		SKCM_VARSCAN2	TCGA-FS-A1ZB-06A-12D-A197-08	TCGA-FS-A1ZB-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.24	50.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45C	0.3571	42.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45C (Missense)		SKCM_VARSCAN2	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.3158	76.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EG-06A-12D-A32N-08	TCGA-D9-A6EG-10A-01D-A32N-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P687S	0.2752	109.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P687S (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P687L	0.2804	107.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P687L (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JN-06A-11D-A196-08	TCGA-D3-A2JN-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41I	0.3243	37.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41I (Missense)		SKCM_VARSCAN2	TCGA-D9-A149-06A-11D-A196-08	TCGA-D9-A149-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S33L	0.3333	12.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S33L (Missense)		SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.3333	21.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		SKCM_VARSCAN2	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.W383G	0.1062	113.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.W383G (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GS-06A-12D-A372-08	TCGA-D3-A8GS-10A-01D-A375-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S48F	0.3555	422.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S48F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R171W	0.8519	27.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R171W (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E656K	0.3043	23.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E656K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.C429G	0.4722	72.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.C429G (Missense)		SKCM_VARSCAN2	TCGA-D3-A1Q5-06A-11D-A196-08	TCGA-D3-A1Q5-10A-01D-A198-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34R	0.5263	38.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34R (Missense)		SKCM_VARSCAN2	TCGA-FS-A4F9-06A-11D-A24R-08	TCGA-FS-A4F9-10A-01D-A24R-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.1404	57.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Frameshift	p.E577Sfs*8	0.7143	14.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.E577Sfs*8 (Frameshift)		SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S981F	0.5075	67.0	0.0	0.0																									MTOR p.S981F (Missense)		SKCM_VARSCAN2	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.M378K	0.5667	30.0	0.0	0.0																									FLI1 p.M378K (Missense)		SKCM_VARSCAN2	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.S390F	0.2973	37.0	0.0	0.0																									FLI1 p.S390F (Missense)		SKCM_VARSCAN2	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q853*	0.7037	27.0	0.0	0.0																									NF1 p.Q853* (Nonsense)		SKCM_VARSCAN2	TCGA-DA-A95X-06A-11D-A372-08	TCGA-DA-A95X-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V438I	0.55	40.0	0.0	0.0																									ROS1 p.V438I (Missense)		SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S569F	0.5333	30.0	0.0	0.0																									RUNX1T1 p.S569F (Missense)		SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P420L	0.3521	71.0	0.0	0.0																									ESRP1 p.P420L (Missense)		SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.S56Qfs*64	0.6667	12.0	0.0	0.0																									CDKN2A p.S56Qfs*64 (Frameshift)		SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P417L	0.2162	37.0	0.0	0.0																									NTRK3 p.P417L (Missense)		SKCM_VARSCAN2	TCGA-W3-A825-06A-11D-A34U-08	TCGA-W3-A825-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G126E	0.5349	43.0	0.0	0.0																									ROS1 p.G126E (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S769F	0.1176	136.0	0.0	0.0																									PMS2 p.S769F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D576N	0.7333	30.0	0.0	0.0																									NTRK3 p.D576N (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1822*	0.4571	105.0	0.0	0.0																									NF1 p.Q1822* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.D1228N	0.2545	165.0	0.0	0.0																									COL1A1 p.D1228N (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R1149W	0.5	78.0	0.0	0.0																									BRD4 p.R1149W (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.G199E	0.2966	118.0	0.0	0.0																									TMPRSS2 p.G199E (Missense)		SKCM_VARSCAN2	TCGA-EE-A29L-06A-12D-A196-08	TCGA-EE-A29L-10A-01D-A198-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.G786E	0.5667	60.0	0.0	0.0																									EML4 p.G786E (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.T93Sfs*53	1.0	10.0	0.0	0.0																									CDKN2A p.T93Sfs*53 (Frameshift)		SKCM_VARSCAN2	TCGA-D3-A8GP-06A-11D-A372-08	TCGA-D3-A8GP-10A-01D-A375-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.N62S	0.2222	27.0	0.0	0.0																									TMPRSS2 p.N62S (Missense)		SKCM_VARSCAN2	TCGA-GN-A9SD-06A-11D-A401-08	TCGA-GN-A9SD-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Q2295H	0.6875	48.0	0.0	0.0																									ROS1 p.Q2295H (Missense)		SKCM_VARSCAN2	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.L79F	0.3448	87.0	0.0	0.0																									FGFR2 p.L79F (Missense)		SKCM_VARSCAN2	TCGA-EE-A184-06A-11D-A196-08	TCGA-EE-A184-10B-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.H856Y	0.6	25.0	0.0	0.0																									ROS1 p.H856Y (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R149H	0.5	46.0	0.0	0.0																									RUNX1T1 p.R149H (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S141L	0.2041	49.0	0.0	0.0																									RUNX1T1 p.S141L (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W784*	0.2	30.0	0.0	0.0																									NF1 p.W784* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W784*	0.2	30.0	0.0	0.0																									NF1 p.W784* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A1ZA-06A-11D-A197-08	TCGA-FS-A1ZA-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S128L	0.1724	116.0	0.0	0.0																									PMS2 p.S128L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E164K	0.129	62.0	0.0	0.0																									RUNX1T1 p.E164K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MC-06A-12D-A197-08	TCGA-EE-A2MC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.K261E	0.5341	88.0	0.0	0.0																									NTRK1 p.K261E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.R151C	0.2981	161.0	0.0	0.0																									PMS2 p.R151C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G288S	0.2308	52.0	0.0	0.0																									RUNX1T1 p.G288S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.6122	49.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.L87P	0.15	80.0	0.0	0.0																									FGFR2 p.L87P (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q2239*	0.5897	78.0	0.0	0.0																									NF1 p.Q2239* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2GI-06A-11D-A196-08	TCGA-EE-A2GI-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2265K	0.3529	68.0	0.0	0.0																									ROS1 p.E2265K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V2125A	0.4082	196.0	0.0	0.0																									ROS1 p.V2125A (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1509K	0.4722	36.0	0.0	0.0																									ROS1 p.E1509K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G316D	0.3208	53.0	0.0	0.0																									FGFR2 p.G316D (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.P367S	0.4222	45.0	0.0	0.0																									POLE2 p.P367S (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S291F	0.3621	58.0	0.0	0.0																									LIMK2 p.S291F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GR-06A-11D-A372-08	TCGA-D3-A8GR-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W1997*	0.375	80.0	0.0	0.0																									NF1 p.W1997* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A82B-01A-11D-A34U-08	TCGA-EB-A82B-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y2285*	0.217	106.0	0.0	0.0																									NF1 p.Y2285* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A82B-01A-11D-A34U-08	TCGA-EB-A82B-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.K768E	0.2017	119.0	0.0	0.0																									NTRK3 p.K768E (Missense)		SKCM_VARSCAN2	TCGA-FR-A69P-06A-21D-A30X-08	TCGA-FR-A69P-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P1001S	0.3378	74.0	0.0	0.0																									PDGFRB p.P1001S (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.K39E	0.3333	168.0	0.0	0.0																									POT1 p.K39E (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22M	0.4516	31.0	0.0	0.0																									CDK4 p.K22M (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C8-06A-12D-A30X-08	TCGA-GF-A6C8-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D167N	0.1163	43.0	0.0	0.0																									NTRK3 p.D167N (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GB-06A-11D-A372-08	TCGA-D3-A8GB-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.L604*	0.3488	43.0	0.0	0.0																									NF1 p.L604* (Nonsense)		SKCM_VARSCAN2	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G728E	0.3579	95.0	0.0	0.0																									COL1A1 p.G728E (Missense)		SKCM_VARSCAN2	TCGA-GN-A26C-01A-11D-A19A-08	TCGA-GN-A26C-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2131D	0.3621	116.0	0.0	0.0																									ROS1 p.E2131D (Missense)		SKCM_VARSCAN2	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.P241S	0.3333	21.0	0.0	0.0																									PMS2 p.P241S (Missense)		SKCM_VARSCAN2	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.3333	30.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-RP-A694-06A-11D-A30X-08	TCGA-RP-A694-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G594R	0.8182	22.0	0.0	0.0																									RUNX1T1 p.G594R (Missense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W1258*	0.8773	277.0	0.0	0.0																									NF1 p.W1258* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G281D	0.8905	347.0	0.0	0.0																									COL1A1 p.G281D (Missense)		SKCM_VARSCAN2	TCGA-EE-A180-06A-11D-A21A-08	TCGA-EE-A180-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R149C	0.1831	71.0	0.0	0.0																									RUNX1T1 p.R149C (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP1-01A-11D-A397-08	TCGA-BF-AAP1-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G192R	0.9318	44.0	0.0	0.0																									ROS1 p.G192R (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q684*	0.4038	52.0	0.0	0.0																									NF1 p.Q684* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S1599F	0.4839	62.0	0.0	0.0																									NF1 p.S1599F (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.L536V	0.551	49.0	0.0	0.0																									LIMK2 p.L536V (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZZ-06A-11D-A197-08	TCGA-FS-A1ZZ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2088F	0.439	82.0	0.0	0.0																									ROS1 p.S2088F (Missense)		SKCM_VARSCAN2	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1065R	0.1667	30.0	0.0	0.0																									BRD4 p.P1065R (Missense)		SKCM_VARSCAN2	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Nonsense	p.R486*	0.3529	51.0	0.0	0.0																									IL12RB1 p.R486* (Nonsense)		SKCM_VARSCAN2	TCGA-ER-A19G-06A-11D-A196-08	TCGA-ER-A19G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1859K	0.3158	38.0	0.0	0.0																									ROS1 p.E1859K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I5-06A-11D-A197-08	TCGA-DA-A1I5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S808L	0.2927	41.0	0.0	0.0																									ROS1 p.S808L (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.G216R	0.46	50.0	0.0	0.0																									AURKA p.G216R (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JP-06A-11D-A19A-08	TCGA-D3-A2JP-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.843	172.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2GM-06B-11D-A196-08	TCGA-EE-A2GM-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.P246L	0.1667	24.0	0.0	0.0																									PMS2 p.P246L (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E778K	0.2247	89.0	0.0	0.0																									NTRK3 p.E778K (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R472Q	0.5556	9.0	0.0	0.0																									COL1A1 p.R472Q (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GO-06A-12D-A27K-08	TCGA-D3-A5GO-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1129T	0.619	21.0	0.0	0.0																									ROS1 p.R1129T (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3P-06A-11D-A38G-08	TCGA-YG-AA3P-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.G629R	1.0	47.0	0.0	0.0																									NF1 p.G629R (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3P-06A-11D-A38G-08	TCGA-YG-AA3P-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.S795F	0.2826	46.0	0.0	0.0																									PDGFRB p.S795F (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S543F	0.4615	429.0	0.0	0.0																									ESRP1 p.S543F (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZC-06A-11D-A197-08	TCGA-FS-A1ZC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A559V	0.1667	66.0	0.0	0.0																									COL1A1 p.A559V (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GH-06A-11D-A196-08	TCGA-EE-A2GH-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.N385I	0.1447	76.0	0.0	0.0																									MTOR p.N385I (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JH-06A-11D-A196-08	TCGA-D3-A2JH-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.K289*	0.5	30.0	0.0	0.0																									RB1 p.K289* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A2JE-06A-11D-A372-08	TCGA-D3-A2JE-10B-01D-A375-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q846*	0.2857	42.0	0.0	0.0																									RB1 p.Q846* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A2JE-06A-11D-A372-08	TCGA-D3-A2JE-10B-01D-A375-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A795V	0.3462	52.0	0.0	0.0																									TACC3 p.A795V (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.6234	77.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.D23N	0.4783	23.0	0.0	0.0																									PDGFB p.D23N (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GP-06A-11D-A197-08	TCGA-EE-A2GP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P612S	0.2281	57.0	0.0	0.0																									TACC3 p.P612S (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T28I	0.2715	151.0	0.0	0.0																									ROS1 p.T28I (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P596S	0.3913	23.0	0.0	0.0																									RUNX1T1 p.P596S (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H166Y	0.2432	111.0	0.0	0.0																									RUNX1T1 p.H166Y (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E711K	0.3219	146.0	0.0	0.0																									FGFR2 p.E711K (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G178E	0.3556	45.0	0.0	0.0																									NTRK3 p.G178E (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q684*	0.2805	82.0	0.0	0.0																									NF1 p.Q684* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1815*	0.25	128.0	0.0	0.0																									NF1 p.Q1815* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P412S	0.303	66.0	0.0	0.0																									COL1A1 p.P412S (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S243F	0.2371	97.0	0.0	0.0																									KEAP1 p.S243F (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.A1245V	0.3333	24.0	0.0	0.0																									BRD4 p.A1245V (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P216S	0.2715	302.0	0.0	0.0																									BRD4 p.P216S (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P351S	0.24	125.0	0.0	0.0																									ERG p.P351S (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	TMPRSS2	Splice Site	p.X80_splice	0.2653	49.0	0.0	0.0																									TMPRSS2 p.X80_splice (Splice Site)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.P287S	0.3519	412.0	0.0	0.0																									CRKL p.P287S (Missense)		SKCM_VARSCAN2	TCGA-FR-A726-01A-11D-A32N-08	TCGA-FR-A726-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2143_splice	0.4915	59.0	0.0	0.0																									NF1 p.X2143_splice (Splice Site)		SKCM_VARSCAN2	TCGA-XV-A9W2-01A-11D-A397-08	TCGA-XV-A9W2-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.L102F	0.3519	54.0	0.0	0.0																									SLC45A3 p.L102F (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XF-01A-31D-A23B-08	TCGA-EB-A3XF-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.T786A	0.3239	71.0	0.0	0.0																									PDGFRB p.T786A (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S602F	0.3171	41.0	0.0	0.0																									FGFR1 p.S602F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R455*	0.4167	12.0	0.0	0.0																									RB1 p.R455* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R579*	0.3333	57.0	0.0	0.0																									RB1 p.R579* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L844F	0.5	42.0	0.0	0.0																									NF1 p.L844F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R1870Q	0.375	56.0	0.0	0.0																									NF1 p.R1870Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X1870_splice	0.3519	54.0	0.0	0.0																									NF1 p.X1870_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P649S	0.3404	47.0	0.0	0.0																									BRD4 p.P649S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MT-06A-11D-A197-08	TCGA-EE-A2MT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P458S	0.3509	57.0	0.0	0.0																									PDGFRB p.P458S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P852S	0.3654	104.0	0.0	0.0																									COL1A1 p.P852S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AC-06A-11D-A196-08	TCGA-EE-A3AC-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.E88Lfs*30	0.5	14.0	0.0	0.0																									CDKN2A p.E88Lfs*30 (Frameshift)		SKCM_VARSCAN2	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.L11F	0.3784	74.0	0.0	0.0																									BRD4 p.L11F (Missense)		SKCM_VARSCAN2	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	EWSR1	Nonsense	p.Q249*	0.3514	37.0	0.0	0.0																									EWSR1 p.Q249* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A44O-01A-11D-A25O-08	TCGA-EB-A44O-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ESRP1	Nonsense	p.R264*	0.6746	209.0	0.0	0.0																									ESRP1 p.R264* (Nonsense)		SKCM_VARSCAN2	TCGA-FW-A5DX-01A-11D-A27K-08	TCGA-FW-A5DX-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.S10L	0.75	8.0	0.0	0.0																									FLI1 p.S10L (Missense)		SKCM_VARSCAN2	TCGA-FW-A5DX-01A-11D-A27K-08	TCGA-FW-A5DX-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.E166Dfs*6	0.7368	19.0	0.0	0.0																									RB1 p.E166Dfs*6 (Frameshift)		SKCM_VARSCAN2	TCGA-FW-A5DX-01A-11D-A27K-08	TCGA-FW-A5DX-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E596K	0.2167	180.0	0.0	0.0																									FGFR2 p.E596K (Missense)		SKCM_VARSCAN2	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.S286F	0.2941	34.0	0.0	0.0																									EWSR1 p.S286F (Missense)		SKCM_VARSCAN2	TCGA-ER-A19K-01A-21D-A197-08	TCGA-ER-A19K-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S1641F	0.3824	102.0	0.0	0.0																									MTOR p.S1641F (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1333K	0.5429	35.0	0.0	0.0																									ROS1 p.E1333K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48L	0.6485	202.0	0.0	0.0																									CDKN2A p.P48L (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E695K	0.3125	48.0	0.0	0.0																									FGFR2 p.E695K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HV-06A-21D-A196-08	TCGA-DA-A1HV-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.5027	183.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A2JD-06A-11D-A19A-08	TCGA-D3-A2JD-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.T660I	0.5468	203.0	0.0	0.0																									ESRP1 p.T660I (Missense)		SKCM_VARSCAN2	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D584N	0.4719	89.0	0.0	0.0																									NTRK3 p.D584N (Missense)		SKCM_VARSCAN2	TCGA-EE-A20H-06A-11D-A197-08	TCGA-EE-A20H-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P418L	0.2174	230.0	0.0	0.0																									RUNX1T1 p.P418L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.D444H	0.3814	118.0	0.0	0.0																									COL1A1 p.D444H (Missense)		SKCM_VARSCAN2	TCGA-EE-A29C-06A-21D-A197-08	TCGA-EE-A29C-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I1268T	0.2564	39.0	0.0	0.0																									ROS1 p.I1268T (Missense)		SKCM_VARSCAN2	TCGA-D3-A3MR-06A-11D-A21A-08	TCGA-D3-A3MR-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.L120F	0.14	50.0	0.0	0.0																									FIP1L1 p.L120F (Missense)		SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.A1033V	0.2329	73.0	0.0	0.0																									PDGFRB p.A1033V (Missense)		SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2271R	0.2979	47.0	0.0	0.0																									ROS1 p.G2271R (Missense)		SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E357K	0.1919	99.0	0.0	0.0																									ESRP1 p.E357K (Missense)		SKCM_VARSCAN2	TCGA-QB-A6FS-06A-11D-A30X-08	TCGA-QB-A6FS-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P2053A	0.3596	267.0	0.0	0.0																									MTOR p.P2053A (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G169R	0.4362	94.0	0.0	0.0																									NTRK1 p.G169R (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.A871T	0.4737	76.0	0.0	0.0																									PDGFRB p.A871T (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Nonsense	p.Q443*	0.5	156.0	0.0	0.0																									PDGFRB p.Q443* (Nonsense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G355E	0.6522	69.0	0.0	0.0																									ESRP1 p.G355E (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.5455	11.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R210Q	0.3394	109.0	0.0	0.0																									FGFR2 p.R210Q (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.W170*	0.3462	52.0	0.0	0.0																									NTRK3 p.W170* (Nonsense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.D654N	0.45	20.0	0.0	0.0																									IL12RB1 p.D654N (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S531F	0.4528	53.0	0.0	0.0																									LIMK2 p.S531F (Missense)		SKCM_VARSCAN2	TCGA-Z2-A8RT-06A-11D-A372-08	TCGA-Z2-A8RT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P305L	0.4242	33.0	0.0	0.0																									TMPRSS2 p.P305L (Missense)		SKCM_VARSCAN2	TCGA-EB-A44Q-06A-11D-A25O-08	TCGA-EB-A44Q-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.R87C	0.191	89.0	0.0	0.0																									CCND3 p.R87C (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GN-06A-11D-A372-08	TCGA-D3-A8GN-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R542Q	0.1105	172.0	0.0	0.0																									NTRK3 p.R542Q (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GN-06A-11D-A372-08	TCGA-D3-A8GN-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.H264Y	0.5069	144.0	0.0	0.0																									RAF1 p.H264Y (Missense)		SKCM_VARSCAN2	TCGA-FS-A4F0-06A-11D-A24R-08	TCGA-FS-A4F0-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.K419E	0.2791	43.0	0.0	0.0																									FGFR1 p.K419E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR1	Nonsense	p.Q309*	0.3375	80.0	0.0	0.0																									FGFR1 p.Q309* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.R316*	0.3125	112.0	0.0	0.0																									RUNX1T1 p.R316* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S150L	0.3242	438.0	0.0	0.0																									ESRP1 p.S150L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.D366E	0.3108	370.0	0.0	0.0																									ESRP1 p.D366E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E828K	0.2571	70.0	0.0	0.0																									COL1A1 p.E828K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2M5-06A-12D-A197-08	TCGA-EE-A2M5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S440F	0.1944	36.0	0.0	0.0																									FGFR2 p.S440F (Missense)		SKCM_VARSCAN2	TCGA-ER-A19N-06A-11D-A197-08	TCGA-ER-A19N-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.8148	27.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P307L	0.328	125.0	0.0	0.0																									BRD4 p.P307L (Missense)		SKCM_VARSCAN2	TCGA-EB-A44P-01A-11D-A25O-08	TCGA-EB-A44P-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P366S	0.3393	56.0	0.0	0.0																									COL1A1 p.P366S (Missense)		SKCM_VARSCAN2	TCGA-GN-A8LN-01A-11D-A372-08	TCGA-GN-A8LN-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Nonsense	p.R364*	0.3846	26.0	0.0	0.0																									LIMK2 p.R364* (Nonsense)		SKCM_VARSCAN2	TCGA-BF-A3DM-01A-11D-A20D-08	TCGA-BF-A3DM-10A-02D-A20D-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.S470F	0.3875	80.0	0.0	0.0																									PDGFRB p.S470F (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U3-06A-11D-A32N-08	TCGA-GN-A4U3-10F-01D-A32N-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S1641F	0.2655	113.0	0.0	0.0																									MTOR p.S1641F (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JL-06A-11D-A196-08	TCGA-D3-A2JL-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E600K	0.3333	18.0	0.0	0.0																									RUNX1T1 p.E600K (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XB-01A-11D-A23B-08	TCGA-EB-A3XB-10B-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.A337T	0.45	20.0	0.0	0.0																									NTRK1 p.A337T (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I7-06A-22D-A197-08	TCGA-DA-A1I7-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1579K	0.3095	42.0	0.0	0.0																									ROS1 p.R1579K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I7-06A-22D-A197-08	TCGA-DA-A1I7-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P2049L	0.4444	18.0	0.0	0.0																									ROS1 p.P2049L (Missense)		SKCM_VARSCAN2	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	PMS2	Nonsense	p.R563*	0.4076	157.0	0.0	0.0																									PMS2 p.R563* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A4F5-06A-11D-A25O-08	TCGA-FS-A4F5-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.3363	113.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_VARSCAN2	TCGA-BF-A5EQ-01A-21D-A27K-08	TCGA-BF-A5EQ-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S1754F	0.1842	38.0	0.0	0.0																									NF1 p.S1754F (Missense)		SKCM_VARSCAN2	TCGA-GN-A269-01A-11D-A19A-08	TCGA-GN-A269-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D235N	0.2258	93.0	0.0	0.0																									RUNX1T1 p.D235N (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.A18T	0.2097	62.0	0.0	0.0																									CD274 p.A18T (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.E434K	0.1132	53.0	0.0	0.0																									PAK1 p.E434K (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.L1361F	0.1143	35.0	0.0	0.0																									BRD4 p.L1361F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AA-06A-11D-A196-08	TCGA-EE-A3AA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R2152C	0.3084	107.0	0.0	0.0																									MTOR p.R2152C (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R1890C	0.1429	63.0	0.0	0.0																									MTOR p.R1890C (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R1616C	0.2571	70.0	0.0	0.0																									MTOR p.R1616C (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.E92K	0.2927	41.0	0.0	0.0																									NTRK1 p.E92K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.R245W	0.303	33.0	0.0	0.0																									SLC45A3 p.R245W (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.P87L	0.2951	61.0	0.0	0.0																									SLC45A3 p.P87L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S368L	0.3874	111.0	0.0	0.0																									MLH1 p.S368L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A479V	0.1034	58.0	0.0	0.0																									TACC3 p.A479V (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.S1041F	0.2361	72.0	0.0	0.0																									PDGFRB p.S1041F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.V810M	0.2424	66.0	0.0	0.0																									PDGFRB p.V810M (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G687R	0.2821	78.0	0.0	0.0																									PDGFRB p.G687R (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2308K	0.459	61.0	0.0	0.0																									ROS1 p.E2308K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1539S	0.1071	56.0	0.0	0.0																									ROS1 p.P1539S (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A1180T	0.4176	91.0	0.0	0.0																									ROS1 p.A1180T (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.H989Y	0.3594	64.0	0.0	0.0																									ROS1 p.H989Y (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.H552R	0.2947	302.0	0.0	0.0																									PMS2 p.H552R (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E349K	0.2756	156.0	0.0	0.0																									RUNX1T1 p.E349K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S237L	0.2289	83.0	0.0	0.0																									ESRP1 p.S237L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.R329C	0.2188	64.0	0.0	0.0																									ESRP1 p.R329C (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.P59L	0.1591	44.0	0.0	0.0																									MYC p.P59L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.P10T	0.1259	143.0	0.0	0.0																									NTRK2 p.P10T (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.V762M	0.16	25.0	0.0	0.0																									NTRK2 p.V762M (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.P775L	0.299	194.0	0.0	0.0																									FGFR2 p.P775L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E718K	0.2909	165.0	0.0	0.0																									FGFR2 p.E718K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E596K	0.2862	311.0	0.0	0.0																									FGFR2 p.E596K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.V311I	0.3146	89.0	0.0	0.0																									FGFR2 p.V311I (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.D15N	0.2	15.0	0.0	0.0																									FLI1 p.D15N (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.E173K	0.25	188.0	0.0	0.0																									FLI1 p.E173K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.D209N	0.2727	121.0	0.0	0.0																									FLI1 p.D209N (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.R257Q	0.2692	26.0	0.0	0.0																									FLI1 p.R257Q (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.E323K	0.2821	39.0	0.0	0.0																									FLI1 p.E323K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R735C	0.4	80.0	0.0	0.0																									NTRK3 p.R735C (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G339R	0.129	124.0	0.0	0.0																									NTRK3 p.G339R (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.L152F	0.2278	79.0	0.0	0.0																									NTRK3 p.L152F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q347*	0.3981	103.0	0.0	0.0																									NF1 p.Q347* (Nonsense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E1238*	0.3907	215.0	0.0	0.0																									NF1 p.E1238* (Nonsense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P964S	0.1389	36.0	0.0	0.0																									COL1A1 p.P964S (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P829L	0.3158	95.0	0.0	0.0																									COL1A1 p.P829L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.D1346E	0.2294	109.0	0.0	0.0																									BRD4 p.D1346E (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S717F	0.1458	48.0	0.0	0.0																									BRD4 p.S717F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S194F	0.2787	244.0	0.0	0.0																									BRD4 p.S194F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P95S	0.2069	29.0	0.0	0.0																									BRD4 p.P95S (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.E207K	0.3504	117.0	0.0	0.0																									IL12RB1 p.E207K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P291L	0.3465	101.0	0.0	0.0																									TPX2 p.P291L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.R337Q	0.3235	136.0	0.0	0.0																									TPX2 p.R337Q (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P423H	0.2808	146.0	0.0	0.0																									TPX2 p.P423H (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P419L	0.2353	102.0	0.0	0.0																									ERG p.P419L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.S80N	0.2766	47.0	0.0	0.0																									ERG p.S80N (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.S61F	0.2308	52.0	0.0	0.0																									TMPRSS2 p.S61F (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.P449S	0.1008	119.0	0.0	0.0																									EWSR1 p.P449S (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.P618S	0.4286	14.0	0.0	0.0																									EWSR1 p.P618S (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.G50R	0.25	32.0	0.0	0.0																									PDGFB p.G50R (Missense)		SKCM_VARSCAN2	TCGA-FW-A3R5-06A-11D-A23B-08	TCGA-FW-A3R5-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S436F	0.2821	39.0	0.0	0.0																									FGFR1 p.S436F (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U5-01A-11D-A32N-08	TCGA-GN-A4U5-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.R391S	0.6667	57.0	0.0	0.0																									RAF1 p.R391S (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E352K	0.2258	62.0	0.0	0.0																									RUNX1T1 p.E352K (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G364E	0.459	61.0	0.0	0.0																									FGFR2 p.G364E (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S833F	0.6875	16.0	0.0	0.0																									NF1 p.S833F (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S544F	0.381	42.0	0.0	0.0																									IL12RB1 p.S544F (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.G232E	0.38	50.0	0.0	0.0																									ERG p.G232E (Missense)		SKCM_VARSCAN2	TCGA-EE-A20C-06A-11D-A196-08	TCGA-EE-A20C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S249*	0.5513	78.0	0.0	0.0																									RB1 p.S249* (Nonsense)		SKCM_VARSCAN2	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E819K	0.8028	71.0	0.0	0.0																									NTRK3 p.E819K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3TU-06A-11D-A23B-08	TCGA-FW-A3TU-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R24H	0.2353	51.0	0.0	0.0																									CDK4 p.R24H (Missense)		SKCM_VARSCAN2	TCGA-EB-A44R-06A-41D-A25O-08	TCGA-EB-A44R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P334S	0.1236	89.0	0.0	0.0																									ESRP1 p.P334S (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.3158	38.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R210Q	0.3864	88.0	0.0	0.0																									FGFR2 p.R210Q (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R116W	0.3242	182.0	0.0	0.0																									NTRK3 p.R116W (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YO-06A-11D-A23B-08	TCGA-FR-A3YO-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G325D	0.4444	36.0	0.0	0.0																									IL12RB1 p.G325D (Missense)		SKCM_VARSCAN2	TCGA-DA-A3F3-06A-11D-A20D-08	TCGA-DA-A3F3-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	PDGFB	Splice Site	p.X153_splice	0.2586	58.0	0.0	0.0																									PDGFB p.X153_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D9-A6E9-06A-12D-A30X-08	TCGA-D9-A6E9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.G442R	0.6	110.0	0.0	0.0																									TMPRSS2 p.G442R (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GU-06A-11D-A27K-08	TCGA-D3-A5GU-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.P751S	0.4124	97.0	0.0	0.0																									EML4 p.P751S (Missense)		SKCM_VARSCAN2	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2305K	0.4583	72.0	0.0	0.0																									ROS1 p.E2305K (Missense)		SKCM_VARSCAN2	TCGA-DA-A960-01A-11D-A372-08	TCGA-DA-A960-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.E59Q	0.5625	48.0	0.0	0.0																									NTRK2 p.E59Q (Missense)		SKCM_VARSCAN2	TCGA-EB-A6R0-01A-12D-A32N-08	TCGA-EB-A6R0-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.L437F	0.338	71.0	0.0	0.0																									NTRK1 p.L437F (Missense)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.52	25.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X1392_splice	0.2568	74.0	0.0	0.0																									NF1 p.X1392_splice (Splice Site)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.E2155Sfs*45	0.2	55.0	0.0	0.0																									NF1 p.E2155Sfs*45 (Frameshift)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A814V	0.25	44.0	0.0	0.0																									COL1A1 p.A814V (Missense)		SKCM_VARSCAN2	TCGA-W3-A828-06A-11D-A34U-08	TCGA-W3-A828-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.M587I	0.5676	37.0	0.0	0.0																									NTRK1 p.M587I (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R685C	0.6216	37.0	0.0	0.0																									PDGFRB p.R685C (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1942W	0.2769	65.0	0.0	0.0																									ROS1 p.R1942W (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.P466L	0.3835	133.0	0.0	0.0																									FGFR1 p.P466L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D398N	0.3944	142.0	0.0	0.0																									RUNX1T1 p.D398N (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E50K	0.5333	45.0	0.0	0.0																									ESRP1 p.E50K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.S469F	0.2456	57.0	0.0	0.0																									NTRK2 p.S469F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E768K	0.5514	107.0	0.0	0.0																									FGFR2 p.E768K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R330Q	0.2326	43.0	0.0	0.0																									FGFR2 p.R330Q (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G76R	0.2125	80.0	0.0	0.0																									FGFR2 p.G76R (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E318K	0.587	46.0	0.0	0.0																									NTRK3 p.E318K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q129*	0.7209	43.0	0.0	0.0																									NF1 p.Q129* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G409E	0.3162	117.0	0.0	0.0																									IL12RB1 p.G409E (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S168F	0.6642	134.0	0.0	0.0																									LIMK2 p.S168F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GI-06A-11D-A372-08	TCGA-D3-A8GI-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1843R	0.1333	105.0	0.0	0.0																									ROS1 p.G1843R (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JD-06A-11D-A20D-08	TCGA-EE-A3JD-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.1136	44.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JD-06A-11D-A20D-08	TCGA-EE-A3JD-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P1851S	0.1304	115.0	0.0	0.0																									NF1 p.P1851S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JD-06A-11D-A20D-08	TCGA-EE-A3JD-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.S523L	0.3008	133.0	0.0	0.0																									POT1 p.S523L (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JA-06A-11D-A196-08	TCGA-D3-A2JA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22M	0.1695	59.0	0.0	0.0																									CDK4 p.K22M (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JA-06A-11D-A196-08	TCGA-D3-A2JA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1569W	0.2963	27.0	0.0	0.0																									ROS1 p.R1569W (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L368I	0.7917	24.0	0.0	0.0																									ROS1 p.L368I (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48L	0.7941	136.0	0.0	0.0																									CDKN2A p.P48L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.D142N	0.3684	133.0	0.0	0.0																									FGFR2 p.D142N (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J7-06A-11D-A20D-08	TCGA-EE-A3J7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.H245Y	0.54	50.0	0.0	0.0																									POT1 p.H245Y (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R1362*	0.3636	121.0	0.0	0.0																									NF1 p.R1362* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A1ZP-06A-11D-A197-08	TCGA-FS-A1ZP-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TACC3	Frameshift	p.K733Rfs*2	0.1813	182.0	0.0	0.0																									TACC3 p.K733Rfs*2 (Frameshift)		SKCM_VARSCAN2	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G552E	0.3968	63.0	0.0	0.0																									FGFR2 p.G552E (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U8-06A-11D-A32N-08	TCGA-GN-A4U8-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1025R	0.3962	53.0	0.0	0.0																									ROS1 p.G1025R (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.C383Yfs*10	0.3793	58.0	0.0	0.0																									NF1 p.C383Yfs*10 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2580_splice	0.4198	131.0	0.0	0.0																									NF1 p.X2580_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A2GR-06A-11D-A197-08	TCGA-EE-A2GR-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EPCAM	Splice Site	p.X220_splice	0.3333	51.0	0.0	0.0																									EPCAM p.X220_splice (Splice Site)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.G237R	0.2619	84.0	0.0	0.0																									EPCAM p.G237R (Missense)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.R316*	0.1065	169.0	0.0	0.0																									RUNX1T1 p.R316* (Nonsense)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.T395I	0.4054	37.0	0.0	0.0																									CCNE1 p.T395I (Missense)		SKCM_VARSCAN2	TCGA-QB-AA9O-06A-11D-A397-08	TCGA-QB-AA9O-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.D928N	0.3175	63.0	0.0	0.0																									MTOR p.D928N (Missense)		SKCM_VARSCAN2	TCGA-D3-A51N-06A-11D-A25O-08	TCGA-D3-A51N-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N65S	0.5	20.0	0.0	0.0																									ROS1 p.N65S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.497	167.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.P250H	0.2889	45.0	0.0	0.0																									CDK4 p.P250H (Missense)		SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G929S	0.1739	69.0	0.0	0.0																									COL1A1 p.G929S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29V-06A-12D-A197-08	TCGA-EE-A29V-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.N161K	0.4118	34.0	0.0	0.0																									RAF1 p.N161K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q257*	0.7297	37.0	0.0	0.0																									RB1 p.Q257* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1009S	0.4286	70.0	0.0	0.0																									COL1A1 p.P1009S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29B-06A-11D-A197-08	TCGA-EE-A29B-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T2207I	0.2576	66.0	0.0	0.0																									MTOR p.T2207I (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P59L	0.2113	71.0	0.0	0.0																									RUNX1T1 p.P59L (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R31C	0.2241	58.0	0.0	0.0																									RUNX1T1 p.R31C (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G926D	0.1417	120.0	0.0	0.0																									COL1A1 p.G926D (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G926S	0.15	120.0	0.0	0.0																									COL1A1 p.G926S (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UN-06A-11D-A30X-08	TCGA-EB-A5UN-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L547F	0.5	94.0	0.0	0.0																									MTOR p.L547F (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P378S	0.1346	52.0	0.0	0.0																									TACC3 p.P378S (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D235N	0.4298	121.0	0.0	0.0																									RUNX1T1 p.D235N (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E357K	0.3427	531.0	0.0	0.0																									ESRP1 p.E357K (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.6106	113.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P577S	0.3692	65.0	0.0	0.0																									NTRK3 p.P577S (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H370N	0.3061	147.0	0.0	0.0																									NTRK3 p.H370N (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y1625*	0.519	79.0	0.0	0.0																									NF1 p.Y1625* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A2JF-06A-11D-A196-08	TCGA-D3-A2JF-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R1098W	0.275	40.0	0.0	0.0																									PDGFRB p.R1098W (Missense)		SKCM_VARSCAN2	TCGA-ER-A199-06A-11D-A197-08	TCGA-ER-A199-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R556*	0.76	50.0	0.0	0.0																									RB1 p.R556* (Nonsense)		SKCM_VARSCAN2	TCGA-GN-A267-06A-21D-A196-08	TCGA-GN-A267-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.9024	41.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_VARSCAN2	TCGA-BF-A1PV-01A-11D-A19A-08	TCGA-BF-A1PV-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H166Y	0.5439	114.0	0.0	0.0																									RUNX1T1 p.H166Y (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZR-06A-21D-A197-08	TCGA-FS-A1ZR-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.F434C	0.1224	49.0	0.0	0.0																									EML4 p.F434C (Missense)		SKCM_VARSCAN2	TCGA-3N-A9WD-06A-11D-A38G-08	TCGA-3N-A9WD-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.T434M	0.2324	185.0	0.0	0.0																									NTRK1 p.T434M (Missense)		SKCM_VARSCAN2	TCGA-BF-A3DL-01A-11D-A20D-08	TCGA-BF-A3DL-10A-02D-A20D-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.E83K	0.5179	56.0	0.0	0.0																									NTRK1 p.E83K (Missense)		SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CCND1	Deletion	p.E275_V281del	0.25	24.0	0.0	0.0																									CCND1 p.E275_V281del (Deletion)		SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.D2095Vfs*16	0.8242	91.0	0.0	0.0																									NF1 p.D2095Vfs*16 (Frameshift)		SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.V2096M	0.8953	86.0	0.0	0.0																									NF1 p.V2096M (Missense)		SKCM_VARSCAN2	TCGA-GN-A8LK-06A-11D-A372-08	TCGA-GN-A8LK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G227E	0.6957	46.0	0.0	0.0																									FGFR2 p.G227E (Missense)		SKCM_VARSCAN2	TCGA-ER-A2NC-06A-11D-A197-08	TCGA-ER-A2NC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.V88A	0.2727	44.0	0.0	0.0																									POT1 p.V88A (Missense)		SKCM_VARSCAN2	TCGA-ER-A195-06A-11D-A196-08	TCGA-ER-A195-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Splice Site	p.X35_splice	0.4779	136.0	0.0	0.0																									COL1A1 p.X35_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A29R-06A-11D-A197-08	TCGA-EE-A29R-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T2045M	0.25	40.0	0.0	0.0																									ROS1 p.T2045M (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TB-06A-12D-A401-08	TCGA-YD-A9TB-10A-01D-A401-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.H162Y	0.4706	68.0	0.0	0.0																									CCNE1 p.H162Y (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TB-06A-12D-A401-08	TCGA-YD-A9TB-10A-01D-A401-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.2778	36.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA4-06A-12D-A38G-08	TCGA-WE-AAA4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CRKL	Nonsense	p.Q31*	0.2097	62.0	0.0	0.0																									CRKL p.Q31* (Nonsense)		SKCM_VARSCAN2	TCGA-WE-AAA4-06A-12D-A38G-08	TCGA-WE-AAA4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E810K	0.198	101.0	0.0	0.0																									NTRK3 p.E810K (Missense)		SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.N251K	0.2071	140.0	0.0	0.0																									AURKB p.N251K (Missense)		SKCM_VARSCAN2	TCGA-DA-A3F8-06A-11D-A20D-08	TCGA-DA-A3F8-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.F360S	0.22	50.0	0.0	0.0																									RAF1 p.F360S (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48L	0.268	97.0	0.0	0.0																									CDKN2A p.P48L (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48S	0.2527	91.0	0.0	0.0																									CDKN2A p.P48S (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.G881R	0.2742	62.0	0.0	0.0																									RB1 p.G881R (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1395*	0.3659	82.0	0.0	0.0																									NF1 p.Q1395* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P46S	0.3146	89.0	0.0	0.0																									BRD4 p.P46S (Missense)		SKCM_VARSCAN2	TCGA-FR-A7U9-06A-11D-A34U-08	TCGA-FR-A7U9-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.2435	115.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P48L	0.3056	36.0	0.0	0.0																									TMPRSS2 p.P48L (Missense)		SKCM_VARSCAN2	TCGA-BF-AAOX-01A-11D-A397-08	TCGA-BF-AAOX-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1768L	0.2476	105.0	0.0	0.0																									ROS1 p.S1768L (Missense)		SKCM_VARSCAN2	TCGA-FR-A44A-06A-11D-A24R-08	TCGA-FR-A44A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83R	0.9189	74.0	0.0	0.0																									CDKN2A p.H83R (Missense)		SKCM_VARSCAN2	TCGA-D9-A1X3-06A-11D-A197-08	TCGA-D9-A1X3-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R220Q	0.3511	94.0	0.0	0.0																									COL1A1 p.R220Q (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UM-01A-11D-A30X-08	TCGA-EB-A5UM-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P335S	0.2239	67.0	0.0	0.0																									TMPRSS2 p.P335S (Missense)		SKCM_VARSCAN2	TCGA-EB-A5UM-01A-11D-A30X-08	TCGA-EB-A5UM-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E527K	0.4091	44.0	0.0	0.0																									ROS1 p.E527K (Missense)		SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.T20I	0.2449	49.0	0.0	0.0																									FGFR1 p.T20I (Missense)		SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S146L	0.2857	49.0	0.0	0.0																									MYC p.S146L (Missense)		SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G356E	0.3019	106.0	0.0	0.0																									NTRK3 p.G356E (Missense)		SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.2979	94.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.S1053*	0.4583	24.0	0.0	0.0																									NF1 p.S1053* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A182-06A-11D-A196-08	TCGA-EE-A182-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.K178R	0.6633	196.0	0.0	0.0																									PMS2 p.K178R (Missense)		SKCM_VARSCAN2	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Splice Site	p.X42_splice	0.3684	19.0	0.0	0.0																									IL12RB1 p.X42_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A29A-06A-12D-A196-08	TCGA-EE-A29A-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G890E	0.1724	29.0	0.0	0.0																									PDGFRB p.G890E (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1627D	0.1613	62.0	0.0	0.0																									ROS1 p.G1627D (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.E242K	0.4524	42.0	0.0	0.0																									NTRK2 p.E242K (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.Q773*	0.2769	65.0	0.0	0.0																									NTRK3 p.Q773* (Nonsense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R2517*	0.5185	27.0	0.0	0.0																									NF1 p.R2517* (Nonsense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1210L	0.2308	39.0	0.0	0.0																									BRD4 p.P1210L (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S469F	0.3906	128.0	0.0	0.0																									IL12RB1 p.S469F (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.Q436E	0.129	62.0	0.0	0.0																									EWSR1 p.Q436E (Missense)		SKCM_VARSCAN2	TCGA-GN-A266-06A-11D-A197-08	TCGA-GN-A266-10A-01D-A199-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.E50K	0.1719	320.0	0.0	0.0																									SLC45A3 p.E50K (Missense)		SKCM_VARSCAN2	TCGA-EB-A85J-01A-12D-A34U-08	TCGA-EB-A85J-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.7647	34.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A3MV-06A-11D-A21A-08	TCGA-D3-A3MV-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.8222	90.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A185-06A-11D-A196-08	TCGA-EE-A185-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.D270N	0.1569	51.0	0.0	0.0																									NTRK1 p.D270N (Missense)		SKCM_VARSCAN2	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1006A	0.4918	61.0	0.0	0.0																									ROS1 p.E1006A (Missense)		SKCM_VARSCAN2	TCGA-FR-A729-06A-11D-A34U-08	TCGA-FR-A729-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.P483L	0.2933	75.0	0.0	0.0																									FGFR1 p.P483L (Missense)		SKCM_VARSCAN2	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.E546K	0.4054	37.0	0.0	0.0																									NTRK2 p.E546K (Missense)		SKCM_VARSCAN2	TCGA-FW-A3TV-06A-11D-A23B-08	TCGA-FW-A3TV-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.D771N	0.1148	122.0	0.0	0.0																									FGFR2 p.D771N (Missense)		SKCM_VARSCAN2	TCGA-GN-A265-06A-21D-A197-08	TCGA-GN-A265-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1278L	0.2414	58.0	0.0	0.0																									COL1A1 p.P1278L (Missense)		SKCM_VARSCAN2	TCGA-GN-A265-06A-21D-A197-08	TCGA-GN-A265-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.I679Dfs*21	0.5556	27.0	0.0	0.0																									NF1 p.I679Dfs*21 (Frameshift)		SKCM_VARSCAN2	TCGA-EB-A82C-01A-11D-A34U-08	TCGA-EB-A82C-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.R421G	0.3	80.0	0.0	0.0																									PMS2 p.R421G (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1O-06A-11D-A38G-08	TCGA-W3-AA1O-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.E369K	0.5176	255.0	0.0	0.0																									MYC p.E369K (Missense)		SKCM_VARSCAN2	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.R316C	0.2258	62.0	0.0	0.0																									LIMK2 p.R316C (Missense)		SKCM_VARSCAN2	TCGA-D3-A1QB-06A-11D-A19A-08	TCGA-D3-A1QB-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L47F	0.36	25.0	0.0	0.0																									ROS1 p.L47F (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GR-06A-11D-A27K-08	TCGA-D3-A5GR-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.A102Gfs*18	0.2564	39.0	0.0	0.0																									CDKN2A p.A102Gfs*18 (Frameshift)		SKCM_VARSCAN2	TCGA-D3-A5GR-06A-11D-A27K-08	TCGA-D3-A5GR-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R692C	0.2464	69.0	0.0	0.0																									NTRK1 p.R692C (Missense)		SKCM_VARSCAN2	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P1042L	0.5319	47.0	0.0	0.0																									PDGFRB p.P1042L (Missense)		SKCM_VARSCAN2	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P1042S	0.5417	48.0	0.0	0.0																									PDGFRB p.P1042S (Missense)		SKCM_VARSCAN2	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G687R	0.403	67.0	0.0	0.0																									PDGFRB p.G687R (Missense)		SKCM_VARSCAN2	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E621K	0.3694	157.0	0.0	0.0																									ROS1 p.E621K (Missense)		SKCM_VARSCAN2	TCGA-ER-A19M-06A-61D-A23B-08	TCGA-ER-A19M-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RB1	Deletion	p.K143_A147del	0.2247	178.0	0.0	0.0																									RB1 p.K143_A147del (Deletion)		SKCM_VARSCAN2	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.L797Yfs*13	0.5036	137.0	0.0	0.0																									RB1 p.L797Yfs*13 (Frameshift)		SKCM_VARSCAN2	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G395R	0.4286	28.0	0.0	0.0																									IL12RB1 p.G395R (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GK-06A-11D-A372-08	TCGA-D3-A8GK-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.3984	128.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		SKCM_VARSCAN2	TCGA-EB-A51B-01A-11D-A27K-08	TCGA-EB-A51B-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.N529D	0.2941	68.0	0.0	0.0																									ESRP1 p.N529D (Missense)		SKCM_VARSCAN2	TCGA-EB-A51B-01A-11D-A27K-08	TCGA-EB-A51B-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.8947	19.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A51B-01A-11D-A27K-08	TCGA-EB-A51B-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.E220K	0.1786	28.0	0.0	0.0																									SLC45A3 p.E220K (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K5-06A-11D-A372-08	TCGA-WE-A8K5-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E1427K	0.5565	115.0	0.0	0.0																									MTOR p.E1427K (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R103G	0.2727	22.0	0.0	0.0																									MTOR p.R103G (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.P494S	0.1613	31.0	0.0	0.0																									NTRK1 p.P494S (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.3833	60.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ROS1	Splice Site	p.X1789_splice	0.6786	28.0	0.0	0.0																									ROS1 p.X1789_splice (Splice Site)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1009K	0.1695	59.0	0.0	0.0																									ROS1 p.E1009K (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G60E	0.1224	49.0	0.0	0.0																									ROS1 p.G60E (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R243Q	0.625	112.0	0.0	0.0																									RUNX1T1 p.R243Q (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P176S	0.6136	44.0	0.0	0.0																									RUNX1T1 p.P176S (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.L360F	0.1942	103.0	0.0	0.0																									ESRP1 p.L360F (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.7692	13.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.F105L	0.3043	69.0	0.0	0.0																									NTRK2 p.F105L (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.T176I	0.2642	53.0	0.0	0.0																									POLE2 p.T176I (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D836H	0.5143	35.0	0.0	0.0																									NTRK3 p.D836H (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.5126	119.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2355_splice	0.1633	49.0	0.0	0.0																									NF1 p.X2355_splice (Splice Site)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.N2780D	0.2115	104.0	0.0	0.0																									NF1 p.N2780D (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G353R	0.3077	65.0	0.0	0.0																									IL12RB1 p.G353R (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1V-06B-11D-A401-08	TCGA-W3-AA1V-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E762K	0.2353	51.0	0.0	0.0																									NTRK3 p.E762K (Missense)		SKCM_VARSCAN2	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P27L	0.3	20.0	0.0	0.0																									TMPRSS2 p.P27L (Missense)		SKCM_VARSCAN2	TCGA-3N-A9WC-06A-11D-A38G-08	TCGA-3N-A9WC-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S259F	0.299	97.0	0.0	0.0																									RAF1 p.S259F (Missense)		SKCM_VARSCAN2	TCGA-BF-A5EO-01A-12D-A27K-08	TCGA-BF-A5EO-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.E88K	0.1333	105.0	0.0	0.0																									CDKN2A p.E88K (Missense)		SKCM_VARSCAN2	TCGA-D3-A3CB-06A-11D-A196-08	TCGA-D3-A3CB-10A-01D-A198-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.K228E	0.46	50.0	0.0	0.0																									EML4 p.K228E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G641E	0.4125	257.0	0.0	0.0																									COL1A1 p.G641E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MF-06A-11D-A21A-08	TCGA-EE-A2MF-10B-01D-A21A-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R692C	0.4138	58.0	0.0	0.0																									NTRK1 p.R692C (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P2613L	0.2017	119.0	0.0	0.0																									NF1 p.P2613L (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G194D	0.3382	68.0	0.0	0.0																									COL1A1 p.G194D (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P313L	0.2545	110.0	0.0	0.0																									ERG p.P313L (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K4-01A-12D-A372-08	TCGA-WE-A8K4-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2143_splice	0.5714	35.0	0.0	0.0																									NF1 p.X2143_splice (Splice Site)		SKCM_VARSCAN2	TCGA-BF-A1PZ-01A-11D-A19A-08	TCGA-BF-A1PZ-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G169R	0.34	50.0	0.0	0.0																									NTRK1 p.G169R (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JK-06A-11D-A196-08	TCGA-D3-A2JK-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R672C	0.2683	41.0	0.0	0.0																									MTOR p.R672C (Missense)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.P200L	0.3611	36.0	0.0	0.0																									POLE2 p.P200L (Missense)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X69_splice	0.2807	57.0	0.0	0.0																									NF1 p.X69_splice (Splice Site)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L274F	0.5	42.0	0.0	0.0																									NF1 p.L274F (Missense)		SKCM_VARSCAN2	TCGA-ER-A19F-06A-11D-A196-08	TCGA-ER-A19F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A1750V	0.2833	60.0	0.0	0.0																									ROS1 p.A1750V (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.Q237*	0.3676	68.0	0.0	0.0																									ROS1 p.Q237* (Nonsense)		SKCM_VARSCAN2	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.T228I	0.3415	41.0	0.0	0.0																									CCNE1 p.T228I (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3O-06A-11D-A38G-08	TCGA-YG-AA3O-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.6207	58.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		SKCM_VARSCAN2	TCGA-ER-A19D-06A-11D-A197-08	TCGA-ER-A19D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S2155F	0.1646	79.0	0.0	0.0																									MTOR p.S2155F (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A101V	0.3103	29.0	0.0	0.0																									MTOR p.A101V (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G166R	0.2097	62.0	0.0	0.0																									NTRK1 p.G166R (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1343N	0.1408	71.0	0.0	0.0																									ROS1 p.D1343N (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E621K	0.1706	170.0	0.0	0.0																									ROS1 p.E621K (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S180F	0.1042	48.0	0.0	0.0																									ROS1 p.S180F (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.G429E	0.1806	72.0	0.0	0.0																									FLI1 p.G429E (Missense)		SKCM_VARSCAN2	TCGA-GF-A6C9-06A-11D-A30X-08	TCGA-GF-A6C9-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E1799K	0.4118	17.0	0.0	0.0																									MTOR p.E1799K (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.R333H	0.2135	89.0	0.0	0.0																									RAF1 p.R333H (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S405F	0.5068	146.0	0.0	0.0																									MLH1 p.S405F (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.D776N	0.2874	87.0	0.0	0.0																									PDGFRB p.D776N (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S79L	0.3714	35.0	0.0	0.0																									ROS1 p.S79L (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S83C	0.3636	66.0	0.0	0.0																									RUNX1T1 p.S83C (Missense)		SKCM_VARSCAN2	TCGA-OD-A75X-06A-12D-A32N-08	TCGA-OD-A75X-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R625Q	0.2899	138.0	0.0	0.0																									FGFR2 p.R625Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R251Q	0.3667	30.0	0.0	0.0																									FGFR2 p.R251Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A29S-06A-11D-A197-08	TCGA-EE-A29S-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.L52P	0.2745	51.0	0.0	0.0																									EML4 p.L52P (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.I281M	0.1053	57.0	0.0	0.0																									RAF1 p.I281M (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A2322T	0.9655	29.0	0.0	0.0																									ROS1 p.A2322T (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2294F	0.8529	34.0	0.0	0.0																									ROS1 p.S2294F (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1539S	0.7647	17.0	0.0	0.0																									ROS1 p.P1539S (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.W354*	0.4492	118.0	0.0	0.0																									RUNX1T1 p.W354* (Nonsense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R147G	0.23	100.0	0.0	0.0																									RUNX1T1 p.R147G (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.4375	48.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.4	20.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.K47R	0.3846	13.0	0.0	0.0																									FLI1 p.K47R (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.G311*	0.8889	45.0	0.0	0.0																									NF1 p.G311* (Nonsense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E435K	0.96	25.0	0.0	0.0																									COL1A1 p.E435K (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R1228C	0.5806	31.0	0.0	0.0																									BRD4 p.R1228C (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.C674W	0.2453	53.0	0.0	0.0																									BRD4 p.C674W (Missense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	LIMK2	Nonsense	p.R364*	0.5385	13.0	0.0	0.0																									LIMK2 p.R364* (Nonsense)		SKCM_VARSCAN2	TCGA-D9-A6EC-06A-11D-A30X-08	TCGA-D9-A6EC-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.W1817*	0.3158	38.0	0.0	0.0																									ROS1 p.W1817* (Nonsense)		SKCM_VARSCAN2	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.T117S	0.3	30.0	0.0	0.0																									COL1A1 p.T117S (Missense)		SKCM_VARSCAN2	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S283F	0.3636	22.0	0.0	0.0																									LIMK2 p.S283F (Missense)		SKCM_VARSCAN2	TCGA-YD-A89C-06A-11D-A372-08	TCGA-YD-A89C-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S486T	0.297	165.0	0.0	0.0																									MLH1 p.S486T (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S486Y	0.2927	164.0	0.0	0.0																									MLH1 p.S486Y (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.Q2216*	0.2687	67.0	0.0	0.0																									ROS1 p.Q2216* (Nonsense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1642K	0.3421	76.0	0.0	0.0																									ROS1 p.E1642K (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.V306L	0.2	30.0	0.0	0.0																									PMS2 p.V306L (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S164F	0.2984	124.0	0.0	0.0																									PMS2 p.S164F (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H166Y	0.2927	41.0	0.0	0.0																									RUNX1T1 p.H166Y (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22Q	0.6	60.0	0.0	0.0																									CDK4 p.K22Q (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.P243L	0.2214	131.0	0.0	0.0																									CCNE1 p.P243L (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA0-06A-11D-A38G-08	TCGA-WE-AAA0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.T340I	0.5714	21.0	0.0	0.0																									NTRK1 p.T340I (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Biologically Relevant				Somatic Variant	SLC45A3	Frameshift	p.T25Wfs*50	0.3434	166.0	0.0	0.0																									SLC45A3 p.T25Wfs*50 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.5692	65.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R24L	0.7436	39.0	0.0	0.0																									CDK4 p.R24L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AD-06A-11D-A196-08	TCGA-EE-A3AD-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.V144I	0.5196	102.0	0.0	0.0																									NTRK1 p.V144I (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GV-06A-11D-A372-08	TCGA-D3-A8GV-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.D125Vfs*21	0.24	25.0	0.0	0.0																									CDKN2A p.D125Vfs*21 (Frameshift)		SKCM_VARSCAN2	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P426L	0.1897	58.0	0.0	0.0																									FLI1 p.P426L (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.P336L	0.1702	47.0	0.0	0.0																									AURKB p.P336L (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP7-01A-11D-A401-08	TCGA-BF-AAP7-10A-01D-A401-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.R665K	0.3171	82.0	0.0	0.0																									EML4 p.R665K (Missense)		SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.P156L	0.3659	123.0	0.0	0.0																									CRKL p.P156L (Missense)		SKCM_VARSCAN2	TCGA-ER-A198-06A-11D-A196-08	TCGA-ER-A198-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W1662*	0.1719	128.0	0.0	0.0																									NF1 p.W1662* (Nonsense)		SKCM_VARSCAN2	TCGA-DA-A95V-06A-11D-A372-08	TCGA-DA-A95V-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.R70S	0.18	50.0	0.0	0.0																									ERG p.R70S (Missense)		SKCM_VARSCAN2	TCGA-DA-A95V-06A-11D-A372-08	TCGA-DA-A95V-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N1834H	1.0	13.0	0.0	0.0																									ROS1 p.N1834H (Missense)		SKCM_VARSCAN2	TCGA-3N-A9WB-06A-11D-A38G-08	TCGA-3N-A9WB-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P569S	0.32	25.0	0.0	0.0																									BRD4 p.P569S (Missense)		SKCM_VARSCAN2	TCGA-HR-A2OG-06A-21D-A197-08	TCGA-HR-A2OG-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.H642Y	0.175	80.0	0.0	0.0																									MTOR p.H642Y (Missense)		SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.I144M	0.219	105.0	0.0	0.0																									PMS2 p.I144M (Missense)		SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R796C	0.1368	190.0	0.0	0.0																									COL1A1 p.R796C (Missense)		SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.R377C	0.2478	113.0	0.0	0.0																									ERG p.R377C (Missense)		SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.S195F	0.2892	83.0	0.0	0.0																									CRKL p.S195F (Missense)		SKCM_VARSCAN2	TCGA-EB-A431-01A-11D-A25O-08	TCGA-EB-A431-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P46S	0.2722	180.0	0.0	0.0																									BRD4 p.P46S (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TPX2	Nonsense	p.R543*	0.2946	112.0	0.0	0.0																									TPX2 p.R543* (Nonsense)		SKCM_VARSCAN2	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.P422L	0.2609	115.0	0.0	0.0																									LIMK2 p.P422L (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I4-06A-11D-A196-08	TCGA-DA-A1I4-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.5789	19.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A51J-06A-11D-A25O-08	TCGA-D3-A51J-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2298K	0.6667	27.0	0.0	0.0																									ROS1 p.E2298K (Missense)		SKCM_VARSCAN2	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E387K	0.375	96.0	0.0	0.0																									RUNX1T1 p.E387K (Missense)		SKCM_VARSCAN2	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	CCND1	Insertion	p.E280dup	0.3214	28.0	0.0	0.0																									CCND1 p.E280dup (Insertion)		SKCM_VARSCAN2	TCGA-D3-A51T-06A-11D-A25O-08	TCGA-D3-A51T-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.Q559L	0.26	50.0	0.0	0.0																									RUNX1T1 p.Q559L (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.4678	466.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S168F	0.219	105.0	0.0	0.0																									LIMK2 p.S168F (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZW-06A-12D-A197-08	TCGA-FS-A1ZW-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R316Q	0.3617	141.0	0.0	0.0																									RUNX1T1 p.R316Q (Missense)		SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.S43Lfs*76	0.5312	128.0	0.0	0.0																									CDKN2A p.S43Lfs*76 (Frameshift)		SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.P322L	0.3879	116.0	0.0	0.0																									MDM2 p.P322L (Missense)		SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.Q255*	0.3478	23.0	0.0	0.0																									NTRK3 p.Q255* (Nonsense)		SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.P176R	0.4286	56.0	0.0	0.0																									EWSR1 p.P176R (Missense)		SKCM_VARSCAN2	TCGA-RP-A695-06A-11D-A30X-08	TCGA-RP-A695-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S769F	0.3864	44.0	0.0	0.0																									PMS2 p.S769F (Missense)		SKCM_VARSCAN2	TCGA-D3-A2JO-06A-11D-A196-08	TCGA-D3-A2JO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P225S	0.3721	43.0	0.0	0.0																									MTOR p.P225S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G623E	0.5	60.0	0.0	0.0																									NTRK3 p.G623E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GU-06A-11D-A196-08	TCGA-EE-A2GU-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E402K	0.65	240.0	0.0	0.0																									ROS1 p.E402K (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZQ-06A-11D-A197-08	TCGA-FS-A1ZQ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.569	58.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZQ-06A-11D-A197-08	TCGA-FS-A1ZQ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1933K	0.4324	37.0	0.0	0.0																									ROS1 p.E1933K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Splice Site	p.X1634_splice	0.3167	60.0	0.0	0.0																									ROS1 p.X1634_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1440S	0.3492	63.0	0.0	0.0																									ROS1 p.P1440S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T1384S	0.2895	38.0	0.0	0.0																									ROS1 p.T1384S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R493C	0.3559	59.0	0.0	0.0																									ROS1 p.R493C (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.V490I	0.4074	54.0	0.0	0.0																									RUNX1T1 p.V490I (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.M486I	0.3929	56.0	0.0	0.0																									RUNX1T1 p.M486I (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R483K	0.5397	63.0	0.0	0.0																									RUNX1T1 p.R483K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.6014	143.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E718K	0.4894	94.0	0.0	0.0																									FGFR2 p.E718K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G356R	0.2703	74.0	0.0	0.0																									NTRK3 p.G356R (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P366S	0.9107	56.0	0.0	0.0																									COL1A1 p.P366S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R326W	0.3611	36.0	0.0	0.0																									BRD4 p.R326W (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R486C	0.3763	93.0	0.0	0.0																									EWSR1 p.R486C (Missense)		SKCM_VARSCAN2	TCGA-EE-A29E-06A-11D-A197-08	TCGA-EE-A29E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1117D	0.7037	27.0	0.0	0.0																									ROS1 p.G1117D (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.P470L	0.1966	117.0	0.0	0.0																									PMS2 p.P470L (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S225L	0.4737	57.0	0.0	0.0																									RUNX1T1 p.S225L (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.8077	26.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.A375S	0.4333	60.0	0.0	0.0																									ERG p.A375S (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1R-06A-11D-A397-08	TCGA-W3-AA1R-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E357K	0.1478	494.0	0.0	0.0																									ESRP1 p.E357K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29N-06A-12D-A197-08	TCGA-EE-A29N-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y80*	0.2439	41.0	0.0	0.0																									NF1 p.Y80* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29N-06A-12D-A197-08	TCGA-EE-A29N-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D697N	0.1364	66.0	0.0	0.0																									NTRK3 p.D697N (Missense)		SKCM_VARSCAN2	TCGA-EB-A44N-01A-11D-A25O-08	TCGA-EB-A44N-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H359Y	0.4366	142.0	0.0	0.0																									RUNX1T1 p.H359Y (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.A102V	0.8824	34.0	0.0	0.0																									CDKN2A p.A102V (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GS-06A-11D-A27K-08	TCGA-D3-A5GS-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1933K	0.6	15.0	0.0	0.0																									ROS1 p.E1933K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.P708S	0.3202	203.0	0.0	0.0																									FGFR2 p.P708S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.A611V	0.3008	502.0	0.0	0.0																									FGFR2 p.A611V (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P2675S	0.275	80.0	0.0	0.0																									NF1 p.P2675S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A2-06A-11D-A196-08	TCGA-EE-A2A2-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S565F	0.1515	33.0	0.0	0.0																									FGFR1 p.S565F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29G-06A-12D-A196-08	TCGA-EE-A29G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D358N	0.1168	137.0	0.0	0.0																									RUNX1T1 p.D358N (Missense)		SKCM_VARSCAN2	TCGA-EE-A29G-06A-12D-A196-08	TCGA-EE-A29G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A1443V	0.1373	102.0	0.0	0.0																									COL1A1 p.A1443V (Missense)		SKCM_VARSCAN2	TCGA-EE-A29G-06A-12D-A196-08	TCGA-EE-A29G-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E527K	0.5283	53.0	0.0	0.0																									ROS1 p.E527K (Missense)		SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.G449E	0.3333	21.0	0.0	0.0																									RB1 p.G449E (Missense)		SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.A562E	0.4	15.0	0.0	0.0																									RB1 p.A562E (Missense)		SKCM_VARSCAN2	TCGA-D3-A51G-06A-11D-A25O-08	TCGA-D3-A51G-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	MTOR	Nonsense	p.Q2007*	0.2903	155.0	0.0	0.0																									MTOR p.Q2007* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.T311I	0.1351	74.0	0.0	0.0																									SLC45A3 p.T311I (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.R44C	0.3333	21.0	0.0	0.0																									EPCAM p.R44C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.H315Y	0.1042	48.0	0.0	0.0																									MLH1 p.H315Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.L234F	0.1111	54.0	0.0	0.0																									RUNX1T1 p.L234F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.H242Y	0.1905	21.0	0.0	0.0																									FGFR2 p.H242Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Splice Site	p.X126_splice	0.1176	85.0	0.0	0.0																									FGFR2 p.X126_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1185L	0.25	40.0	0.0	0.0																									COL1A1 p.P1185L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P925S	0.1176	85.0	0.0	0.0																									COL1A1 p.P925S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E77K	0.1007	149.0	0.0	0.0																									COL1A1 p.E77K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S796L	0.2778	36.0	0.0	0.0																									BRD4 p.S796L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S470F	0.1042	48.0	0.0	0.0																									BRD4 p.S470F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G378E	0.1961	51.0	0.0	0.0																									IL12RB1 p.G378E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.R59C	0.16	25.0	0.0	0.0																									IL12RB1 p.R59C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.S302L	0.1357	140.0	0.0	0.0																									CCNE1 p.S302L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.G142E	0.1875	48.0	0.0	0.0																									TMPRSS2 p.G142E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	EWSR1	Nonsense	p.Q436*	0.1474	95.0	0.0	0.0																									EWSR1 p.Q436* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MR-06A-11D-A196-08	TCGA-EE-A2MR-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.M340R	0.1139	237.0	0.0	0.0																									RUNX1T1 p.M340R (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZM-06A-11D-A372-08	TCGA-WE-A8ZM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W1952*	0.7255	51.0	0.0	0.0																									NF1 p.W1952* (Nonsense)		SKCM_VARSCAN2	TCGA-WE-A8ZM-06A-11D-A372-08	TCGA-WE-A8ZM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G476R	0.4087	367.0	0.0	0.0																									ESRP1 p.G476R (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MQ-06A-11D-A197-08	TCGA-EE-A2MQ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.P698Lfs*50	0.7207	111.0	0.0	0.0																									NF1 p.P698Lfs*50 (Frameshift)		SKCM_VARSCAN2	TCGA-FW-A3I3-06A-11D-A21A-08	TCGA-FW-A3I3-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.S304F	0.4231	26.0	0.0	0.0																									NTRK1 p.S304F (Missense)		SKCM_VARSCAN2	TCGA-EB-A5FP-01A-11D-A27K-08	TCGA-EB-A5FP-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G997S	0.3958	48.0	0.0	0.0																									PDGFRB p.G997S (Missense)		SKCM_VARSCAN2	TCGA-FS-A4FD-06A-11D-A25O-08	TCGA-FS-A4FD-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.D232N	0.3898	59.0	0.0	0.0																									EPCAM p.D232N (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.S313L	0.3571	42.0	0.0	0.0																									AURKB p.S313L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GS-06A-12D-A197-08	TCGA-EE-A2GS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P551L	0.4533	75.0	0.0	0.0																									MTOR p.P551L (Missense)		SKCM_VARSCAN2	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.R107W	0.38	50.0	0.0	0.0																									PMS2 p.R107W (Missense)		SKCM_VARSCAN2	TCGA-IH-A3EA-01A-11D-A20D-08	TCGA-IH-A3EA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.A110V	0.5	62.0	0.0	0.0																									NTRK1 p.A110V (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1293F	0.3273	55.0	0.0	0.0																									ROS1 p.S1293F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.S1273*	0.4783	46.0	0.0	0.0																									ROS1 p.S1273* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P9S	0.3435	131.0	0.0	0.0																									ROS1 p.P9S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.G176V	0.4198	131.0	0.0	0.0																									POT1 p.G176V (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R31C	0.5432	81.0	0.0	0.0																									RUNX1T1 p.R31C (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.W195*	0.5797	69.0	0.0	0.0																									RB1 p.W195* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R1870Q	0.625	32.0	0.0	0.0																									NF1 p.R1870Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X1870_splice	0.6364	33.0	0.0	0.0																									NF1 p.X1870_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P621L	0.2222	72.0	0.0	0.0																									COL1A1 p.P621L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J5-06A-11D-A20D-08	TCGA-EE-A3J5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.F264I	0.6232	69.0	0.0	0.0																									PDGFRB p.F264I (Missense)		SKCM_VARSCAN2	TCGA-EB-A4XL-01A-11D-A27K-08	TCGA-EB-A4XL-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R243Q	0.3729	118.0	0.0	0.0																									RUNX1T1 p.R243Q (Missense)		SKCM_VARSCAN2	TCGA-EB-A4XL-01A-11D-A27K-08	TCGA-EB-A4XL-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	MTOR	Splice Site	p.X2483_splice	0.4444	99.0	0.0	0.0																									MTOR p.X2483_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S218F	0.375	96.0	0.0	0.0																									MLH1 p.S218F (Missense)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E364K	0.6	25.0	0.0	0.0																									PDGFRB p.E364K (Missense)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R448L	0.449	49.0	0.0	0.0																									FGFR1 p.R448L (Missense)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S74N	0.5135	37.0	0.0	0.0																									IL12RB1 p.S74N (Missense)		SKCM_VARSCAN2	TCGA-D3-A3ML-06A-11D-A21A-08	TCGA-D3-A3ML-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.N115H	0.264	125.0	0.0	0.0																									RAF1 p.N115H (Missense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.M667I	0.2034	59.0	0.0	0.0																									NTRK3 p.M667I (Missense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P226L	0.1839	174.0	0.0	0.0																									BRD4 p.P226L (Missense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.P271L	0.2845	116.0	0.0	0.0																									CCNE1 p.P271L (Missense)		SKCM_VARSCAN2	TCGA-GF-A3OT-06A-23D-A23B-08	TCGA-GF-A3OT-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1114M	0.3125	16.0	0.0	0.0																									NF1 p.L1114M (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S126F	0.2	55.0	0.0	0.0																									IL12RB1 p.S126F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.P32S	0.2308	52.0	0.0	0.0																									AURKA p.P32S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MI-06A-11D-A197-08	TCGA-EE-A2MI-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.5227	88.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_VARSCAN2	TCGA-GN-A26A-06A-11D-A19A-08	TCGA-GN-A26A-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1908I	0.2273	22.0	0.0	0.0																									MTOR p.T1908I (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L1206F	0.7736	53.0	0.0	0.0																									ROS1 p.L1206F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P446S	0.3333	18.0	0.0	0.0																									ERG p.P446S (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GL-06A-11D-A372-08	TCGA-D3-A8GL-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.L40F	0.3333	174.0	0.0	0.0																									MDM2 p.L40F (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HW-06A-11D-A19A-08	TCGA-DA-A1HW-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.M2264I	0.3774	53.0	0.0	0.0																									ROS1 p.M2264I (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.P24S	0.382	89.0	0.0	0.0																									CD274 p.P24S (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.T370I	0.4444	54.0	0.0	0.0																									FGFR2 p.T370I (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.L769Ffs*26	0.6324	68.0	0.0	0.0																									RB1 p.L769Ffs*26 (Frameshift)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E1395K	0.35	60.0	0.0	0.0																									COL1A1 p.E1395K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P15L	0.198	101.0	0.0	0.0																									BRD4 p.P15L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GM-06A-11D-A372-08	TCGA-D3-A8GM-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G192E	0.3386	127.0	0.0	0.0																									ROS1 p.G192E (Missense)		SKCM_VARSCAN2	TCGA-EB-A6QY-01A-12D-A32N-08	TCGA-EB-A6QY-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P233S	0.1639	61.0	0.0	0.0																									ESRP1 p.P233S (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YE-06A-11D-A372-08	TCGA-FR-A8YE-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.M264I	0.1071	56.0	0.0	0.0																									COL1A1 p.M264I (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YE-06A-11D-A372-08	TCGA-FR-A8YE-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.T347I	0.381	21.0	0.0	0.0																									MLH1 p.T347I (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P453S	0.6029	418.0	0.0	0.0																									ESRP1 p.P453S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114L	0.8	150.0	0.0	0.0																									CDKN2A p.P114L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G690R	0.2759	29.0	0.0	0.0																									FGFR2 p.G690R (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.Y1169Sfs*22	0.7241	29.0	0.0	0.0																									NF1 p.Y1169Sfs*22 (Frameshift)		SKCM_VARSCAN2	TCGA-EE-A3AE-06A-11D-A196-08	TCGA-EE-A3AE-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R702C	0.254	126.0	0.0	0.0																									NTRK1 p.R702C (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G1016E	0.2935	92.0	0.0	0.0																									COL1A1 p.G1016E (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.M93I	0.1923	26.0	0.0	0.0																									PDGFB p.M93I (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JA-06A-11D-A20D-08	TCGA-EE-A3JA-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S706F	0.2182	55.0	0.0	0.0																									BRD4 p.S706F (Missense)		SKCM_VARSCAN2	TCGA-RP-A693-06A-13D-A30X-08	TCGA-RP-A693-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	TPX2	Nonsense	p.R496*	0.1386	101.0	0.0	0.0																									TPX2 p.R496* (Nonsense)		SKCM_VARSCAN2	TCGA-RP-A693-06A-13D-A30X-08	TCGA-RP-A693-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S257L	0.3023	43.0	0.0	0.0																									RAF1 p.S257L (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.P536S	0.4235	85.0	0.0	0.0																									MLH1 p.P536S (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2177E	0.3235	34.0	0.0	0.0																									ROS1 p.G2177E (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L1385F	0.4043	47.0	0.0	0.0																									ROS1 p.L1385F (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.E489K	0.3908	87.0	0.0	0.0																									PMS2 p.E489K (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P593L	0.4	15.0	0.0	0.0																									RUNX1T1 p.P593L (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.R392C	0.5075	67.0	0.0	0.0																									ERG p.R392C (Missense)		SKCM_VARSCAN2	TCGA-W3-A824-06A-21D-A34U-08	TCGA-W3-A824-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E1857K	0.8955	67.0	0.0	0.0																									MTOR p.E1857K (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.D223N	0.3396	53.0	0.0	0.0																									CCND3 p.D223N (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1707N	0.8636	44.0	0.0	0.0																									ROS1 p.S1707N (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R475Q	0.5061	164.0	0.0	0.0																									FGFR1 p.R475Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D44N	0.5079	63.0	0.0	0.0																									RUNX1T1 p.D44N (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Deletion	p.L32_L37del	0.3353	173.0	0.0	0.0																									CDKN2A p.L32_L37del (Deletion)		SKCM_VARSCAN2	TCGA-EE-A3AG-06A-31D-A196-08	TCGA-EE-A3AG-10A-01D-A198-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.H156Y	0.1064	47.0	0.0	0.0																									SLC45A3 p.H156Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.G708E	0.25	76.0	0.0	0.0																									EML4 p.G708E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.P373S	0.6	30.0	0.0	0.0																									FIP1L1 p.P373S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R863W	0.7419	31.0	0.0	0.0																									ROS1 p.R863W (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S192L	0.4364	55.0	0.0	0.0																									MYC p.S192L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X548_splice	0.1707	41.0	0.0	0.0																									NF1 p.X548_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L929P	0.5758	99.0	0.0	0.0																									NF1 p.L929P (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.P342L	0.3011	93.0	0.0	0.0																									IL12RB1 p.P342L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MS-06A-11D-A197-08	TCGA-EE-A2MS-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TACC3	Nonsense	p.Q808*	0.1923	52.0	0.0	0.0																									TACC3 p.Q808* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A5UL-06A-11D-A30X-08	TCGA-EB-A5UL-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.2388	67.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.H458Y	0.3977	88.0	0.0	0.0																									TPX2 p.H458Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MM-06A-11D-A196-08	TCGA-EE-A2MM-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G327E	0.2647	34.0	0.0	0.0																									ROS1 p.G327E (Missense)		SKCM_VARSCAN2	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.S889F	0.4545	22.0	0.0	0.0																									COL1A1 p.S889F (Missense)		SKCM_VARSCAN2	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ERG	Nonsense	p.W460*	0.4	20.0	0.0	0.0																									ERG p.W460* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A20F-06A-21D-A196-08	TCGA-EE-A20F-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.W392*	0.4923	130.0	0.0	0.0																									RUNX1T1 p.W392* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A29Q-06A-11D-A197-08	TCGA-EE-A29Q-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.D776N	0.4239	92.0	0.0	0.0																									PDGFRB p.D776N (Missense)		SKCM_VARSCAN2	TCGA-Z2-AA3S-06A-11D-A397-08	TCGA-Z2-AA3S-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.G108R	0.5625	32.0	0.0	0.0																									ERG p.G108R (Missense)		SKCM_VARSCAN2	TCGA-Z2-AA3S-06A-11D-A397-08	TCGA-Z2-AA3S-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P81L	0.6304	92.0	0.0	0.0																									CDKN2A p.P81L (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P375L	0.3099	71.0	0.0	0.0																									BRD4 p.P375L (Missense)		SKCM_VARSCAN2	TCGA-DA-A1HY-06A-11D-A19A-08	TCGA-DA-A1HY-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N2268T	0.4912	57.0	0.0	0.0																									ROS1 p.N2268T (Missense)		SKCM_VARSCAN2	TCGA-FR-A3YN-06A-11D-A23B-08	TCGA-FR-A3YN-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G219E	0.1912	68.0	0.0	0.0																									IL12RB1 p.G219E (Missense)		SKCM_VARSCAN2	TCGA-BF-A1Q0-01A-21D-A19A-08	TCGA-BF-A1Q0-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.S20L	0.1591	88.0	0.0	0.0																									TPX2 p.S20L (Missense)		SKCM_VARSCAN2	TCGA-BF-A1Q0-01A-21D-A19A-08	TCGA-BF-A1Q0-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.P145L	0.2222	54.0	0.0	0.0																									EML4 p.P145L (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1614S	0.2857	35.0	0.0	0.0																									ROS1 p.P1614S (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1607L	0.5714	35.0	0.0	0.0																									ROS1 p.P1607L (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S461F	0.1765	51.0	0.0	0.0																									FGFR1 p.S461F (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83Q	0.3023	43.0	0.0	0.0																									CDKN2A p.H83Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D700N	0.4167	12.0	0.0	0.0																									NTRK2 p.D700N (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E163K	0.3269	52.0	0.0	0.0																									FGFR2 p.E163K (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.4578	83.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L2604F	0.5294	119.0	0.0	0.0																									NF1 p.L2604F (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.H409Y	0.3256	43.0	0.0	0.0																									ERG p.H409Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A181-06A-11D-A196-08	TCGA-EE-A181-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.L461P	0.55	40.0	0.0	0.0																									RB1 p.L461P (Missense)		SKCM_VARSCAN2	TCGA-FS-A1Z0-06A-11D-A197-08	TCGA-FS-A1Z0-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.M110L	0.1439	139.0	0.0	0.0																									MYC p.M110L (Missense)		SKCM_VARSCAN2	TCGA-ER-A19T-01A-11D-A19A-08	TCGA-ER-A19T-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A2420V	0.4107	56.0	0.0	0.0																									MTOR p.A2420V (Missense)		SKCM_VARSCAN2	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.N440S	0.2912	182.0	0.0	0.0																									NTRK1 p.N440S (Missense)		SKCM_VARSCAN2	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2296K	0.284	81.0	0.0	0.0																									ROS1 p.E2296K (Missense)		SKCM_VARSCAN2	TCGA-FS-A4FC-06A-11D-A24R-08	TCGA-FS-A4FC-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G235E	0.1579	19.0	0.0	0.0																									NTRK3 p.G235E (Missense)		SKCM_VARSCAN2	TCGA-EB-A5SH-06A-11D-A30X-08	TCGA-EB-A5SH-10A-01D-A30X-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.3466	176.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_VARSCAN2	TCGA-W3-AA1W-06A-11D-A38G-08	TCGA-W3-AA1W-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.S158F	0.2174	115.0	0.0	0.0																									TACC3 p.S158F (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA3-06A-11D-A38G-08	TCGA-WE-AAA3-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2265K	0.4054	37.0	0.0	0.0																									ROS1 p.E2265K (Missense)		SKCM_VARSCAN2	TCGA-WE-AAA3-06A-11D-A38G-08	TCGA-WE-AAA3-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S257L	0.37	100.0	0.0	0.0																									RAF1 p.S257L (Missense)		SKCM_VARSCAN2	TCGA-GN-A4U4-06A-11D-A32N-08	TCGA-GN-A4U4-10B-01D-A32N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E234K	0.4231	78.0	0.0	0.0																									COL1A1 p.E234K (Missense)		SKCM_VARSCAN2	TCGA-D3-A1Q6-06A-11D-A196-08	TCGA-D3-A1Q6-10A-01D-A198-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.V648G	0.5354	99.0	0.0	0.0																									EML4 p.V648G (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.L376F	0.2049	859.0	0.0	0.0																									ESRP1 p.L376F (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.L765P	0.6579	38.0	0.0	0.0																									COL1A1 p.L765P (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.R316C	0.4928	69.0	0.0	0.0																									LIMK2 p.R316C (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZK-06A-11D-A197-08	TCGA-FS-A1ZK-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.3241	108.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A1Q4-06A-11D-A196-08	TCGA-D3-A1Q4-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1083K	0.25	60.0	0.0	0.0																									ROS1 p.E1083K (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.T79Nfs*41	0.65	40.0	0.0	0.0																									CDKN2A p.T79Nfs*41 (Frameshift)		SKCM_VARSCAN2	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P523S	0.4	155.0	0.0	0.0																									COL1A1 p.P523S (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GN-06A-11D-A27K-08	TCGA-D3-A5GN-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.T1004I	0.1163	86.0	0.0	0.0																									PDGFRB p.T1004I (Missense)		SKCM_VARSCAN2	TCGA-ER-A19P-06A-11D-A196-08	TCGA-ER-A19P-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2241K	0.3636	22.0	0.0	0.0																									ROS1 p.E2241K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1154S	0.5789	19.0	0.0	0.0																									ROS1 p.P1154S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E444K	0.2533	150.0	0.0	0.0																									RUNX1T1 p.E444K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.S35F	0.4	50.0	0.0	0.0																									NTRK2 p.S35F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G227R	0.2679	56.0	0.0	0.0																									FGFR2 p.G227R (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.H46Y	1.0	9.0	0.0	0.0																									FLI1 p.H46Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.S359F	0.28	150.0	0.0	0.0																									NTRK3 p.S359F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S141F	0.2958	71.0	0.0	0.0																									LIMK2 p.S141F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29D-06A-11D-A197-08	TCGA-EE-A29D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A2272V	0.3462	52.0	0.0	0.0																									MTOR p.A2272V (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R119P	0.4815	27.0	0.0	0.0																									NTRK1 p.R119P (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P73L	0.2747	91.0	0.0	0.0																									RUNX1T1 p.P73L (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G371E	0.25	76.0	0.0	0.0																									ESRP1 p.G371E (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P1232A	0.29	100.0	0.0	0.0																									NF1 p.P1232A (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.H458Y	0.2857	133.0	0.0	0.0																									TPX2 p.H458Y (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y7-01A-11D-A23B-08	TCGA-EB-A3Y7-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1062K	0.4928	69.0	0.0	0.0																									ROS1 p.E1062K (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.6667	12.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G727E	0.4324	37.0	0.0	0.0																									NTRK3 p.G727E (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W336*	0.2653	49.0	0.0	0.0																									NF1 p.W336* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W336*	0.2708	48.0	0.0	0.0																									NF1 p.W336* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E2469*	0.4366	71.0	0.0	0.0																									NF1 p.E2469* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1179S	0.6531	49.0	0.0	0.0																									COL1A1 p.P1179S (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YC-06A-11D-A372-08	TCGA-FR-A8YC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A2416V	0.5169	89.0	0.0	0.0																									MTOR p.A2416V (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H658Q	0.2667	45.0	0.0	0.0																									NTRK3 p.H658Q (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Y-06A-11D-A372-08	TCGA-DA-A95Y-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.E120K	0.7885	52.0	0.0	0.0																									CDKN2C p.E120K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1705L	0.4211	76.0	0.0	0.0																									ROS1 p.S1705L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S941F	0.2703	37.0	0.0	0.0																									ROS1 p.S941F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.L320F	0.2444	45.0	0.0	0.0																									ESRP1 p.L320F (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2215_splice	0.2632	38.0	0.0	0.0																									NF1 p.X2215_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A8GQ-06A-11D-A372-08	TCGA-D3-A8GQ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.A439T	0.4333	30.0	0.0	0.0																									ERG p.A439T (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP6-01A-11D-A401-08	TCGA-BF-AAP6-10A-01D-A401-08
Biologically Relevant				Somatic Variant	RAF1	Nonsense	p.S287*	0.3214	56.0	0.0	0.0																									RAF1 p.S287* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G812D	0.3898	59.0	0.0	0.0																									COL1A1 p.G812D (Missense)		SKCM_VARSCAN2	TCGA-FS-A1YY-06A-11D-A197-08	TCGA-FS-A1YY-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22M	0.253	83.0	0.0	0.0																									CDK4 p.K22M (Missense)		SKCM_VARSCAN2	TCGA-FR-A728-01A-11D-A32N-08	TCGA-FR-A728-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.S673A	0.4118	17.0	0.0	0.0																									COL1A1 p.S673A (Missense)		SKCM_VARSCAN2	TCGA-FR-A728-01A-11D-A32N-08	TCGA-FR-A728-10A-01D-A32N-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S2496F	0.1757	74.0	0.0	0.0																									NF1 p.S2496F (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P817L	0.2041	49.0	0.0	0.0																									COL1A1 p.P817L (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.S513F	0.2982	57.0	0.0	0.0																									COL1A1 p.S513F (Missense)		SKCM_VARSCAN2	TCGA-DA-A1I0-06A-11D-A20D-08	TCGA-DA-A1I0-10B-01D-A20D-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A598T	0.2	35.0	0.0	0.0																									TACC3 p.A598T (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E63K	0.2162	37.0	0.0	0.0																									PDGFRB p.E63K (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GO-06A-11D-A372-08	TCGA-D3-A8GO-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.D616N	0.2576	66.0	0.0	0.0																									NTRK1 p.D616N (Missense)		SKCM_VARSCAN2	TCGA-EB-A3Y6-01A-21D-A23B-08	TCGA-EB-A3Y6-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.P130L	0.1538	39.0	0.0	0.0																									KEAP1 p.P130L (Missense)		SKCM_VARSCAN2	TCGA-D3-A2J7-06A-11D-A196-08	TCGA-D3-A2J7-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G251S	0.1667	72.0	0.0	0.0																									COL1A1 p.G251S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K1-06A-21D-A372-08	TCGA-WE-A8K1-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR1	Splice Site	p.X729_splice	0.1905	21.0	0.0	0.0																									FGFR1 p.X729_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.P423S	0.2245	98.0	0.0	0.0																									FGFR2 p.P423S (Missense)		SKCM_VARSCAN2	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.A525T	0.25	24.0	0.0	0.0																									RB1 p.A525T (Missense)		SKCM_VARSCAN2	TCGA-EB-A551-01A-21D-A27K-08	TCGA-EB-A551-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E836K	0.45	40.0	0.0	0.0																									PDGFRB p.E836K (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S413F	0.3709	151.0	0.0	0.0																									RUNX1T1 p.S413F (Missense)		SKCM_VARSCAN2	TCGA-WE-A8ZX-06A-11D-A372-08	TCGA-WE-A8ZX-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.T1419I	0.5417	48.0	0.0	0.0																									COL1A1 p.T1419I (Missense)		SKCM_VARSCAN2	TCGA-D3-A3C6-06A-12D-A196-08	TCGA-D3-A3C6-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E402K	0.3311	456.0	0.0	0.0																									ROS1 p.E402K (Missense)		SKCM_VARSCAN2	TCGA-ER-A19C-06A-11D-A196-08	TCGA-ER-A19C-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.A636V	0.3871	31.0	0.0	0.0																									NTRK1 p.A636V (Missense)		SKCM_VARSCAN2	TCGA-BF-A1PU-01A-11D-A19A-08	TCGA-BF-A1PU-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G728E	0.4328	67.0	0.0	0.0																									COL1A1 p.G728E (Missense)		SKCM_VARSCAN2	TCGA-BF-A1PU-01A-11D-A19A-08	TCGA-BF-A1PU-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1539L	0.1071	56.0	0.0	0.0																									ROS1 p.P1539L (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I594N	0.1807	83.0	0.0	0.0																									ROS1 p.I594N (Missense)		SKCM_VARSCAN2	TCGA-W3-AA1Q-06A-11D-A38G-08	TCGA-W3-AA1Q-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R533Q	0.2	75.0	0.0	0.0																									RUNX1T1 p.R533Q (Missense)		SKCM_VARSCAN2	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P807S	0.3118	93.0	0.0	0.0																									COL1A1 p.P807S (Missense)		SKCM_VARSCAN2	TCGA-GN-A263-01A-11D-A196-08	TCGA-GN-A263-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.D231N	0.1957	46.0	0.0	0.0																									MDM2 p.D231N (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP4-01A-11D-A401-08	TCGA-BF-AAP4-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E715*	0.1294	85.0	0.0	0.0																									NF1 p.E715* (Nonsense)		SKCM_VARSCAN2	TCGA-BF-AAP4-01A-11D-A401-08	TCGA-BF-AAP4-10A-01D-A401-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.E1458K	0.4091	66.0	0.0	0.0																									NF1 p.E1458K (Missense)		SKCM_VARSCAN2	TCGA-BF-AAP4-01A-11D-A401-08	TCGA-BF-AAP4-10A-01D-A401-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P456L	0.3125	32.0	0.0	0.0																									TACC3 p.P456L (Missense)		SKCM_VARSCAN2	TCGA-D3-A8GJ-06A-11D-A372-08	TCGA-D3-A8GJ-10A-01D-A375-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.S697F	0.2092	153.0	0.0	0.0																									TACC3 p.S697F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S796F	0.4052	116.0	0.0	0.0																									FGFR2 p.S796F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.S383F	0.4545	66.0	0.0	0.0																									FLI1 p.S383F (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.Y834N	0.2525	99.0	0.0	0.0																									NTRK3 p.Y834N (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G626S	0.4561	57.0	0.0	0.0																									IL12RB1 p.G626S (Missense)		SKCM_VARSCAN2	TCGA-EE-A29M-06A-11D-A196-08	TCGA-EE-A29M-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L570F	0.5636	55.0	0.0	0.0																									MTOR p.L570F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A5-06A-11D-A197-08	TCGA-EE-A2A5-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2136R	0.2979	94.0	0.0	0.0																									ROS1 p.G2136R (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G111R	0.4231	52.0	0.0	0.0																									ROS1 p.G111R (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D313N	0.1605	81.0	0.0	0.0																									RUNX1T1 p.D313N (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H166Y	0.3784	37.0	0.0	0.0																									RUNX1T1 p.H166Y (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.R58Efs*88	0.5455	11.0	0.0	0.0																									CDKN2A p.R58Efs*88 (Frameshift)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S129L	0.5455	44.0	0.0	0.0																									FGFR2 p.S129L (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.S359F	0.3765	85.0	0.0	0.0																									NTRK3 p.S359F (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.G675R	0.3333	45.0	0.0	0.0																									NF1 p.G675R (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.T464S	0.3191	47.0	0.0	0.0																									TPX2 p.T464S (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S41L	0.3333	45.0	0.0	0.0																									LIMK2 p.S41L (Missense)		SKCM_VARSCAN2	TCGA-YG-AA3N-01A-11D-A38G-08	TCGA-YG-AA3N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E163K	0.1774	62.0	0.0	0.0																									FGFR2 p.E163K (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JE-06A-11D-A20D-08	TCGA-EE-A3JE-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G733R	0.2931	58.0	0.0	0.0																									ROS1 p.G733R (Missense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.H647Y	0.256	125.0	0.0	0.0																									NF1 p.H647Y (Missense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L844F	0.6757	37.0	0.0	0.0																									NF1 p.L844F (Missense)		SKCM_VARSCAN2	TCGA-ER-A194-01A-11D-A197-08	TCGA-ER-A194-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q282*	0.2286	35.0	0.0	0.0																									NF1 p.Q282* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1070*	0.2609	23.0	0.0	0.0																									NF1 p.Q1070* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A3R1-01A-11D-A23B-08	TCGA-FR-A3R1-10B-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R439W	0.4615	143.0	0.0	0.0																									PDGFRB p.R439W (Missense)		SKCM_VARSCAN2	TCGA-EB-A97M-01A-11D-A38G-08	TCGA-EB-A97M-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P551L	0.4388	98.0	0.0	0.0																									MTOR p.P551L (Missense)		SKCM_VARSCAN2	TCGA-EE-A20B-06A-11D-A196-08	TCGA-EE-A20B-10A-01D-A198-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.551	49.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A20B-06A-11D-A196-08	TCGA-EE-A20B-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S220C	0.1707	41.0	0.0	0.0																									FGFR2 p.S220C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MG-06A-11D-A197-08	TCGA-EE-A2MG-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.K22M	0.2609	46.0	0.0	0.0																									CDK4 p.K22M (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MG-06A-11D-A197-08	TCGA-EE-A2MG-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.P59S	0.4286	35.0	0.0	0.0																									MYC p.P59S (Missense)		SKCM_VARSCAN2	TCGA-EB-A4P0-01A-41D-A25O-08	TCGA-EB-A4P0-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2132N	0.3061	98.0	0.0	0.0																									ROS1 p.S2132N (Missense)		SKCM_VARSCAN2	TCGA-ER-A19O-06A-11D-A197-08	TCGA-ER-A19O-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D584N	0.3571	56.0	0.0	0.0																									NTRK2 p.D584N (Missense)		SKCM_VARSCAN2	TCGA-EE-A29T-06A-11D-A197-08	TCGA-EE-A29T-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.2131	61.0	0.0	0.0																									TACC3 p.P417S (Missense)		SKCM_VARSCAN2	TCGA-FS-A4F8-06A-11D-A25O-08	TCGA-FS-A4F8-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S799F	0.2951	61.0	0.0	0.0																									FGFR2 p.S799F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GT-06A-12D-A197-08	TCGA-EE-A2GT-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.S210F	0.1364	44.0	0.0	0.0																									TACC3 p.S210F (Missense)		SKCM_VARSCAN2	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1943K	0.2078	77.0	0.0	0.0																									ROS1 p.E1943K (Missense)		SKCM_VARSCAN2	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.T150I	0.1296	108.0	0.0	0.0																									RUNX1T1 p.T150I (Missense)		SKCM_VARSCAN2	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S105F	0.1529	85.0	0.0	0.0																									RUNX1T1 p.S105F (Missense)		SKCM_VARSCAN2	TCGA-D9-A3Z1-06A-11D-A23B-08	TCGA-D9-A3Z1-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.M2264I	0.3208	53.0	0.0	0.0																									ROS1 p.M2264I (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L862F	0.2963	54.0	0.0	0.0																									ROS1 p.L862F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.2407	108.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.4719	89.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.W771*	0.6555	119.0	0.0	0.0																									NTRK3 p.W771* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MD-06A-11D-A197-08	TCGA-EE-A2MD-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2237E	0.5968	62.0	0.0	0.0																									ROS1 p.G2237E (Missense)		SKCM_VARSCAN2	TCGA-EE-A3AH-06A-11D-A196-08	TCGA-EE-A3AH-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P2049L	0.3372	86.0	0.0	0.0																									ROS1 p.P2049L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1282S	0.3667	30.0	0.0	0.0																									ROS1 p.P1282S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.Q220H	0.2879	66.0	0.0	0.0																									ERG p.Q220H (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GJ-06A-11D-A196-08	TCGA-EE-A2GJ-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.D2077E	0.3065	62.0	0.0	0.0																									MTOR p.D2077E (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.P484S	0.2632	38.0	0.0	0.0																									SLC45A3 p.P484S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.A20V	0.4	75.0	0.0	0.0																									RAF1 p.A20V (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1092N	0.3768	69.0	0.0	0.0																									ROS1 p.S1092N (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1006K	0.1803	61.0	0.0	0.0																									ROS1 p.E1006K (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.H437P	0.3039	102.0	0.0	0.0																									POT1 p.H437P (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R243Q	0.2581	124.0	0.0	0.0																									RUNX1T1 p.R243Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.556	259.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q2239*	0.4815	81.0	0.0	0.0																									NF1 p.Q2239* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P978S	0.5116	43.0	0.0	0.0																									COL1A1 p.P978S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.D144N	0.5556	45.0	0.0	0.0																									TMPRSS2 p.D144N (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GC-06A-11D-A197-08	TCGA-EE-A2GC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.E88K	0.5556	36.0	0.0	0.0																									CDKN2A p.E88K (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.S539L	0.3728	169.0	0.0	0.0																									TPX2 p.S539L (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JB-06A-11D-A21A-08	TCGA-EE-A3JB-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X654_splice	0.2083	48.0	0.0	0.0																									RB1 p.X654_splice (Splice Site)		SKCM_VARSCAN2	TCGA-D3-A1Q7-06A-11D-A19A-08	TCGA-D3-A1Q7-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P718L	0.1458	48.0	0.0	0.0																									COL1A1 p.P718L (Missense)		SKCM_VARSCAN2	TCGA-EE-A183-06A-11D-A196-08	TCGA-EE-A183-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G658S	0.4906	106.0	0.0	0.0																									ROS1 p.G658S (Missense)		SKCM_VARSCAN2	TCGA-EB-A430-01A-11D-A24R-08	TCGA-EB-A430-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.G23D	0.3103	29.0	0.0	0.0																									CDKN2A p.G23D (Missense)		SKCM_VARSCAN2	TCGA-Z2-AA3V-06A-11D-A397-08	TCGA-Z2-AA3V-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G517R	0.1765	68.0	0.0	0.0																									NTRK1 p.G517R (Missense)		SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.P425S	0.3182	44.0	0.0	0.0																									FIP1L1 p.P425S (Missense)		SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A452P	0.1818	33.0	0.0	0.0																									RUNX1T1 p.A452P (Missense)		SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E1395K	0.3654	52.0	0.0	0.0																									COL1A1 p.E1395K (Missense)		SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1030S	0.44	75.0	0.0	0.0																									COL1A1 p.P1030S (Missense)		SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.S222F	0.28	50.0	0.0	0.0																									ERG p.S222F (Missense)		SKCM_VARSCAN2	TCGA-ER-A193-06A-12D-A197-08	TCGA-ER-A193-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.6186	97.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		SKCM_VARSCAN2	TCGA-ER-A19H-06A-12D-A196-08	TCGA-ER-A19H-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PDGFRB	Splice Site	p.X456_splice	0.3409	88.0	0.0	0.0																									PDGFRB p.X456_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I468L	0.8462	13.0	0.0	0.0																									ROS1 p.I468L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D347N	0.4583	48.0	0.0	0.0																									RUNX1T1 p.D347N (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.M722I	0.4	50.0	0.0	0.0																									FGFR2 p.M722I (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P931L	0.5417	24.0	0.0	0.0																									NF1 p.P931L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.N1254S	0.7444	133.0	0.0	0.0																									COL1A1 p.N1254S (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GO-06A-11D-A196-08	TCGA-EE-A2GO-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.R793*	0.6	30.0	0.0	0.0																									NTRK3 p.R793* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A8GC-06A-11D-A372-08	TCGA-D3-A8GC-10A-01D-A375-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1988N	0.1818	33.0	0.0	0.0																									ROS1 p.D1988N (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZM-06A-12D-A197-08	TCGA-FS-A1ZM-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.P223T	0.28	50.0	0.0	0.0																									ERG p.P223T (Missense)		SKCM_VARSCAN2	TCGA-FS-A1ZM-06A-12D-A197-08	TCGA-FS-A1ZM-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1929S	0.4615	39.0	0.0	0.0																									ROS1 p.P1929S (Missense)		SKCM_VARSCAN2	TCGA-HR-A5NC-01A-11D-A27K-08	TCGA-HR-A5NC-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G1118D	0.1351	74.0	0.0	0.0																									COL1A1 p.G1118D (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A1-06A-11D-A197-08	TCGA-EE-A2A1-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2242C	0.2424	33.0	0.0	0.0																									ROS1 p.S2242C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.K682R	0.1127	71.0	0.0	0.0																									ROS1 p.K682R (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.H634Y	0.1515	99.0	0.0	0.0																									PMS2 p.H634Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.R175Q	0.1043	393.0	0.0	0.0																									ESRP1 p.R175Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R1241*	0.1656	157.0	0.0	0.0																									NF1 p.R1241* (Nonsense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S2599F	0.1068	103.0	0.0	0.0																									NF1 p.S2599F (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R528C	0.1587	63.0	0.0	0.0																									COL1A1 p.R528C (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P60L	0.3	70.0	0.0	0.0																									TPX2 p.P60L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.G359R	0.1429	56.0	0.0	0.0																									ERG p.G359R (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MJ-06A-11D-A197-08	TCGA-EE-A2MJ-10A-01D-A199-08
Biologically Relevant				Somatic Variant	TMPRSS2	Nonsense	p.W106*	0.1429	28.0	0.0	0.0																									TMPRSS2 p.W106* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A3C8-06A-12D-A19A-08	TCGA-D3-A3C8-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.V292A	0.2254	71.0	0.0	0.0																									FIP1L1 p.V292A (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.198	101.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.R191Q	0.3962	106.0	0.0	0.0																									PDGFB p.R191Q (Missense)		SKCM_VARSCAN2	TCGA-EB-A3XC-01A-11D-A23B-08	TCGA-EB-A3XC-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1108S	0.4	30.0	0.0	0.0																									ROS1 p.P1108S (Missense)		SKCM_VARSCAN2	TCGA-D3-A1Q8-06A-11D-A19A-08	TCGA-D3-A1Q8-10A-01D-A19A-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E590K	0.5357	56.0	0.0	0.0																									NTRK3 p.E590K (Missense)		SKCM_VARSCAN2	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1143L	0.6765	34.0	0.0	0.0																									BRD4 p.P1143L (Missense)		SKCM_VARSCAN2	TCGA-EE-A29H-06A-12D-A197-08	TCGA-EE-A29H-10A-01D-A199-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.P34L	0.2356	225.0	0.0	0.0																									POT1 p.P34L (Missense)		SKCM_VARSCAN2	TCGA-D3-A1Q5-06A-11D-A196-08	TCGA-D3-A1Q5-10A-01D-A198-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.D1003N	0.4691	81.0	0.0	0.0																									PDGFRB p.D1003N (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PDGFRB	Nonsense	p.R849*	0.4286	56.0	0.0	0.0																									PDGFRB p.R849* (Nonsense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.L585F	0.3886	229.0	0.0	0.0																									PMS2 p.L585F (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S451F	0.7293	133.0	0.0	0.0																									FGFR1 p.S451F (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.H407Y	0.2573	171.0	0.0	0.0																									NF1 p.H407Y (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q756*	0.5246	61.0	0.0	0.0																									NF1 p.Q756* (Nonsense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.E352K	0.7246	69.0	0.0	0.0																									BRD4 p.E352K (Missense)		SKCM_VARSCAN2	TCGA-DA-A95Z-06A-11D-A372-08	TCGA-DA-A95Z-10A-01D-A375-08
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.Q168R	0.3478	46.0	0.0	0.0																									CDKN2C p.Q168R (Missense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E431K	0.3699	146.0	0.0	0.0																									PDGFRB p.E431K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.E36K	0.7195	82.0	0.0	0.0																									CCND1 p.E36K (Missense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q282*	0.3571	28.0	0.0	0.0																									NF1 p.Q282* (Nonsense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W696*	0.2714	70.0	0.0	0.0																									NF1 p.W696* (Nonsense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.F294S	0.375	136.0	0.0	0.0																									CCNE1 p.F294S (Missense)		SKCM_VARSCAN2	TCGA-DA-A1IC-06A-11D-A197-08	TCGA-DA-A1IC-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.5652	46.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		SKCM_VARSCAN2	TCGA-ER-A19L-06A-12D-A197-08	TCGA-ER-A19L-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E88*	0.7364	129.0	0.0	0.0																									CDKN2A p.E88* (Nonsense)		SKCM_VARSCAN2	TCGA-FS-A1YW-06A-11D-A197-08	TCGA-FS-A1YW-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.F275L	0.4366	71.0	0.0	0.0																									CCNE1 p.F275L (Missense)		SKCM_VARSCAN2	TCGA-GN-A262-06A-11D-A196-08	TCGA-GN-A262-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G757R	0.1875	64.0	0.0	0.0																									NTRK3 p.G757R (Missense)		SKCM_VARSCAN2	TCGA-EE-A2GD-06A-11D-A196-08	TCGA-EE-A2GD-10A-01D-A198-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G661E	0.4493	69.0	0.0	0.0																									NTRK1 p.G661E (Missense)		SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S257L	0.4731	93.0	0.0	0.0																									RAF1 p.S257L (Missense)		SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.M796I	0.3857	70.0	0.0	0.0																									NTRK2 p.M796I (Missense)		SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.Y49F	0.3091	55.0	0.0	0.0																									NF1 p.Y49F (Missense)		SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.D605V	0.447	132.0	0.0	0.0																									BRD4 p.D605V (Missense)		SKCM_VARSCAN2	TCGA-EE-A17X-06A-11D-A197-08	TCGA-EE-A17X-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R2230K	0.5294	34.0	0.0	0.0																									ROS1 p.R2230K (Missense)		SKCM_VARSCAN2	TCGA-D9-A4Z6-06A-12D-A25O-08	TCGA-D9-A4Z6-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.T207I	0.725	40.0	0.0	0.0																									NTRK2 p.T207I (Missense)		SKCM_VARSCAN2	TCGA-D9-A4Z6-06A-12D-A25O-08	TCGA-D9-A4Z6-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1539S	0.4333	60.0	0.0	0.0																									ROS1 p.P1539S (Missense)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A746V	0.3846	91.0	0.0	0.0																									ROS1 p.A746V (Missense)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R625Q	0.5088	114.0	0.0	0.0																									FGFR2 p.R625Q (Missense)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.3798	129.0	0.0	0.0																									NF1 p.R440* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2539_splice	0.4	35.0	0.0	0.0																									NF1 p.X2539_splice (Splice Site)		SKCM_VARSCAN2	TCGA-EB-A41A-01A-11D-A24R-08	TCGA-EB-A41A-10A-01D-A24R-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.L502Q	0.6226	53.0	0.0	0.0																									RUNX1T1 p.L502Q (Missense)		SKCM_VARSCAN2	TCGA-EB-A553-01A-12D-A27K-08	TCGA-EB-A553-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.V144Lfs*9	0.45	40.0	0.0	0.0																									RB1 p.V144Lfs*9 (Frameshift)		SKCM_VARSCAN2	TCGA-EB-A553-01A-12D-A27K-08	TCGA-EB-A553-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D477N	0.3571	56.0	0.0	0.0																									RUNX1T1 p.D477N (Missense)		SKCM_VARSCAN2	TCGA-D3-A5GL-06A-11D-A27K-08	TCGA-D3-A5GL-10A-01D-A27N-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1274H	0.52	125.0	0.0	0.0																									NF1 p.L1274H (Missense)		SKCM_VARSCAN2	TCGA-FS-A1Z3-06A-11D-A197-08	TCGA-FS-A1Z3-10A-01D-A199-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P1667S	0.2727	121.0	0.0	0.0																									NF1 p.P1667S (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K6-06A-11D-A372-08	TCGA-WE-A8K6-10A-01D-A375-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R796C	0.2772	101.0	0.0	0.0																									COL1A1 p.R796C (Missense)		SKCM_VARSCAN2	TCGA-WE-A8K6-06A-11D-A372-08	TCGA-WE-A8K6-10A-01D-A375-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.H133Y	0.4521	73.0	0.0	0.0																									EML4 p.H133Y (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S67F	0.3171	41.0	0.0	0.0																									MYC p.S67F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.P295S	0.76	50.0	0.0	0.0																									NTRK2 p.P295S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G1127A	0.1442	104.0	0.0	0.0																									COL1A1 p.G1127A (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.N155S	0.3768	69.0	0.0	0.0																									TMPRSS2 p.N155S (Missense)		SKCM_VARSCAN2	TCGA-EE-A3JI-06A-11D-A21A-08	TCGA-EE-A3JI-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P81L	0.3611	144.0	0.0	0.0																									CDKN2A p.P81L (Missense)		SKCM_VARSCAN2	TCGA-EE-A2A6-06A-11D-A197-08	TCGA-EE-A2A6-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.6667	18.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		SKCM_VARSCAN2	TCGA-WE-A8ZT-06A-11D-A372-08	TCGA-WE-A8ZT-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.V341Cfs*12	0.3462	26.0	0.0	0.0																									NF1 p.V341Cfs*12 (Frameshift)		SKCM_VARSCAN2	TCGA-FS-A4F4-06A-12D-A25O-08	TCGA-FS-A4F4-10B-01D-A25O-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R1026Q	0.4561	57.0	0.0	0.0																									COL1A1 p.R1026Q (Missense)		SKCM_VARSCAN2	TCGA-EE-A2MK-06A-11D-A196-08	TCGA-EE-A2MK-10A-01D-A198-08
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.L507*	0.3705	224.0	0.0	0.0																									MLH1 p.L507* (Nonsense)		SKCM_VARSCAN2	TCGA-D3-A1QA-06A-11D-A196-08	TCGA-D3-A1QA-10A-01D-A198-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L2155F	0.425	40.0	0.0	0.0																									ROS1 p.L2155F (Missense)		SKCM_VARSCAN2	TCGA-EE-A3J8-06A-11D-A20D-08	TCGA-EE-A3J8-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.Q237*	0.1744	86.0	0.0	0.0																									ROS1 p.Q237* (Nonsense)		SKCM_VARSCAN2	TCGA-EB-A4IS-01A-21D-A25O-08	TCGA-EB-A4IS-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83Y	0.4444	27.0	0.0	0.0																									CDKN2A p.H83Y (Missense)		SKCM_VARSCAN2	TCGA-EB-A4IS-01A-21D-A25O-08	TCGA-EB-A4IS-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P698L	0.2637	91.0	0.0	0.0																									NF1 p.P698L (Missense)		SKCM_VARSCAN2	TCGA-EB-A4IS-01A-21D-A25O-08	TCGA-EB-A4IS-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.L1109*	0.5946	37.0	0.0	0.0																									NF1 p.L1109* (Nonsense)		SKCM_VARSCAN2	TCGA-FR-A8YD-06A-11D-A372-08	TCGA-FR-A8YD-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.M1149V	0.2571	35.0	0.0	0.0																									NF1 p.M1149V (Missense)		SKCM_VARSCAN2	TCGA-FR-A8YD-06A-11D-A372-08	TCGA-FR-A8YD-10A-01D-A375-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.Q660L	0.3077	52.0	0.0	0.0																									NTRK1 p.Q660L (Missense)		SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.F17S	0.1562	32.0	0.0	0.0																									RAF1 p.F17S (Missense)		SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.H86Y	0.36	50.0	0.0	0.0																									PAK1 p.H86Y (Missense)		SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R24S	0.84	25.0	0.0	0.0																									CDK4 p.R24S (Missense)		SKCM_VARSCAN2	TCGA-ER-A19E-06A-11D-A197-08	TCGA-ER-A19E-10A-01D-A199-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1810F	0.64	25.0	0.0	0.0																									ROS1 p.S1810F (Missense)		SKCM_VARSCAN2	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.A264T	0.5	12.0	0.0	0.0																									FGFR2 p.A264T (Missense)		SKCM_VARSCAN2	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.P1487S	0.4412	68.0	0.0	0.0																									NF1 p.P1487S (Missense)		SKCM_VARSCAN2	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.E31K	0.3125	16.0	0.0	0.0																									LIMK2 p.E31K (Missense)		SKCM_VARSCAN2	TCGA-D3-A51R-06A-11D-A25O-08	TCGA-D3-A51R-10A-01D-A25O-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.E470A	0.1228	57.0	0.0	0.0																									TACC3 p.E470A (Missense)		SKCM_VARSCAN2	TCGA-ER-A19W-06A-41D-A23B-08	TCGA-ER-A19W-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R24C	0.1786	84.0	0.0	0.0																									CDK4 p.R24C (Missense)		SKCM_VARSCAN2	TCGA-ER-A19W-06A-41D-A23B-08	TCGA-ER-A19W-10A-01D-A23B-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P382S	0.6957	23.0	0.0	0.0																									FLI1 p.P382S (Missense)		SKCM_VARSCAN2	TCGA-EB-A24D-01A-11D-A197-08	TCGA-EB-A24D-10A-01D-A199-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S2127F	0.6729	107.0	0.0	0.0																									MTOR p.S2127F (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1108S	0.5893	56.0	0.0	0.0																									ROS1 p.P1108S (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1007E	0.2453	53.0	0.0	0.0																									ROS1 p.G1007E (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1007R	0.2642	53.0	0.0	0.0																									ROS1 p.G1007R (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y491*	0.6571	35.0	0.0	0.0																									NF1 p.Y491* (Nonsense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L492I	0.6571	35.0	0.0	0.0																									NF1 p.L492I (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G800E	0.7692	39.0	0.0	0.0																									COL1A1 p.G800E (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G614E	0.7895	19.0	0.0	0.0																									COL1A1 p.G614E (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1134L	0.2979	47.0	0.0	0.0																									BRD4 p.P1134L (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.D202N	0.68	50.0	0.0	0.0																									TMPRSS2 p.D202N (Missense)		SKCM_VARSCAN2	TCGA-YD-A9TA-06A-11D-A397-08	TCGA-YD-A9TA-10A-01D-A39A-08
Biologically Relevant				Microsatellite Stability	Supporting variants		DOCK3 p.Q1050* (Nonsense), MSH3 p.Q46* (Nonsense), PRDM2 p.Q1435* (Nonsense), ESRP1 p.R264* (Nonsense), DOCK3 p.W1081* (Nonsense), ACVR2A p.K447* (Nonsense), MSH3 p.X343_splice (Splice Site), PMS2 p.R563* (Nonsense), DOCK3 p.X1172_splice (Splice Site), MSH2 p.Q395* (Nonsense), DOCK3 p.X1590_splice (Splice Site), ACVR2A p.Q378* (Nonsense), DOCK3 p.X1135_splice (Splice Site), MSH2 p.Q462* (Nonsense), DOCK3 p.R719* (Nonsense), DOCK3 p.P1852Qfs*45 (Frameshift), POLE p.W369* (Nonsense), RNF43 p.Q577* (Nonsense), DOCK3 p.W1033* (Nonsense), JAK1 p.E765* (Nonsense), RNF43 p.Q563* (Nonsense), POLE p.X1021_splice (Splice Site), MSH2 p.R680* (Nonsense), MLH1 p.L507* (Nonsense)																													Supporting variants: DOCK3 p.Q1050* (Nonsense), MSH3 p.Q46* (Nonsense), PRDM2 p.Q1435* (Nonsense), ESRP1 p.R264* (Nonsense), DOCK3 p.W1081* (Nonsense), ACVR2A p.K447* (Nonsense), MSH3 p.X343_splice (Splice Site), PMS2 p.R563* (Nonsense), DOCK3 p.X1172_splice (Splice Site), MSH2 p.Q395* (Nonsense), DOCK3 p.X1590_splice (Splice Site), ACVR2A p.Q378* (Nonsense), DOCK3 p.X1135_splice (Splice Site), MSH2 p.Q462* (Nonsense), DOCK3 p.R719* (Nonsense), DOCK3 p.P1852Qfs*45 (Frameshift), POLE p.W369* (Nonsense), RNF43 p.Q577* (Nonsense), DOCK3 p.W1033* (Nonsense), JAK1 p.E765* (Nonsense), RNF43 p.Q563* (Nonsense), POLE p.X1021_splice (Splice Site), MSH2 p.R680* (Nonsense), MLH1 p.L507* (Nonsense)		SKCM_VARSCAN2		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.911																													COSMIC Signature (version 2) 7 (91%)		SKCM_VARSCAN2		
